cephalosporin c has been researched along with Infections, Pseudomonas in 602 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 176 (29.24) | 18.7374 |
1990's | 73 (12.13) | 18.2507 |
2000's | 78 (12.96) | 29.6817 |
2010's | 154 (25.58) | 24.3611 |
2020's | 121 (20.10) | 2.80 |
Authors | Studies |
---|---|
Bremmer, DN; Kline, EG; Nicolau, DP; Shah, S; Shields, RK | 1 |
Benvenuti, MR; Borghesi, L; Franzetti, M; Luzzaro, F; Mauri, C; Moioli, G; Montoli, M; Piconi, S; Viaggi, V | 1 |
DePestel, DD; DeRyke, CA; Garrison, MW; Harris, KA; Moise, PA; Pfaller, MA; Sader, HS; Shortridge, D | 1 |
Horcajada, JP; López Montesinos, I; Montero, M; Sorlí, L | 1 |
Carvalhaes, CG; Castanheira, M; Sader, HS; Shortridge, D | 1 |
Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS | 1 |
Angulo-Brunet, A; Campillo, N; Domene-Ochoa, S; Ferrer-Alapont, L; Grau, S; Horcajada, JP; López-Causapé, C; Luque, S; Montero, MM; Oliver, A; Padilla, E; Prim, N; Sorlí, L | 1 |
Alcalde-Rico, M; Arias, CA; García, P; Khan, A; Martínez, JRW; Miller, WR; Moreno, MV; Munita, JM; Olivares-Pacheco, J; Rivas, L; Rojas, P; Wozniak, A | 1 |
Chen, WT; DeRyke, CA; Kazmierczak, KM; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Fernández-Pérez, B; Fraile-Ribot, PA; Gato, E; González-Bello, C; Guijarro-Sánchez, P; Gutiérrez-Urbón, JM; Lasarte-Monterrubio, C; Oliver, A; Oviaño, M; Ruedas-López, A; Vallejo, JA; Vázquez-Ucha, JC; Velasco, D | 1 |
Baylac, P; Bercot, B; Camelena, F; de Fontbrune, FS; Gras, J; Lafaurie, M; Molina, JM; Touratier, S; Valade, S; Villar-Fernandez, S; Xhaard, A | 1 |
Cabot, G; Gomis-Font, MA; Juan, C; López-Argüello, S; Moyá, B; Oliver, A; Zamorano, L | 1 |
Al Musawa, M; Alattas, M; Alfahad, W; Alfozan, A; Alghamdi, A; Alhameed, AF; Aljabri, A; Almangour, TA; Almohaizeie, A; Almuhisen, S; Alraddadi, BM; AlShahrani, FS; Binkhamis, KM; Damfu, N; Khuwaja, M; Qutub, M | 1 |
Al-Alawi, MM; Ali, HE; Almutairi, AF; AlTurki, R; Bahabri, NM; Janah, SS; Khalil, S; Qutub, MO; Tashkandi, WA | 1 |
Bennis, Y; Dubée, V; Jaubert, P; Luque-Paz, D; Mortaza, S; Wolff, M | 1 |
Carratalà, J; Cuervo, G; González Laguna, M; Llop Talaveron, J; Padullés, A; Pérez-Recio, S; Ronda, M; Soldevila-Boixader, L; Tubau Quintano, MF | 1 |
Csékó, AB; Gál, J; Hermann, C; Iványi, ZD; Mogyoródi, B | 1 |
Chew, KL; Leong, Q | 1 |
Ali, O; Cortes-Lara, S; Del Barrio-Tofiño, E; Goossens, H; Kluytmans, J; Köhler, T; Kumar-Singh, S; Lammens, C; López-Causapé, C; MacLean, RC; Malhotra-Kumar, S; Oliver, A; Paling, F; Ruzin, A; Timbermont, L; Torrens, G; van der Schalk, TE; Xavier, BB; Zamorano, L | 1 |
Candel, FJ; González Del Castillo, J; Julián Jiménez, A; Matesanz, M | 1 |
DeRyke, CA; Hilbert, DW; Karlowsky, JA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Wong, MT; Young, K | 1 |
Canton, R; Doi, Y; Simner, PJ | 1 |
Benítez-Cano, A; Grau, S; Luque, S; Navarrete-Rouco, ME; Roberts, JA; Sorlí, L | 1 |
Adam, HJ; Baxter, MR; Bay, D; Karlowsky, JA; Lagacé-Wiens, PRS; Lynch, JP; Mulvey, MR; Schweizer, F; Walkty, AJ; Zhanel, GG | 1 |
Antonelli, A; Brenciani, A; Brescini, L; Castelletti, S; Cirioni, O; D'Achille, G; Di Pilato, V; Fioriti, S; Giacometti, A; Giani, T; Giovanetti, E; Masucci, A; Mingoia, M; Morroni, G; Rossolini, GM | 1 |
Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Fraile-Ribot, PA; Galán-Sánchez, F; Guijarro-Sánchez, P; Lasarte-Monterrubio, C; Oliver, A; Rumbo-Feal, S; Vázquez-Ucha, JC | 1 |
Castanheira, M; Collingsworth, TD; DeVries, S; Doyle, TB; Hubler, CM; Mendes, RE | 1 |
Albarracín Orio, AG; Bonomo, RA; Colque, CA; Dotta, G; Feliziani, S; Hedemann, LG; Hickman, RA; K Johansen, H; Molin, S; Moreno, DM; Moyano, AJ; Smania, AM; Sommer, LM; Tomatis, PE; Vila, AJ | 1 |
Abbara, D; Afaneh, L; Al Duhailib, Z; Al Qahtani, MM; Al Sulaiman, K; Aldhayyan, N; Askar, G; Dyab, N; Hakeam, HA; Islami, M; Mansour, R | 1 |
Bachta, KER; Bertucci, HK; Brunzelle, JS; Gatesy, SWM; Hauser, AR; Lebrun-Corbin, M; Minasov, G; Ozer, EA; Pincus, NB; Rosas-Lemus, M; Satchell, KJF; Shuvalova, LA | 1 |
Haines, RR; Hammer, KA; Putsathit, P; Tai, AS | 1 |
Alekseeva, I; DeRyke, CA; Estabrook, MA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
Baretta, V; Calore, E; Carraro, F; Cesaro, S; Colombini, A; Meazza, C; Muggeo, P; Onofrillo, D; Perruccio, K; Rosaria D'Amico, M; Zama, D | 1 |
Dessein, R; Gosset, P; Kipnis, E; Le Guern, R; Nordmann, P; Poirel, L; Sadek, M | 1 |
Gill, CM; Nicolau, DP | 1 |
Alekseeva, I; DeRyke, CA; Hawser, SP; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
Böhringer, N; Horst, J; Hübner, J; Kappler, M; Kolberg, L; Kresna, IDM; Liu, Y; Marner, M; Mettal, U; Meyer-Bühn, M; Mihajlovic, S; Schäberle, TF; von Both, U; Wang, L | 1 |
Amara, M; Barraud, O; Bastide, M; Bernabeu, S; Bille, E; Bonnin, RA; Brun, CL; Cattoir, V; Corvec, S; d'Epenoux, LR; Degand, N; Dortet, L; Emeraud, C; Farfour, E; Fihman, V; Grillon, A; Guillard, T; Isnard, C; Jacquier, H; Janvier, F; Jousset, AB; Laurent, F; Lemonnier, A; Lomont, A; Merens, A; Mizrahi, A; Plouzeau, C; Ranc, AG; Soismier, N; Yin, N; Zahar, JR | 1 |
Cabot, G; Khajehpour, M; Kim, K; Mark, BL; Oliver, A | 1 |
Jia, P; Xu, Y; Yang, Q; Yu, W; Zhang, H; Zhu, Y | 1 |
Arends, SJR; Carvalhaes, CG; Castanheira, M; Mendes, RE; Sader, HS; Shortridge, D | 1 |
Akrich, B; DeRyke, CA; Hawser, SP; Karlowsky, JA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
Aja-Macaya, P; Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Fernández-González, A; Galán-Sánchez, F; González-Mayo, E; Guijarro-Sánchez, P; Lada-Salvador, P; Lasarte-Monterrubio, C; Martínez-Guitián, M; Muíño-Andrade, M; Oliver, A; Rodríguez-Iglesias, M; Rumbo-Feal, S; Vázquez-Ucha, JC; Vela-Fernández, R | 1 |
Gilboa, M; van Duin, D; Yahav, D | 1 |
Hsueh, PR; Lee, YL | 1 |
Bell, SC; Lamont, IL; Martin, LW; Patrick, WM; Ramsay, KA; Rehman, A; Wardell, ST; Winstanley, C | 1 |
Hsueh, PR; Ko, WC; Lee, YL | 1 |
Fujimori, T; Hagiya, H; Higashikage, A; Iio, K; Kakehi, A; Minabe, H; Okura, M; Otsuka, F; Yokoyama, Y | 1 |
Cabot, G; Gomis-Font, MA; Oliver, A; Sastre-Femenia, MÀ; Taltavull, B | 1 |
Faurholt-Jepsen, D; Jensen, PØ; Johansen, HK; Katzenstein, TL; Kolpen, M; Pressler, T; Qvist, T | 1 |
Challa, HPR; Dubbudu, RR; Gupta, A; Kumar, LS; Reddy, PN; Sree, RA; Tirlangi, PK; Wanve, BS; Yadav, BS | 1 |
Agyeman, AA; Boyce, JD; Bulitta, JB; Cortés-Lara, S; Figuerola, J; Fraile-Ribot, P; Franklyn, ERT; Gomis-Font, MA; Landersdorfer, CB; Lang, Y; Lee, WL; López-Causapé, C; Lucas, DD; Nation, RL; Oliver, A; Rogers, KE; Zhang, Y; Zhou, J | 1 |
Abbott, IJ; Chang, CC; Dennison, A; Kostoulias, X; Peleg, AY; Spelman, DW; Wisniewski, J; Zisis, H | 1 |
Egge, SL; Hakki, M; Lewis, JS | 1 |
Al Musawa, M; Alanazi, MQ; Alassiri, D; Alfahad, W; Alghaith, J; Alharbi, A; Aljefri, D; Aljurbua, A; Almangour, TA; Almohaizeie, A; Almuhisen, S; Alsowaida, YS; Damfu, N; Ghonem, L; Khormi, Y | 1 |
Clark, JR; Gu Liu, C; Maresso, AW; Nicholls, P; Terwilliger, A | 1 |
Bakthavatchalam, YD; Bano, N; Dubey, D; Dubey, M; Imran, A; Jain, B; Kulshrestha, V; Mitra, S; Roy, M; Sangwan, P; Shah, TH; Veeraraghavan, B; Velmurugan, A | 1 |
Bour, M; Da Silva, M; Jeannot, K; Landon, C; Plésiat, P; Vuillemin, X | 1 |
Albur, M; Attwood, M; Griffin, P; Macgowan, AP; Noel, AR | 1 |
Cosentino, F; Giannella, M; Viale, P | 1 |
Bou, G; Cabot, G; Cortes-Lara, S; Del Barrio-Tofiño, E; López-Causapé, C; Martínez-Martínez, L; Oliver, A; Sánchez-Diener, I; Zamorano, L | 1 |
Abdel Hadi, H; Abu Jarir, S; Al-Maslamani, MA; Bonomo, RA; Dousa, KM; Eltai, NO; Hassan, AAI; Hujer, AM; Ibrahim, EB; Jass, J; Omrani, AS; Sid Ahmed, MA; Soderquist, B; Sultan, AA | 1 |
Cuesta, M; Gonzalez-Zorn, B; Hoefer, A; Ortega-Huedo, R | 1 |
Bonomo, RA; Davis, SL; Dhar, S; File, TM; Gerlach, AT; Kaye, KS; Olson, S; Patel, TS; Perez, F; Pogue, JM; Puzniak, LA; Veve, MP | 1 |
Clancy, M; Stevens, RW | 1 |
Abdelraouf, K; Kidd, JM; Nicolau, DP | 1 |
Flamm, RK; Pfaller, MA; Shortridge, D; Streit, JM | 1 |
Aguilar, G; Blasco, ML; Calabuig, M; Carbonell, N; Colomina, J; Ezquer, C; Ferreres, J; Ferriols, R; Huerta, R; Juan, M | 1 |
Cheng, S; He, J; Jia, X; Liu, H; Ma, W; Tian, X; Zou, H | 1 |
Allan, RN; Cai, Y; Connett, GJ; Davies, JC; Faust, SN; Feelisch, M; Howlin, RP; Kelso, MJ; Rineh, A; Silva, DG; Soren, O; Webb, JS | 1 |
Buonomo, AR; Gentile, I; Maraolo, AE; Mazzitelli, M; Torti, C; Trecarichi, EM | 1 |
Alves, V; Cantón, R; Chaves, C; Diogo, J; Ferreira, R; García-Castillo, M; García-Fernández, S; Gonçalves, E; Melo-Cristino, J; Paixão, L; Pássaro, L; Pinto, MF; Ramalheira, E; Sancho, L; Silva, D; Vieira, AR | 1 |
Buonomo, AR; Congera, P; Foggia, M; Gentile, I; Maraolo, AE; Parente, S; Scotto, R; Zappulo, E | 1 |
Shields, RK | 1 |
Abdulhamid, I; Ang, JY; Molloy, L; Srivastava, R | 1 |
Kharat, AS; Khobragade, K; Palwe, S; Periasamy, H; Veeraraghavan, B | 1 |
Cabot, G; Fernández-Esgueva, M; Fraile-Ribot, PA; Huarte, R; López-Calleja, AI; Mulet, X; Oliver, A; Rezusta, A | 1 |
Juhász, E; Katona, K; Kristóf, K; Melegh, S; O'Neall, D; Szabó, J; Tóth, Á; Urbán, E | 1 |
Amore, D; Anile, M; Bassi, M; Cagnetti, S; Carillo, C; D'Agostino, FG; De Giacomo, T; Diso, D; Mantovani, S; Mottola, E; Pagini, A; Pecoraro, Y; Poggi, C; Pugliese, F; Rendina, EA; Russo, G; Vannucci, J; Venuta, F | 1 |
Cayô, R; Cuba, GT; Gales, AC; Kiffer, CRV; Nicolau, DP; Nodari, CS; Pignatari, ACC; Rocha-Santos, G; Streling, AP | 1 |
DePestel, DD; Karlowsky, JA; Lob, SH; Motyl, MR; Raddatz, J; Sahm, DF; Young, K | 1 |
Gatermann, SG; Körber-Irrgang, B; Korte-Berwanger, M; Kresken, M; Pfennigwerth, N; Seifert, H | 1 |
Adamou, P; Antoniadou, A; Damala, M; Deliolanis, I; Fountoulis, K; Galani, I; Galani, L; Giamarellou, H; Karaiskos, I; Karantani, I; Kirikou, H; Kodonaki, A; Maraki, S; Markopoulou, M; Papadogeorgaki, E; Papoutsaki, V; Petinaki, E; Prifti, E; Souli, M; Tsiplakou, S; Vagiakou, E | 1 |
Arends, SJR; Duncan, LR; Flamm, RK; Pfaller, MA; Shortridge, D; Streit, JM | 1 |
Carvalhaes, CG; Duncan, LR; Flamm, RK; Sader, HS; Shortridge, D | 1 |
Bisanti, A; Diaz, E; Martin-Loeches, I; Rodriguez, A | 1 |
Bidell, MR; Lodise, TP; O'Donnell, JN | 1 |
Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Fraile-Ribot, PA; Galán-Sánchez, F; González-Bello, C; Lasarte-Monterrubio, C; Lence, E; Martínez-Guitián, M; Oliver, A; Rodríguez-Iglesias, M; Vázquez-Ucha, JC | 1 |
Carniel, E; da Cunha, RSR; Dias, CG; Narvaez, GA; Perez, LRR | 1 |
Forland, SC; Guerrero-Wooley, RL; Hino, G; Park, SH; Winans, SA | 1 |
Avdic, E; Beisken, S; Bergman, Y; Cosgrove, SE; Posch, AE; Sharara, SL; Simner, PJ; Tamma, PD | 1 |
Bookstaver, PB; Bouchard, J; Gould, AP; Hucks, J; Justo, JA; Nelson, D; Nicolau, D; O'Neal, M; Sheffield, M | 1 |
Bacca, E; Bedini, A; Bianco, V; Cuomo, G; Franconi, I; Meschiari, M; Mussini, C; Orlando, G | 1 |
Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Galán-Sánchez, F; González-Bello, C; Lasarte-Monterrubio, C; Oliver, A; Rodiño-Janeiro, BK; Rodríguez-Iglesias, M; Vázquez-Ucha, JC | 1 |
Alves, V; Bou, G; Cantón, R; Cercenado, E; Chaves, C; Delgado-Valverde, M; Díaz-Regañón, J; Diogo, J; Ferreira, R; García-Castillo, M; García-Fernández, S; Gonçalves, E; Hernández-García, M; López-Mendoza, D; Melo-Cristino, J; Oliver, A; Paixão, L; Pássaro, L; Pinto, MF; Pitart, C; Ramalheira, E; Rodríguez-Lozano, J; Romano, J; Sancho, L; Silva, T; Tormo, N; Vieira, AR | 1 |
Bhalodi, AA; Gamage, D; Humphries, RM; Oppermann, N; Shamsheyeva, A; Sikorski, A | 1 |
Ibrahim, D; Jabbour, JF; Kanj, SS | 1 |
Cohen, L; Finklea, JD; Jain, R; Nolan, PJ; Smith, TT | 1 |
Al-Delaimi, MS; Yacoob Aldosky, HY | 1 |
Blomquist, KC; Nix, DE | 1 |
Asensio-Martín, MJ; Balandin, B; Ballesteros, D; Chicot, M; Fernández-Simón, I; Iranzo, R; López-Vergara, L; Martínez-Sagasti, F; Pérez-Pedrero, MJ; Pintado, V; Rodríguez-Serrano, D; Royuela, A; Ruiz de Luna, R; Sancho-González, M; Silva, A; Soriano-Cuesta, C | 1 |
Bruno, C; Carmelitano, P; Castanheira, M; De Anda, C; Huntington, JA; Johnson, MG; Motyl, M; Rhee, EG; Yu, B | 1 |
Epps, KL; Epps, QJ; Zobell, JT | 1 |
Khan, S; Phe, K; Tam, VH | 1 |
Arcay, RM; Cantón, R; Castillo, FJ; Cercenado, E; Cisterna, R; Díaz-Regañón, J; Gálvez-Benítez, L; González Romo, F; Hernández-Cabezas, A; López-Mendoza, D; Loza, E; Rodríguez-Lozano, J; Suárez-Barrenechea, AI; Tubau, F | 1 |
Baccani, I; Bartalesi, F; Bartoloni, A; Borchi, B; Bresci, S; Cavallo, A; Ottino, L; Rossolini, GM | 1 |
Sivashanmugam, K; Srivastava, P | 1 |
Cooper, K; Gould, IM; Hijazi, K; Ironside, C; Okoliegbe, IN | 1 |
Collings, H; Dillon, R; Enstone, A; Palmer, T; Puzniak, L | 1 |
Murri, R; Sacco, E | 1 |
Betthauser, KD; Kollef, MH; Lizza, BD; Micek, ST; Ritchie, DJ | 1 |
Barrio-Tofiño, ED; Cortes-Lara, S; López-Causapé, C; Oliver, A | 1 |
Akrich, B; Amode, A; Berthelot, A; Boutoille, D; Castan, B; Levy-Bachelot, L; Mackosso, C; Mathis, L; Mootien, J; Ruimy, R; Ruiz, F; Timsit, JF | 1 |
Anstey, KM; Choi, L; Dawson, D; Kleinhenz, ME; Otani, IM | 1 |
Baquero-Artigao, F; Calvo, C; Del Rosal, T; Gerig, N; Gómez-Gil, MR; Grasa, CD; Moreno, F; Ochoa Fernández, B; San Román Pacheco, S | 1 |
Cortes-Lara, S; Del Barrio-Tofiño, E; Gomis-Font, MA; López-Causapé, C; Marco, F; Mulet, X; Oliver, A; Pitart, C; Vila, J; Zboromyrska, Y | 1 |
Ebisui, A; Goto, R; Inose, R; Ishii, S; Ishikane, M; Kawabe, A; Koizumi, R; Kusama, Y; Muraki, Y; Ohmagari, N; Yagi, T | 1 |
Cazorla-Poderoso, L; Huarte-Lacunza, R; Larrodé-Leciñena, I; López-Calleja, AI; Magallón-Martínez, A; Martínez-Álvarez, RM; Pereira-Blanco, O; Pérez-Moreno, M; Pinilla-Rello, A | 1 |
Holland, P; Jahnke, N | 1 |
Daragon, B; Fournier, D; Jeannot, K; Plésiat, P | 1 |
Gatti, M; Pea, F | 1 |
Brink, A; Chu, CY; Coetzee, J; Dimopoulos, G; Gill, CM; Moodley, C; Nicolau, DP; Opperman, CJ; Pournaras, S; Tenover, FC; Tickler, IA; Tootla, HD; Vourli, S | 1 |
Cantón, R; García-Castillo, M; García-Fernández, S; Hernández-García, M; Pássaro, L | 1 |
Aktaş, E; Alfouzan, W; Bourassa, L; Brink, A; Burnham, CD; Canton, R; Carmeli, Y; Falcone, M; Gill, CM; Kiffer, C; Marchese, A; Martinez, O; Nicolau, DP; Pournaras, S; Seifert, H; Thabit, AK; Villegas, MV; Westblade, LF | 1 |
Abbo, LM; Adachi, J; Aitken, SL; Araos, R; Arias, CA; Bonomo, RA; Jain, R; Lichtenberger, PN; Miller, WR; Munita, JM; Nigo, M; Perez, F; Rakita, R; Rosa, R; Shelburne, S; Shimose, LA; Tran, TT; Wanger, A | 1 |
Castanheira, M; Flamm, RK; Jones, RN; Rhomberg, PR; Sader, HS | 1 |
Álvarez Lerma, F; Gracia Arnillas, MP; Grau, S; Mico García, M; Muñoz Bermudez, R; Recasens, L; Sorli, L | 1 |
Berenson, CS; Kurtzhalts, KE; Manohar, A; Mergenhagen, KA | 1 |
Béraud, G; Bouchand, F; Canouï, E; Davido, B; Dinh, A; Duran, C; Ferry, T; Hénard, S; Kernéis, S; Lazaro, P; Lebeaux, D; Wolff, M; Wyplosz, B | 1 |
Bassetti, M; Castaldo, N; Givone, F; Peghin, M; Righi, E; Sartor, A | 1 |
Borgia, G; Buonomo, AR; De Zottis, F; Di Renzo, G; Gentile, I; Maraolo, AE; Scotto, R | 1 |
Epps, KL; Young, DC; Zobell, JT | 1 |
Echols, R; Hoover, J; Matsumoto, S; Nakamura, R; Rittenhouse, S; Singley, CM; Tsuji, M; Yamano, Y | 1 |
Cho, YL; Kim, HS; Kwak, JH; Oh, K; Oh, SH; Park, HS; Yun, JY | 1 |
Cho, B; Chung, NG; Han, SB; Jeong, DC; Kang, JH; Kim, HS; Kim, SK; Lee, DG; Lee, JW; Park, BK | 1 |
Chia, JH; Huang, CT; Lee, MH; Su, TY; Yang, CC; Ye, JJ | 1 |
Grupper, M; Nicolau, DP; Sutherland, C | 1 |
Borgia, G; Cascella, M; Corcione, S; Cuomo, A; De Rosa, FG; Gentile, I; Maraolo, AE; Nappa, S | 1 |
Goodlet, KJ; Nailor, MD; Nicolau, DP | 1 |
Chen, L; Kreiswirth, BN; MacVane, SH; Pandey, R; Steed, LL | 1 |
Bhattacharjee, A; Chakravarty, A; Dhar Chanda, D; Ingti, B; Krishnatreya, DB; Maurya, AP | 1 |
Becker, K; Bletz, S; Idelevich, EA; Mellmann, A; Schaumburg, F | 1 |
Bodro, M; Marco, F; Martínez, JA; Soriano, A; Xipell, M | 1 |
Hindler, JA; Humphries, RM; Miller, SA; Wong-Beringer, A | 1 |
Cheng, S; Clancy, CJ; Cooper, VS; Doi, Y; Haidar, G; Hao, B; Nguyen, MH; Philips, NJ; Potoski, BA; Press, EG; Shields, RK; Snyder, D | 1 |
Castanheira, M; Flamm, RK; Pfaller, MA; Shortridge, D | 2 |
Bassetti, M; Castaldo, N; Givone, F; Lechiancole, A; Livi, U; Maiani, M; Pea, F; Peghin, M; Righi, E; Sartor, A | 1 |
Lodise, TP; Natesan, S; Pai, MP | 1 |
Lasco, TM; Ledesma, KR; Skoglund, E; Tam, VH | 1 |
Cabot, G; Fraile-Ribot, PA; Juan, C; Martín-Pena, ML; Mulet, X; Oliver, A; Pérez, JL; Periañez, L | 1 |
Arcenillas, P; Boix-Palop, L; Calbo, E; Cuchi, E; Dietl, B; Gómez, L; González de Molina, FJ; Nicolás, J; Sánchez, I | 1 |
Arena, F; Bassetti, M; D'Andrea, MM; Di Pilato, V; Giani, T; Henrici De Angelis, L; Pollini, S; Rossolini, GM | 1 |
Adam, H; Baxter, M; Hoban, DJ; Karlowsky, JA; Lagacé-Wiens, P; Walkty, A; Zhanel, GG | 2 |
Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS; Shortridge, D | 1 |
Monogue, ML; Nicolau, DP | 1 |
Bodro, M; Fresco, L; Marco, F; Martínez, JA; Paredes, S; Soriano, A; Xipell, M | 1 |
Hussain, BM; Hussin, H; Phoon, HYP; Thong, KL | 1 |
Hakki, M; Lewis, JS | 1 |
Allworth, AM; Legg, A; McCarthy, KL; Roberts, JA; Stewart, A; Wallis, SC | 1 |
Bassetti, M; De Rosa, FG; Del Bono, V; Giacobbe, DR; Grossi, PA; Menichetti, F; Pea, F; Rossolini, GM; Tumbarello, M; Viale, P; Viscoli, C | 1 |
Almirante, B; Arévalo, Á; Campany, D; Escolà-Vergé, L; Ferrer, R; Larrosa, N; Len, O; Los-Arcos, I; Nuvials, X; Pigrau, C; Viñado, B | 1 |
Caro, L; Huntington, JA; Long, J; Xiao, AJ | 1 |
Chaves, F; Lora-Tamayo, J; Orellana, MÁ; Recio, R; Viedma, E; Villa, J | 1 |
Alessa, MA; Alhokail, M; Alhossan, A; Alkholief, MA; Almangour, TA; Tabb, DE | 1 |
Dunn, A; Plant, AJ; Porter, RJ | 1 |
Finklea, JD; Hollaway, R; Jain, R; Le, J; Lee, F; Lowe, K | 1 |
Jones, AL; Lee, AC | 1 |
Avendano, EE; Chan, J; Merchant, S; Puzniak, L; Raman, G | 1 |
Jiménez-Delgado, JD; Monterrubio-Villar, J; Rodríguez-Garrido, S | 1 |
Asensio, J; Ayestarán, I; Colomar, A; Delgado, O; Díaz-Cañestro, M; Fraile-Ribot, PA; López-Causapé, C; Maciá, M; Martin-Pena, ML; Mulet, X; Murillas, J; Novo, A; Nuñez, B; Oliver, A; Pérez, JL; Periañez, L; Riera, M; Torres, V | 1 |
Bahat-Dinur, A; El-Seid, S; Kaplan, D; Kraus, M; Peled, C; Tzvi-Ran, LR | 1 |
Bonomo, RA; Chambers, HF; Chen, L; Domitrovic, TN; Evans, SR; Farmer, M; Fowler, VG; Hill, CB; Hujer, AM; Hujer, KM; Jacobs, MR; Kreiswirth, BN; Manca, C; Mediavilla, JR; Patel, R; Perez, F; Pitzer, KM; Tran, TTT; Wilson, BM | 1 |
Galega, R; Greene, JN; Lee, GC; Quilitz, R; Shurko, J; So, W | 1 |
Bassetti, M; Montravers, P | 1 |
Dubois, V; Jayol, A; Kieffer, N; Nordmann, P; Ortiz De La Rosa, JM; Poirel, L | 1 |
Abdou, A; Hassam, B | 1 |
Henderson, A; McCarthy, KL; Paterson, DL; Tan, E | 1 |
Artioli, S; Bassetti, M; Capone, A; Carannante, N; Castaldo, N; Cattelan, A; Cipriani, L; Coletto, D; Digaetano, M; Grossi, P; Losito, AR; Mastroianni, CM; Menichetti, F; Mussini, C; Nicolè, S; Peghin, M; Righi, E; Russo, A; Tascini, C; Tumbarello, M; Vena, A | 1 |
Ariyasu, M; Beale, R; Den Nagata, T; Edgeworth, JD; Jones, A; Jones, P; Livermore, DM; Merante, D; Patel, S; Roberts, P; Vithlani, S; Wyncoll, D; Young, C | 1 |
Abbara, S; Cherrier, P; Diamantis, S; Hodjat, K; Jochmans, S; Monchi, M; Pitsch, A; Vinsonneau, C | 1 |
Fernández Esgueva, M; Ferrer Cerón, I; García-Lechuz Moya, JM; López-Calleja, AI; Morilla Morales, E; Nuñez Medina, R; Rezusta López, A; Sahagún Pareja, J; Viñuelas Bayon, J | 1 |
Basak, GW; Saran, O; Sulik-Tyszka, B; Wróblewska, MM | 1 |
Arena, F; Cassetta, MI; Contorni, M; Henrici De Angelis, L; Maglioni, E; Marchetti, L; Novelli, A; Rossolini, GM | 1 |
Ariza, J; Benavent, E; El Haj, C; Gómez-Junyent, J; Murillo, O; Rigo-Bonnin, R; Sierra, Y; Soldevila, L; Torrejón, B; Tubau, F | 1 |
Blázquez-Gamero, D; Brañas, P; Epalza, C; Flores, M; Grau, S; Martín-Cazaña, M; Olmedilla, M | 1 |
Di Bonaventura, G; Fiscarelli, E; Gherardi, G; Linardos, G; Pompilio, A | 1 |
Aitken, E; Gould, IM; Hijazi, K; Joshi, C; Oggioni, MR; Zamudio, R | 1 |
DePestel, DD; DeRyke, CA; Gupta, V; Merchant, S; Murray, J; Puzniak, L; Srinivasan, A; Ye, G | 1 |
Hishinuma, T; Kirikae, T; Shimojima, M; Tada, T; Uchida, H | 1 |
Avery, LM; Nicolau, DP; Sutherland, CA | 1 |
Akova, M; Albasanz-Puig, A; Araos, R; Bote, A; Brunel, AS; Calik, S; Carratalà, J; Del Pozo, JL; Drgona, L; García, E; Gomes, MZR; Gudiol, C; Hemmati, P; Herrera, F; Ibrahim, KY; Isler, B; Kanj, S; Kern, W; Maestro de la Calle, G; Manzur, A; Marin, JI; Márquez-Gómez, I; Martín-Dávila, P; Mikulska, M; Montejo, JM; Montero, M; Morales, HMP; Morales, I; Novo, A; Oltolini, C; Parody, R; Peghin, M; Puerta-Alcalde, P; Ruiz-Camps, I; Sipahi, OR; Tebe, C; Tilley, R; Yáñez, L | 1 |
Nordmann, P; Ortiz de la Rosa, JM; Poirel, L | 1 |
Ann Justo, J; Bookstaver, PB; Elizabeth Davis, S; Foster, R; Gould, A; Ham, J; Hucks, J; Nicolau, DP | 1 |
Boulanger, B; Cizeau, F; Decousser, JW; Ducellier, D; Fourreau, F; Mercier-Darty, M; Mongardon, N; Podglajen, I; Potron, A; Royer, G | 1 |
Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Fraile-Ribot, P; Galán-Sánchez, F; González-Bello, C; Lence, E; Martínez-Guitián, M; Oliver, A; Rodríguez-Iglesias, M; Vázquez-Ucha, JC | 1 |
Anwar, Z; Guy, JR; Lam, BL; Schatz, NJ; Sternau, LL; Winter, TW | 1 |
Bauer, KA; Goff, DA; O'Brien, JM; West, JE | 1 |
Araki, H; Suemaru, K; Takechi, K; Tanaka, A; Tanaka, M; Watanabe, S | 1 |
Hashiguchi, R; Komatsu, M; Matsuyama, S; Moronaga, Y; Nagahara, C; Oshiro, Y; Sameshima, I; Takeyama, H; Tottori, N; Yaita, K; Yamaguchi, Y | 1 |
Goff, DA; Nicolau, DP | 1 |
Chia, JH; Hsu, PC; Lee, MH; Su, TY; Wu, HF; Ye, JJ | 1 |
Akpolat, N; Aydemir, O; Deniz, N; Güler, M; Kizirgil, A | 1 |
Kuti, JL; MacVane, SH; Nicolau, DP | 1 |
Fatemi, O; Najjar, SS; Ruiz, ME; Sperry, BW | 1 |
Baek, JY; Cho, SY; Chung, DR; Kang, CI; Kim, J; Kim, SH; Ko, KS; Peck, KR; Song, JH | 1 |
Bruchmann, S; Cabot, G; Haussler, S; Juan, C; Moyà, B; Mulet, X; Oliver, A; Zamorano, L | 1 |
Kirikae, T; Miyoshi-Akiyama, T; Narahara, K; Ohmagari, N; Shimojima, M; Tada, T; Tanaka, M; Tojo, M | 1 |
Castanheira, M; Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS | 1 |
Mugnai, G; Pesarini, G; Vassanelli, C | 1 |
Boutoille, D; Bretonnière, C; Caillon, J; Desessard, C; Guitton, C; Jacqueline, C; Potel, G | 1 |
Gu, B; Mei, Y; Wen, Y; Xia, W; Zhang, X | 1 |
Bhattacharjee, A; Chakravarty, A; Chanda, DD; Maurya, AP; Talukdar, AD | 1 |
Castanheira, M; Farrell, DJ; Jones, RN; Mills, JC | 1 |
Bhalodi, AA; Crandon, JL; Nicolau, DP; Williams, G | 1 |
Bhardwaj, N; Biswas, D; Kakati, B; Kotwal, A; Thakuria, B | 1 |
Heil, EL; Lowery, AV; Nicolau, DP; Thom, KA | 1 |
Airapetian, N; Ammenouche, N; Dupont, H; Friggeri, A; Levrard, M; Mahjoub, Y; Mammeri, H; Marciniak, S; Tinturier, F; Zogheib, E | 1 |
Cleveland, KO; Gelfand, MS | 1 |
Chahine, EB; Cogan, P; Fete, M; Sucher, AJ | 1 |
Chia, JH; Hsu, PC; Kuo, AJ; Lee, CH; Lee, MH; Su, TY; Ye, JJ | 1 |
Bofarull, AM; Cantón, R; García-Castillo, M; Tato, M | 1 |
Gonzales, JP; Heil, EL; Mehrotra, S; Nicolau, DP; Oliver, WD; Robinett, K; Saleeb, P | 1 |
Bradley, JS; Capparelli, EV; Domonoske, C; Reed, MD; Shoji, K; van den Anker, JN | 1 |
Kuti, JL; Nicolau, DP; Nugent, J; Shepard, A; So, W | 1 |
Greenwood-Quaintance, KE; Karau, MJ; Kohner, PC; Patel, R; Schmidt-Malan, SM; Velez Perez, AL | 1 |
Aitken, SL; Bhatti, MM; DePombo, AM; Gettys, SC; Kontoyiannis, DP; Nicolau, DP; Nunez, CA; Tverdek, FP | 1 |
Higuchi, H; Horikoshi, Y; Isogai, M; Ito, K; Shoji, T; Suwa, J | 1 |
Ghazi, IM; Kuti, JL; Nicolau, DP; Quintiliani, R; Shore, E | 1 |
McClain, D; Vickery, SB; Wargo, KA | 1 |
Cies, JJ; Kuti, JL; Monogue, ML; Muhlebach, M; Nicolau, DP; Pettit, RS | 1 |
Ardebili, A; Azimi, L; Bijari, A; Fallah, F; Lari, AR; Lari, ER | 1 |
Chalhoub, H; Denis, O; Deplano, A; Elborn, JS; Kahl, BC; Mustafa, MH; Rodriguez-Villalobos, H; Traore, H; Tulkens, PM; Tunney, MM; Van Bambeke, F; Vanderbist, F; Vergison, A | 1 |
Borgia, G; Gentile, I; Maraolo, AE | 1 |
Algora-Weber, A; de la Calle-Pedrosa, N; Delgado-Iribarren, A; Gabán-Díez, Á; González-Jiménez, AI; Hernández-Tejedor, A; Martín-Vivas, A; Merino-Vega, CD; Ruiz de Luna-González, R; Temprano-Gómez, I | 1 |
Cabot, G; Domínguez, MÁ; Juan, C; López-Causapé, C; Martínez-Martínez, L; Moyà, B; Ocampo-Sosa, AA; Oliver, A; Peña, C; Plesiat, P; Rodríguez, C; Sommer, LM; Tubau, F; Zamorano, L | 1 |
Elphick, HE; Scott, A | 1 |
Castón, JJ; De la Torre, Á; Ruiz-Camps, I; Sorlí, ML; Torre-Cisneros, J; Torres, V | 1 |
Crespo Casal, M; Martinez-Lamas, L; Nodar, A; Perez-Landeiro, A; Perez-Rodríguez, MT; Sousa Dominguez, A | 1 |
Gentry, CA; Ratliff, AR; Williams, RJ | 1 |
Bassetti, M; Castanheira, M; Duncan, LR; Pfaller, MA | 1 |
Diaz-Martinez, LA; Ramirez-Blanco, CE; Ramirez-Rivero, CE; Sosa-Avila, LM | 1 |
Chaudhary, M; Sehgal, R; Shrivastava, SM; Varughese, L | 1 |
Cruz, OL; de Oliveira Penido, N; Inoue, DP; Testa, JR | 1 |
Bassetti, M; Repetto, E | 1 |
Alquezar, A; Castro, P; Codina, C; Delgado, E; Marco, F; Martí, S; Martínez, JA; Mensa, J; Nicolás, JM; Soriano, A; Torres, A; Trilla, A; Vila, J | 1 |
Hauber, HP; Mack, D; Pforte, A; Schulz, M; Schumacher, U; Zabel, P | 1 |
Micek, ST; Neuner, EA; Ritchie, DJ | 1 |
Deal, EN; Micek, ST; Reichley, RM; Ritchie, DJ | 1 |
Bou, G; Torres, E; Villanueva, R | 1 |
Alişkan, H; Güçlü, M; Husamettin, E; Serin, E; Yakar, T | 1 |
Eagye, KJ; Kuti, JL; Nicasio, AM; Nicolau, DP; Palter, M; Pepe, J; Shore, E | 1 |
Ge, Y; Livermore, DM; Mushtaq, S; Warner, M | 1 |
Ge, J; Giske, CG; Nordmann, P | 1 |
Ariza, J; Dominguez, MA; Juan, C; Moya, B; Oliver, A; Peña, C; Pujol, M; Suarez, C; Tubau, F | 1 |
Fraser, A; Leibovici, L; Paul, M; Yahav, D | 1 |
Boonkerd, N; Niumsup, PR; Pibalpakdi, P; Tiloklurs, M | 1 |
Albertí, S; Juan, C; Mulet, X; Oliver, A; Pérez, JL; Zamorano, L | 1 |
Abbanat, D; Bush, K; Fernandez, J; Flamm, RK; Hilliard, JJ; Melton, JL; Santoro, CM; Zhang, W | 1 |
De Luca, F; Docquier, JD; Ide, L; Nordmann, P; Poirel, L; Rossolini, GM; Verlinde, A | 1 |
Ge, Y; Juan, C; Oliver, A; Pérez, JL; Zamorano, L | 1 |
Cantón, R; Fernández-Olmos, A; Ge, Y; Juan, C; Oliver, A; Zamorano, L | 1 |
Bulik, CC; Crandon, JL; Kuti, JL; Nicolau, DP | 1 |
Kotsakis, SD; Legakis, NJ; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
Ge, Y; Juan, C; Moya, B; Oliver, A; Pérez, JL; Zamorano, L | 1 |
Doherty, JA; Khan, J; Kollef, MH; Micek, ST; Pervez, M; Reichley, RM; Welch, EC | 1 |
Cerceo, E; Lichaa, H; Rachoin, JS; Rajput, V; Surkis, W | 1 |
Ge, Y; Macià, MD; Mena, A; Mulet, X; Oliver, A; Pérez, JL; Riera, E | 1 |
Chong, Y; Ito, Y; Kamimura, T; Yakushiji, H | 1 |
Aoki, Y; Fukuoka, M; Magarifuchi, H; Nagasawa, Z; Nagata, M; Urakami, T | 1 |
Bivas, A; Fraser, A; Leibovici, L; Paul, M; Yahav, D | 1 |
Willcox, MD | 1 |
Davis, GA; Feola, DJ; Hayes, D; Kuhn, RJ; Murphy, BS | 1 |
Bosso, JA; Church, EC; Mauldin, PD | 1 |
Mercuri, LG; Psutka, D | 1 |
Campo Esquisabel, AB; Campo-Sosa, AO; Martínez-Martínez, L; Rodríguez, C; Rodríguez, MC | 1 |
Bordon, JM; Clark, RB; Karlowsky, JA; Master, RN; Ramirez, J | 1 |
Akhabue, E; Bilker, WB; Lautenbach, E; Synnestvedt, M; Weiner, MG | 1 |
Ozbilim, G; Ozbudak, IH; Ozbudak, O; Ozdem, S; Sahin, N; Turkay, C; Turkay, M | 1 |
Bahniuk, N; Bonomo, RA; Brown, D; Bulitta, JB; Defiglio, H; Drawz, SM; Drusano, GL; Fikes, S; Kulawy, R; Louie, A; Vanscoy, B | 1 |
Bulik, CC; Keel, RA; Nicolau, DP; Sutherland, CA; Tessier, PR | 1 |
Jardine, D; McNally, A; Pithie, A | 1 |
Alberti, S; Beceiro, A; Cabot, G; Juan, C; Moyá, B; Oliver, A; Zamorano, L | 1 |
Faoagali, J; Gallagher, JE; George, N; Gidding, HF; Ginn, AN; Iredell, JR; Lipman, J; O'Driscoll, JS; O'Toole, BI; Partridge, SR; Perri, RA; Wiklendt, AM | 1 |
Amador, G; Asehnoune, K; Boutoille, D; Broquet, A; Caillon, J; Desessard, C; Jacqueline, C; Le Mabecque, V; Potel, G; Roquilly, A | 1 |
Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT | 1 |
Andes, DR; Craig, WA | 1 |
Chanteux, H; Mingeot-Leclercq, MP; Servais, H; Tulkens, PM; Viaene, E | 1 |
Bonnet, R; Chanal, C; De Champs, C; Nordmann, P; Poirel, L; Sirot, D; Sirot, J | 1 |
Abou-Madi, N; Kern, TJ | 1 |
Matsuda, H; Miwa, H; Miyazaki, S; Tsuji, M | 1 |
Drusano, GL; Lomaestro, BM; Louie, A; Tam, VH | 1 |
Oishi, K | 1 |
Adriensen, B; Husson, MO; Loiez, C; Massoni-Cristante, S | 1 |
Kuwahara, S; Miwa, H; Shimada, J; Takema, M; Tsuji, M | 1 |
Ceran, N; Erdem, I; Kucukercan, M | 1 |
Keene, WE; Markum, AC; Samadpour, M | 1 |
Aoki, S; Gotoh, N; Hirakata, Y; Kamihira, S; Kohno, S; Kondoh, A; Miyazaki, Y; Tomono, K; Yamada, Y; Yanagihara, K | 1 |
Babalola, CP; Nicolau, DP; Nightingale, CH | 1 |
Bugnon, D; Caillon, J; Gras-Le Guen, C; Jacqueline, C; Kergueris, MF; Navas, D; Potel, G | 1 |
Cefalo, G; Massimino, M; Mazza, E; Scaramuzza, D; Spreafico, F | 1 |
Betsunoh, H; Hamasuna, R; Nagano, M; Osada, Y; Sueyoshi, T; Takehara, T; Tsukino, H; Yakushiji, K | 1 |
Adamis, T; Baziaka, F; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Koussoulas, V; Mouktaroudi, M; Perrea, D | 1 |
Arnal, JM; Berger, P; Franceschini, B; Gainnier, M; Michel, F; Papazian, L; Sainty, JM | 1 |
Ho, SW; Hsueh, PR; Teng, LJ; Tseng, SP | 1 |
Alvarez, A; Baquero, F; Cantón, R; Cobos, N; de Gracia, J; García-Quetglas, E; Gartner, S; Honorato, J; Oliver, A; Salcedo, A | 1 |
Araki-Sasaki, K; Asari, S; Matsumoto, K; Mutoh, K; Nishi, I; Takatsuka, H; Tanihara, H; Yonemura, N | 1 |
Rumbaugh, JA; Sinha, G; Spalding, C; Speedie, A; Venkatesan, A | 1 |
Dubovik, LG; Kolbatova, ES; Polikarpova, SV; Postnikov, SS; Semykin, SIu | 1 |
Koulenti, D; Rello, J | 1 |
Li, C; Nicolau, DP; Nightingale, CH; Ong, CT; Tessier, PR | 1 |
Bulitta, J; Kirkpatrick, CM; Lipman, J; Roos, JF | 1 |
Konkoly-Thege, M; Kuti, JL; Ludwig, E; Nicolau, DP | 1 |
Hatano, K; Ikeda, F; Nakai, T; Takeda, S; Wakai, Y | 1 |
Bertrand, X; Blanc, K; Hocquet, D; Monnet, DL; Muller, A; Plésiat, P; Talon, D | 1 |
Decorby, M; Hoban, DJ; Karlowsky, JA; Nichol, K; Walkty, A; Zhanel, GG | 1 |
Fujimura, N; Kurokawa, K; Uema, K; Yuasa, K | 1 |
Belohradsky, BH; Bruch, K; Geiss, D; Kafetzis, D; Marget, W; Peters, G | 1 |
Fujita, K; Sakata, H; Yoshioka, H | 1 |
Burdon, DW; Keighley, MR; Morris, DL; Young, D | 1 |
Barza, M; Murphy, TF | 1 |
Cherubin, CE; Corrado, ML; Landesman, SH | 1 |
Aguirre, M; Alés, JM; Torres, A; Vega, J | 1 |
Caparosa, R; Haverkos, HW; Kamerer, D; Yu, VL | 1 |
Johnson, CE; Pennington, JE; Platt, R | 1 |
Giger, DK; Goering, RV; Penn, RG; Preheim, LC; Sanders, CC | 1 |
Eaglstein, NF; Hernandez, AD; Marley, NF; Marley, WM; Rosenberg, EW | 1 |
Nishino, T; Saito, M; Shibata, K; Tanino, T | 1 |
Fitzpatrick, SB; Rosenstein, BJ | 1 |
Appleman, MD; Berne, TV; Chenella, FC; Gill, MA; Heseltine, PN; Kern, JW; Yellin, AE | 1 |
Gimbrère, JS; Muytjens, HL; van Dalen, R | 1 |
Eron, LJ; Goldenberg, RI; Hixon, DL; Park, CH; Poretz, DM | 1 |
Modai, J; Nevot, P; Philippon, A; Vittecoq, D | 1 |
Goodwin, CS | 1 |
Canton, P; Dureux, JB; Gérard, A; Roche, G; Weber, M | 1 |
Borderon, JC; Boulard, P; Despert, F; Grenier, B; Laugier, J; Santini, JJ | 1 |
Gérard, A; Paris, J; Paris, JC | 1 |
Slack, MP | 1 |
Neu, HC; Prince, AS | 1 |
Crawford, ED; Plimpton, HW | 1 |
Agostini, M; Barlocco, G; Bonomi, U; Borgo, G; Bozzino, L; Cabrini, G; Cappelletti, LM; Castellani, L; Conforti, M; Mastella, G | 1 |
Guggenbichler, JP | 1 |
Stille, W | 1 |
Baumgärtner, M | 1 |
Meulemans, A; Modai, J; Vittecoq, D | 1 |
Assael, BM; Brienza, A; Crossignani, RM; Giunta, A; Granata, F; Lodi, G; Padoan, R; Passarella, E; Vallaperta, PA; Xerri, L | 1 |
Davies, BI; Maesen, FP; van Noord, JA | 1 |
Bint, AJ; Constable, FL; Constable, J; Patton, KR | 1 |
Abbas, AM; Cantor, AM; Haste, AR; Jones, RB; Newby, D; Rigby, CC; Taylor, MC | 1 |
Butzler, JP; Clumeck, N; Dab, I; Gordts, B; Jaspar, N; Van Laethem, Y | 1 |
Fliegelman, RM; Karakusis, PH; Levin, S; Pottage, JC; Trenholme, GM | 1 |
Dutoy, JP; Wauters, G | 1 |
Alfredson, H; Ericsson, A; Malmborg, AS; Strandvik, B | 1 |
Blumer, JL; Kercsmar, CM; Murdell, D; Myers, CM; Reed, MD; Stern, RC | 1 |
Christensen, HO; Høiby, N; Koch, C; Møller, AF; Møller, S; Permin, H | 1 |
Dodge, J; Goodchild, M; Ingram, P; Zamiri, I | 1 |
Fleming, PC; Gold, R; Isles, A; Jin, E; Levison, H | 1 |
Connor, PJ; David, TJ; Phillips, BM | 1 |
Assael, BM; Boccazzi, A; Caccamo, ML; Giunta, A; Marini, A; Padoan, R; Rusconi, F; Sereni, F | 1 |
Kaar, ML; Lautala, P; Vare, M; Vuorinen, O | 1 |
Cullen, RT; Govan, J; Ingram, TM; McCrae, WM; Raeburn, JA | 1 |
Nakayama, I | 1 |
Ingham, HR; Selkon, JB; Snow, MH; Wardle, JK | 1 |
Foord, RD | 1 |
Cox, CE | 1 |
Childs, SJ; Douthit, MB; Gentry, LO; Madsen, PO | 1 |
Kawamura, N | 1 |
Allan, SG; Glover, SC; Hadley, KM; Han, K; Ingram, PM; Murdoch, JM; Reid, TM; Smith, CC | 1 |
Butzler, JP; Clumeck, N; Gordts, B; Jaspar, N; Van Laethem, Y | 1 |
Choudhary, BP; Elliott, TS; Ispahani, P | 1 |
Assael, BM; Florioli, A; Rusconi, F; Zaffaroni, G | 1 |
Kawamura, N; Kishi, Y; Kumamoto, Y; Miyamoto, S; Niijima, T; Nishimura, Y; Ohkoshi, M; Okada, K; Saito, I; Yuge, J | 1 |
Bauernfeind, A; Blaser, J; Lüthy, R; Vogt, M | 1 |
El-Sadr, W; Maslow, MJ; Pollock, AA; Press, RA; Rahal, JJ; Richmond, AS; Rosenberg, A; Silverman, D; Simberkoff, MS | 1 |
Gabler-Sandberger, E | 1 |
Eykyn, S; King, A; Phillips, I; Shannon, K | 1 |
Heilesen, AM; Høiby, N; Koch, C; Permin, H | 1 |
Neu, HC; Scully, BE | 1 |
Cabezudo, I; Guenthner, SH; Selden, RF; Thompson, RL; Wenzel, RP | 1 |
Drake, TA; Hackbarth, CJ; Rusnak, MG; Sande, MA | 1 |
Cattin, J; Dupont, MJ; Jouvenot, M; Michel-Briand, Y | 1 |
Harper, PB | 1 |
Gold, R; Isles, AF; Leeder, JS; MacLeod, SM; Spino, M; Tesoro, AM | 1 |
Nishimura, T; Takashima, T | 1 |
Ohkoshi, M | 1 |
Modde, H | 1 |
Yu, VL | 1 |
Carson, M; McDonald, M; Miles, H | 1 |
Busuttil, RW; Kurtz, TO; Winston, DJ; Young, LS | 1 |
Hajsig, D; Skalova, R; Smerdel, S | 1 |
Endo, K; Imamura, K; Kumasaka, Y; Masaki, N; Matsuhashi, A; Nakahata, H; Narita, S; Sasaki, K; Takebe, K; Tamura, T | 1 |
Kemp, R | 1 |
McGregor, DN; Price, KE | 1 |
Flensborg, EW; Høiby, N; Szaff, M | 1 |
Futaki, T; Oda, M | 1 |
Bergogne-Berezin, E; Berthelot, G; Even, P; Kafe, H; Safran, D | 1 |
McGinness, L; Sherwood, CF; Vanore, JV | 1 |
Bouvet, E; Regnier, B; Schlemmer, B; Vachon, F; Witchitz, J; Witchitz, S | 1 |
Baba, S; Boku, S; Chikuie, D; Fujii, K; Goto, K; Harada, Y; Hirata, K; Inafuku, S; Maruo, T; Maruyama, H; Miyake, H; Miyamae, M; Miyano, K; Murata, K; Nakai, Y; Nomura, T; Ogawa, A; Ohashi, Y; Ohta, F; Saito, N; Sakai, M; Sasaki, T; Sato, K; Sugiyama, M; Takimoto, I; Ueda, T; Yajin, K; Yamashita, K; Yonei, K; Yoshizumi, T | 1 |
Rozhavin, MA | 1 |
Dreznik, Z; Mark, Z; Rubinstein, E | 1 |
Balmayer, B; Bertrand, A; Despaux, E; Janbon, F; Jonquet, O; Lepeu, G; Santoni, A | 1 |
Jensen, K; Koch, C; Møller, NE; Vesterhauge, S | 1 |
Abergel, P; Reignier, B; Vachon, F; Witchitz, J; Witchitz, S; Wolff, M | 1 |
Kasanen, A; Nikoskelainen, J; Saarimaa, H; Toivanen, P | 1 |
Hirooka, J; Hori, M; Kitani, N; Kurosu, Y; Nishiyama, H; Sugita, M; Takahashi, T; Toyonaga, Y; Yokoi, S | 1 |
Hoshina, H; Ichihashi, H; Yanagisawa, K | 1 |
Iwai, N; Mizoguchi, F; Nakamura, H; Sasaki, A; Taneda, Y | 1 |
Hiromatsu, K; Nishimura, T; Tabuki, K; Takashima, T | 1 |
Cho, N; Deguchi, K; Doko, F; Domon, H; Endo, K; Fugono, T; Fukae, T; Fukunaga, K; Goto, T; Hagiwara, K; Hanaoka, S; Hasegawa, Y; Hayasaki, M; Hayashi, S; Hirabayashi, K; Hogaki, M; Ichinohe, K; Ihara, Y; Iwasa, S; Kaku, R; Kodama, M; Kohlita, Y; Kubota, K; Kunii, K; Kusaba, N; Kutsuzawa, T; Matsuda, S; Mizuta, E; Motomura, R; Muronosono, E; Nakamura, H; Ninomiya, K; Noda, K; Ohbayashi, F; Osada, H; Seiga, K; Shiojima, Y; Sumiyoshi, Y; Tabei, T; Takase, Z; Tsuruta, S; Wagatsuma, T; Yabuki, A; Yamabe, T; Yamada, F; Yamada, Y; Yorozu, Y | 1 |
Preheim, LC; Sanders, WE | 1 |
Green, RA | 1 |
Haruta, T; Kobayashi, Y | 1 |
Davies, AJ | 1 |
Donta, ST; Villar, LA | 1 |
Ortel, S | 1 |
Aoyama, R; Izumi, Y; Kakizaki, Y; Kuronuma, T; Nomura, Y; Ohnishi, A | 1 |
Fujii, R; Hashimoto, G; Hashira, S; Hiraiwa, M; Koike, Y; Meguro, H; Ozawa, S; Takahashi, A | 1 |
Chikaoka, H; Hirama, Y; Nakazawa, S; Narita, A; Niino, K; Sato, H; Tazoe, K | 1 |
Akita, H; Hattori, H; Hotta, M; Ichihashi, Y; Iwasaki, Y; Iwata, S; Iwata, T; Jozaki, K; Kanemitsu, T; Nanri, S; Osano, M; Sunagawa, K; Yamashita, N | 1 |
Hachimori, K; Minamitani, M; Suzuki, M | 1 |
Fuke, H; Okamoto, K; Ozaki, H; Shino, K; Watanabe, K | 1 |
Weinstein, AJ | 1 |
Makishima, K; Masuda, T; Nakashima, T; So, N; Watanabe, H | 1 |
Deguchi, K; Fujimaki, Y; Kawamura, S; Sugita, R | 1 |
Matsuoka, H; Mizukoshi, F; Mizukoshi, O; Nakamura, A; Nishimura, T; Okawa, K; Saito, A; Saito, H; Sato, F; Tachibana, M; Takenouchi, S; Yanohara, K | 1 |
Kannae, S; Makishima, K; Murata, Y; Nakashima, T; Toriya, Y; Watanabe, H | 1 |
Kojima, S; Komatsuzaki, A; Osafune, H; Satake, K; Unoki, S | 1 |
Fukuda, K; Furuta, S; Iida, F; Ogawa, K; Ohhori, Y; Ohyama, M | 1 |
Ferguson, M; Sleigh, JD; Wright, PA | 1 |
Hajiro, A; Hamagaki, H; Henmi, K; Hikasa, Y; Kikuchi, S; Kobayashi, M; Maki, Y; Masuda, K; Matsukawa, Y; Mukaihara, S; Nakajima, K; Nio, Y; Sugimoto, S; Takenada, M; Tanimura, H; Usui, H; Yasumoto, H | 1 |
Dusehu, E; Veyssier, P | 1 |
Rosenkranz, A | 1 |
Shannon, KP | 1 |
Cappelletty, DM; Kang, SL; Palmer, SM; Rybak, MJ | 1 |
Hikida, M; Kawashima, K; Mitsuhashi, S; Nishiki, K; Yamazaki, Y; Yoshida, M | 1 |
Anderhuber, W; Köle, W; Walch, C | 1 |
Munakata, K; Satoh, M; Takeuchi, H; Yoshida, O | 3 |
Carbon, C; Fantin, B; Farinotti, R; Thabaut, A | 1 |
Fung-Tomc, J; Gradelski, E; Huczko, E; Kessler, RE | 1 |
Klastersky, J | 1 |
Hayashi, R; Iizawa, Y; Imada, A; Iwahi, T; Okonogi, K; Yamazaki, T | 1 |
Hasegawa, T; Hirano, M; Imae, K; Imura, S; Kamachi, H; Kamei, H; Okita, T | 1 |
Byrne, S; Connor, P; David, TJ; Dodd, M; Doughty, I; Jenney, M; Maddison, J; Webb, AK | 1 |
Brouqui, P; Drancourt, M; Raoult, D; Rousseau, MC; Stein, A | 1 |
Klepser, ME; Nicolau, DP; Nightingale, CH; Patel, KB; Quintiliani, R | 1 |
Ishibashi, K; Ogihara, M; Shigeta, S; Shiraiwa, Y; Yamaguchi, O | 1 |
Furuya, N; Hirakata, Y; Matsumoto, T; Tateda, K; Yamaguchi, K | 1 |
Geletko, SM; Melbourne, KM; Mikolich, DJ | 1 |
Lee, CP; Lim, AS; Tan, DT | 1 |
Calegari, L; Carmona, C; Gezuele, E; Torres, E | 1 |
Banas, B; Combe, C; Manns, MP; Schlöndorff, D; Zoller, WG | 1 |
Arenas, JI; Arriola, JA; Gil, I; Montalvo, II | 1 |
Beauchamp, D; Bergeron, MG; Morin, NJ; Simard, M; Turcotte, A | 1 |
Okonogi, K; Tsuchimori, N; Yamazaki, T | 1 |
Adachi, Y; Fuse, A; Hashizume, T; Kato, E; Nagano, R; Nakagawa, S; Ohtake, N; Okamoto, O; Shibata, K | 1 |
Alfaro, DV; Barton, CP; Beverly, DT; Brucker, AJ; Hudson, SJ; Kasowski, EJ; King, LP; Lopez, JD | 1 |
Helm, CJ; Holland, GN; Maloney, RK; Mondino, BJ; Webster, RG | 1 |
Farca, AM; Maffei, F; Piromalli, G; Re, G | 1 |
Daschner, FD; Engels, I; Lemmen, SW | 1 |
D'Amico, DT; Ng, EW | 1 |
Battles, A; Liu, QF; Liu, W; Louie, A; Miller, DA; Miller, MH; Sucke, AC | 1 |
Ghani, M; Soothill, JS | 1 |
Donzis, PB | 1 |
Akbal, H; Coşkunkan, F; Ozturk, R; Saribas, S; Tansel, O; Vahaboglu, H | 1 |
Bailly, P; Mulin, B; Rouget, C; Talon, D; Thouverez, M; Viel, JF | 1 |
Breysem, L; De Boeck, K | 1 |
Belli, DC; Dayer Pastore, F; Dudez, TS; Rochat, T; Schlegel-Haueter, SE; Suter, S | 1 |
Horii, T; Ichiyama, S; Kobayashi, M; Ohta, M; Sato, K | 1 |
Barberán, J; Campos, A; García, MC; Khorrami, S | 1 |
Arrouet-Lagande, C; Ategbo, S; Deschildre, A; Druon, D; Husson, MO; Launay, V; Loeuille, GA; Sardet, A; Turck, D; Vic, P | 1 |
Akbal, H; Ozturk, R; Saribaş, S; Vahaboglu, H; Yucel, A | 1 |
Ategbo, S; Canis, F; Husson, MO; Trivier, D; Turck, D; Vic, P | 1 |
Burns, JM; Dominick, D; Freeman, K; Horn, D; Lim, M; Mariano, N; Marks, S; Maurer, J; Rahal, JJ; Segal-Maurer, S; Urban, C | 1 |
Biedenbach, DJ; Doern, GV; Jones, RN; Marshall, SA; Pfaller, MA | 1 |
Bhutta, ZA; Ladhani, S | 1 |
Blondeau, JM; Borsos, S; Misfeldt, C; Suter, ME | 1 |
Berger, D; Heinemann, M; Möricke, A; Seidelmann, M; Trautmann, M; Zick, R | 1 |
Blackshear, P; Branch, S; Chernoff, N; Hall, L | 1 |
Ikeda, N; Matsuyama, N; Watanabe, K | 1 |
Avisar, R; Gaton, D; Kremer, I; Robinson, A; Savir, H; Yassur, Y | 1 |
Chen, SC; Fung, CP; Lee, N; Lee, SC; Liu, PY; See, LC; Shieh, WB; Wang, TC | 1 |
Bowler, SD; McCormack, JG; Wolter, JM | 1 |
Asumang, A; Dryden, M; Goldsmith, AL | 1 |
Endo, K; Itabashi, S; Kano, M; Sasaki, H | 1 |
Lipener, C; Ribeiro, AL | 1 |
Po, AL; Scott, EM; Tariq, VN; Wu, YL | 1 |
Elhelali, N; Jacolot, A; Laurent, F; Léotard, S; Mimoz, O; Nordmann, P; Petitjean, O; Samii, K | 1 |
Banevicius, MA; Nicolau, DP; Nightingale, CH; Quintiliani, R | 1 |
Banevicius, MA; Bui, KQ; Nicolau, DP; Nightingale, CH; Quintiliani, R | 1 |
Gagnon, L; Huletsky, A; Langaee, TY | 1 |
Burgos, A; Campillos, P; Gonzalo, N; López-Lozano, JM; Monnet, DL; Saez, M; Yagüe, A | 1 |
D'Errico, G; Esposito, S; Ianniello, F; Noviello, S | 1 |
Aebischer, CC; Bettinelli, A; Bianchetti, MG; Truttmann, AC; von Vigier, RO; Wermuth, B; Zindler-Schmocker, K | 1 |
Buyan-Dent, L; Dixit, S; Kurle, P; Sheth, RD | 1 |
Collins, J; Disney, A; Harris, DC; Ibels, LS; Murphy, BF; Rigby, R; Saltissi, D; Suranyi, M | 1 |
Bucaneve, G; Del Favero, A; Dionisi, MS; Furno, P; Menichetti, F | 1 |
Kawano, C; Kirikae, T; Muroi, K; Ozawa, K; Yozhizawa, M | 1 |
Akiyama, M; Matsumoto, K; Oishi, K; Pollack, M; Tao, M | 1 |
Fialkowski, JP; Lautzenhiser, SJ; Moore, KW; Rosin, E; Trepanier, LA | 1 |
Bébéar, JP; Darrouzet, V; Duclos, JY; Guyot, M; Martel, J | 1 |
Felts, AG; Grainger, DW; Slunt, JB | 1 |
Bagge, N; Ciofu, O; Høiby, N; Skovgaard, LT | 1 |
Feldman, DP; Picerno, NA; Porubsky, ES | 1 |
Bélaz, N; Bille, J; Decosterd, LA; Pilet, M; Rappaz, I; Roulet, M | 1 |
Iizawa, Y; Ishikawa, T; Miyake, A; Okonogi, K | 1 |
Iizawa, Y; Ishikawa, T; Kamiyama, K; Matsunaga, N; Miyake, A; Okonogi, K; Tawada, H | 1 |
Comes, G; Harms, K; Paul, K; Posselt, HG; Ratjen, F; Wagner, TO | 1 |
Iwatsubo, E; Kawakami, Y; Manabe, N; Matsumoto, T; Takahashi, K | 1 |
Amicosante, G; Lombardi, G; Luzzaro, F; Mantengoli, E; Orlandi, V; Orsatti, A; Perilli, M; Rossolini, GM; Toniolo, A | 1 |
Baghurst, PA; Colebatch, KA; Coulthard, KP; Hansman, D; Holmes, M; Jarvinen, A; Kennedy, D; Linke, RJ; Martin, A; Martin, AJ; Master, V; Onishko, CR; Parsons, DW; Roberts, GW; Roberts, ME | 1 |
Andre, C; Arpin, C; Dubois, V; Frigo, C; Melon, B; Melon, M; Quentin, C | 1 |
Chow, KM; Leung, CB; Li, PK; Lui, SF; Szeto, CC; Wang, AY; Wong, TY; Wu, AK | 1 |
Mayer, I; Nagy, E | 1 |
Cassetta, MI; Conti, S; Fallani, S; Novelli, A | 1 |
Carmeli, Y; Harbarth, S; Harris, AD; Samore, MH | 1 |
Smyth, A; Walters, S | 1 |
Cavallo, JD; Fabre, R; Fourticq-Esqueöute, A; Leblanc, F | 1 |
Wareham, DW | 1 |
Leblanc, PE; Leotard, S; Nordmann, P; Poirel, L | 1 |
Higashiyama, Y; Hirakata, Y; Kadota, JI; Kakeya, H; Kaneko, Y; Kohno, S; Kuroki, M; Miyazaki, Y; Ohi, H; Tomono, K; Yanagihara, K | 1 |
Fennewald, M; Girlich, D; Leelaporn, A; Naas, T; Nordmann, P; Poirel, L | 1 |
Ambrose, PG; Garvey, MJ; Jones, RN; Owens, RC | 1 |
Burns, JL | 1 |
Beach, ML; Biedenbach, DJ; Jones, RN; Kirby, JT; Pfaller, MA | 1 |
Stratford, BC | 1 |
Adam, D | 1 |
Chico Rizzo, E | 1 |
Kondo, M; Tsuchiya, K | 1 |
Balcke, P; Graninger, W; Kopsa, H; Pils, P; Schimatzek, A; Schmidt, P; Zazgornik, J | 1 |
Ahronheim, GA | 1 |
Hopefl, AW | 1 |
Naumann, P; Rosin, H | 2 |
Fowst, G; Nessi, R | 1 |
Hitzenberger, G | 1 |
Hutschenreiter, G; Klippel, KF | 1 |
Kondo, M; Nagatomo, H; Tsuchiya, K | 1 |
Levine, LR; McCain, E | 1 |
Ellis, LF; Herron, DK; Preston, DA; Schlegel, RA; Simmons, LK | 1 |
Donovan, TL; Gordon, RO; Nagel, DA | 1 |
Asmal, AC; Bima, B; Leary, WP; Lockett, CJ | 1 |
Imai, K; Kamiya, T; Koie, K; Ono, R; Yoshikawa, H | 1 |
Giamarellou, H | 1 |
Bailey, EM; Lamp, KC; McGrath, BJ; Rybak, MJ | 1 |
Pechère, JC; Vladoianu, IR | 1 |
Tabuki, K | 1 |
Abe, S | 1 |
Pizzo, P | 1 |
Baltch, AL; Franke, M; Michelsen, P; Ritz, WJ; Singh, J; Smith, RP; Valdes, JM; Williams, S | 1 |
Atsumi, K; Inouye, S; Iwamatsu, K; Kondo, S; Ogino, H; Sakagami, K; Shibahara, S; Tsuruoka, T; Yoshida, T | 1 |
Jiang, XF | 1 |
Inouye, S; Iwamatsu, K; Katano, K; Kondo, S; Nakabayashi, S; Ogino, H; Tsuruoka, T; Yoshida, T | 1 |
Inouye, S; Iwamatsu, K; Katano, K; Kondo, S; Nakabayashi, S; Ogino, H; Shibahara, S; Tsuruoka, T; Yoshida, T | 1 |
Arai, S; Hayashi, S; Kobayashi, S | 1 |
Yu, GH; Yuan, JP; Zhong, NS | 1 |
Ukhin, AV | 1 |
Inouye, S; Kondo, S; Kudo, T; Murai, Y; Okonogi, T; Shibahara, S; Yoshida, T | 1 |
Gadebusch, HH; Gilfillan, EC; Pelak, BA; Valiant, ME | 1 |
DeOrio, FJ; Dougherty, TJ; Fung-Tomc, J; Kessler, RE; Simich-Jacobson, V | 1 |
Asahi, Y; Hashizume, T; Matsuda, K; Nakagawa, S; Ohtake, N; Sanada, M; Tanaka, N; Ushijima, R | 1 |
Benecke, JE | 1 |
Abruzzo, GK; Bland, JA; Fromtling, RA; Gadebusch, HH; Gilfillan, EC; Hadley, SK; Pelak, BA; Weissberger, BA | 1 |
Donowitz, GR | 1 |
Ingerman, MJ; Levison, ME; Pitsakis, PG; Rosenberg, AF | 1 |
Borner, K; Brückner, O; Collmann, H; Hoffmann, HG; Trautmann, M | 1 |
Burdeska, A; Costa, E; Follath, F; Frei, R; Meyer, J; Thommen, A | 1 |
Blumer, JL; Myers, CM; Reed, MD; Stern, RC; Yamashita, TS | 1 |
Bustamante, CI; Johnson, DE; Wade, JC | 1 |
Nonomura, M; Yoshida, O | 1 |
Fu, KP; Gregory, FJ; Hetzel, N; Hung, PP | 2 |
Badenoch, PR; Coster, DJ; McDonald, PJ | 1 |
Fu, KP; Gregory, JF; Hung, PP; Vince, T | 1 |
Badenoch, PR; Coster, DJ; Hay, GJ; McDonald, PJ | 1 |
Buxton, TB; Rissing, JP; Shockley, RK; Yannis, RA | 1 |
Guenthner, SH; Norris, SM; Wenzel, RP | 1 |
Bryskier, A; Chantot, JF | 1 |
Chiang, ST; Fu, KP; Gregory, FJ; Hung, PP; McCloud, S; Vince, T | 1 |
Young, LS | 1 |
Bodey, GP; Horikoshi, N; Rodriguez, V; Valdivieso, M | 1 |
Schwab, W | 1 |
Plotkin, SA | 1 |
Neff, G; Plaue, R | 1 |
Guenther, M; Mössner, G | 1 |
Lang, GR; Levin, S | 1 |
Boxerbaum, B | 1 |
Eudy, WW | 1 |
Ellorhaoui, M; Tauchnitz, C | 1 |
Haschek, H; Porpaczy, P; Schmidt, W | 1 |
Minakawa, M; Miyoshi, K; Seika, K; Sugiyama, Y; Yamaji, K | 1 |
Finsterbush, A; Weinberg, H | 1 |
Hodson, AH; Holloway, WJ | 1 |
Marr, JJ | 1 |
Lüthy, R; Siegenthaler, G; Siegenthaler, W; Vetter, H | 1 |
Bullock, WE | 1 |
Kanda, M; Maekawa, N; Nakanishi, M; Tsukuma, S; Yamashita, M | 1 |
Geddes, AM; Munro, JF; Murdoch, JM | 1 |
52 review(s) available for cephalosporin c and Infections, Pseudomonas
Article | Year |
---|---|
Ceftolozane-tazobactam: When, how and why using it?
Topics: Anti-Bacterial Agents; Cephalosporins; Colistin; Humans; Intraabdominal Infections; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Ceftolozane-tazobactam in nosocomial pneumonia.
Topics: Adult; Cephalosporins; Cross Infection; Healthcare-Associated Pneumonia; Humans; Pseudomonas Infections; Tazobactam | 2022 |
Treatment of carbapenem-resistant
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2022 |
MDR/XDR/PDR or DTR? Which definition best fits the resistance profile of Pseudomonas aeruginosa?
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Seizures | 2023 |
Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Intraabdominal Infections; Observational Studies as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam; Urinary Tract Infections | 2020 |
Approach to the Treatment of Patients with Serious Multidrug-Resistant Pseudomonas aeruginosa Infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Use of continuous-infusion ceftolozane/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature.
Topics: Adult; Aged; Anti-Bacterial Agents; Area Under Curve; beta-Lactamase Inhibitors; Cephalosporins; Drug Combinations; Drug Monitoring; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Young Adult | 2020 |
Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Current choices of antibiotic treatment for Pseudomonas aeruginosa infections.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; beta-Lactamase Inhibitors; beta-Lactams; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Phage Therapy; Pseudomonas aeruginosa; Pseudomonas Infections | 2020 |
A Critical Evaluation of Newer β-Lactam Antibiotics for Treatment of
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2021 |
Real-world use of ceftolozane/tazobactam: a systematic literature review.
Topics: Cephalosporins; Comorbidity; Critical Illness; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Urinary Tract Infections | 2021 |
New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Cephalosporins; Child; Cystic Fibrosis; Drug Therapy, Combination; Humans; Injections, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiratory Tract Infections | 2021 |
Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Critical Illness; Drug Combinations; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2021 |
Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Critical Illness; Disease Management; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Intensive Care Units; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Tazobactam; Treatment Outcome | 2017 |
Ceftolozane/tazobactam: place in therapy.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Intraabdominal Infections; Off-Label Use; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2018 |
Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis.
Topics: Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Prognosis; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2018 |
Risk factors for hospitalized patients with resistant or multidrug-resistant
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cephalosporins; Critical Care; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Humans; Intensive Care Units; Male; Middle Aged; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Risk Factors; Vancomycin | 2018 |
The ideal patient profile for new beta-lactam/beta-lactamase inhibitors.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenem-Resistant Enterobacteriaceae; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Liver abscess caused by multidrug-resistant Pseudomonas aeruginosa treated with colistin; a case report and review of the literature.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Cholangitis; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Kidney; Liver Abscess, Pyogenic; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2013 |
Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Drug Resistance, Bacterial; Humans; Intraabdominal Infections; Mice; Penicillanic Acid; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2015 |
Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Cephalosporins; Cystic Fibrosis; Drug Therapy, Combination; Humans; Injections, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiratory Tract Infections | 2016 |
[Diagnostic and therapeutic management of Gram-negative infections].
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Cross Infection; Disease Management; Drug Resistance, Multiple, Bacterial; Drug Synergism; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Italy; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
New antibiotics for healthcare-associated pneumonia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Ceftaroline; Cephalosporins; Cross Infection; Doripenem; Glycopeptides; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Pseudomonas Infections; Pyrimidines; Staphylococcal Infections; Teicoplanin | 2009 |
Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Fever; Humans; Imipenem; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Thienamycins | 2010 |
Review of resistance of ocular isolates of Pseudomonas aeruginosa and staphylococci from keratitis to ciprofloxacin, gentamicin and cephalosporins.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Ciprofloxacin; Drug Resistance, Bacterial; Drug Therapy, Combination; Gentamicins; Humans; Keratitis; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus | 2011 |
Eradication of Pseudomonas aeruginosa in an adult patient with cystic fibrosis.
Topics: Adult; Anti-Infective Agents; Cefepime; Cephalosporins; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2011 |
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Cefepime; Ceftazidime; Cephalosporins; Clavulanic Acids; Cystic Fibrosis; Disease Progression; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin | 2013 |
[Pseudomonas aeruginosa infection].
Topics: 4-Quinolones; Anti-Infective Agents; Bacteremia; Biofilms; Carbapenems; Cephalosporins; Fimbriae, Bacterial; Flagella; Humans; Immunocompromised Host; Multidrug Resistance-Associated Proteins; Prognosis; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Sepsis; Trans-Activators; Urinary Tract Infections | 2003 |
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bronchopneumonia; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Inhalation; Injections, Intravenous; Lung Diseases; Pneumonia, Bacterial; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2005 |
Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care.
Topics: Acinetobacter Infections; Administration, Inhalation; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cross Infection; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Methicillin Resistance; Pneumonia, Bacterial; Pneumonia, Staphylococcal; Practice Guidelines as Topic; Pseudomonas Infections; Respiration, Artificial; Vancomycin | 2006 |
Antipseudomonal beta-lactams.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefoperazone; Cefotaxime; Cefsulodin; Ceftazidime; Ceftriaxone; Cephalosporins; Cephamycins; Drug Stability; Lactams; Moxalactam; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1981 |
[Drug resistance of bacteria--the current status and future prospect. 5. Pseudomonas aeruginosa].
Topics: Adolescent; Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Humans; Infant; Penicillin Resistance; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; R Factors | 1984 |
[Antipseudomonal activities of new cephem antibiotics].
Topics: Cephalosporins; Drug Resistance, Microbial; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship; Urinary Tract Infections | 1984 |
[Modern aspects of the treatment of Pseudomonas aeruginosa infection].
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Drug Synergism; Humans; Immunotherapy; Penicillin Resistance; Penicillins; Plant Extracts; Pseudomonas aeruginosa; Pseudomonas Infections; Virulence | 1980 |
[Prospects of antibiotic treatment in pediatric field].
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Meningitis; Pneumonia; Pseudomonas Infections; Whooping Cough | 1981 |
Combination intravenous ceftazidime and aminoglycosides in the treatment of pseudomonal scleritis.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoglycosides; Ceftazidime; Cephalosporins; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; Ophthalmic Solutions; Pseudomonas aeruginosa; Pseudomonas Infections; Sclera; Scleritis; Visual Acuity | 1997 |
[Pseudomonas aeruginosa pneumonia].
Topics: Cefoperazone; Cephalosporins; Diagnosis, Differential; Humans; Immunocompromised Host; Penicillins; Piperacillin; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections | 1999 |
Ceftriaxone versus beta-lactams with antipseudomonal activity for empirical, combined antibiotic therapy in febrile neutropenia: a meta-analysis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ceftriaxone; Cephalosporins; Drug Therapy, Combination; Fever; Humans; Middle Aged; Mortality; Neutropenia; Odds Ratio; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2000 |
Cephalosporins: a pharmacological update.
Topics: Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2000 |
Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cefepime; Cephalosporins; Clinical Trials as Topic; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2002 |
Empiric therapy of febrile granulocytopenic patients.
Topics: Agranulocytosis; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Blood Transfusion; Cephalosporins; Drug Therapy, Combination; Gentamicins; Granulocytes; Humans; Klebsiella Infections; Neoplasms; Penicillins; Pseudomonas Infections; Staphylococcal Infections; Tobramycin | 1979 |
Clinical use of rifampicin in combination for non-mycobacterial infections: a survey of published evidence.
Topics: Amphotericin B; Cephalosporins; Chloramphenicol; Colistin; Drug Therapy, Combination; Endocarditis, Bacterial; Erythromycin; Gentamicins; Humans; Kanamycin; Lincomycin; Mycoses; Nalidixic Acid; Penicillins; Pseudomonas Infections; Respiratory Tract Infections; Rifampin; Staphylococcal Infections; Sulfamethoxazole; Tetracyclines; Trimethoprim; Urinary Tract Infections; Vancomycin | 1979 |
Malignant otitis externa: the therapeutic evolution of a lethal infection.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Fluoroquinolones; Humans; Otitis Externa; Pseudomonas Infections | 1992 |
Use of third-generation cephalosporins. Pseudomonas.
Topics: Ceftriaxone; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 1991 |
Third generation cephalosporins.
Topics: Bacteria; Cephalosporins; Cross Infection; Humans; Meningitis; Pseudomonas Infections; Structure-Activity Relationship | 1989 |
Cephalosporin therapeutics in cystic fibrosis.
Topics: Cefsulodin; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Cystic Fibrosis; Humans; Kinetics; Lung Diseases; Pseudomonas Infections; Structure-Activity Relationship | 1986 |
Monotherapy for empiric treatment of fever in granulocytopenic cancer patients.
Topics: Agranulocytosis; Animals; Anti-Bacterial Agents; Bacterial Infections; Blood Bactericidal Activity; Cephalosporins; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Fever; Gram-Negative Bacteria; Humans; Neoplasms; Penicillins; Pseudomonas Infections; Sepsis; Thienamycins | 1986 |
[Chemotherapy of urinary tract infections caused by Pseudomonas].
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Humans; Penicillins; Pseudomonas; Pseudomonas Infections; Urinary Tract Infections | 1986 |
[Sulfonamide and antibiotic usage in otolaryngology (author's transl)].
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Child; Chloramphenicol; Erythromycin; Escherichia coli Infections; Gentamicins; Humans; Infant; Klebsiella Infections; Microbial Sensitivity Tests; Neomycin; Otorhinolaryngologic Diseases; Penicillins; Pneumococcal Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Streptococcal Infections; Streptomycin; Sulfonamides; Tetracycline; Tracheoesophageal Fistula | 1974 |
Diagnosis and treatment of urinary tract infections.
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Bacteriuria; Cephalosporins; Chloramphenicol; Culture Media; Cycloserine; Cystitis; Erythromycin; Escherichia coli Infections; Gentamicins; Hemagglutination Tests; Humans; Kanamycin; Methenamine; Methods; Nalidixic Acid; Nitrofurantoin; Penicillins; Polymyxins; Pseudomonas Infections; Pyelonephritis; Rifampin; Streptomycin; Sulfonamides; Tetracycline; Trimethoprim; Urinary Tract Infections | 1971 |
[Clinical picture and antibiotic therapy of bacterial septicemias in internal medicine].
Topics: Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Chloramphenicol; Drug Combinations; Endocarditis, Bacterial; Enterobacter; Escherichia coli Infections; Germany, West; Humans; Klebsiella Infections; Penicillins; Proteus Infections; Pseudomonas Infections; Sepsis; Staphylococcal Infections | 1971 |
39 trial(s) available for cephalosporin c and Infections, Pseudomonas
Article | Year |
---|---|
Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Genomics; Humans; Intensive Care Units; Microbial Sensitivity Tests; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections | 2022 |
Which trial do we need? How to treat Pseudomonas aeruginosa bacteraemia-proposal for an umbrella randomized controlled trial.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftazidime; Cephalosporins; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections | 2023 |
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cephalosporins; DNA, Bacterial; Double-Blind Method; Drug Resistance, Bacterial; Healthcare-Associated Pneumonia; Humans; Meropenem; Multicenter Studies as Topic; Multilocus Sequence Typing; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Tazobactam; Treatment Outcome | 2021 |
Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Cefepime; Cephalosporins; Dose-Response Relationship, Drug; Female; Hospitals; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Treatment Outcome | 2017 |
Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
Topics: Acute Disease; Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Female; Humans; Infusions, Intravenous; Lung; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Patient Safety; Penicillanic Acid; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Tazobactam | 2016 |
Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients.
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Cefepime; Cephalosporins; Cross Infection; Drug Combinations; Female; Humans; Injections, Intravenous; Male; Middle Aged; Pneumonia, Bacterial; Pseudomonas Infections; Treatment Outcome | 2008 |
Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
Topics: Administration, Inhalation; Adult; Aminoglycosides; C-Reactive Protein; Cell Count; Cephalosporins; Cystic Fibrosis; Drug Therapy, Combination; Female; Fucose; Galactose; Gene Expression; Humans; Immunoglobulin Isotypes; Leukocytes, Mononuclear; Liver Function Tests; Male; Neutrophils; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Sputum; Treatment Outcome; Tumor Necrosis Factor-alpha | 2008 |
Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Topics: Anti-Bacterial Agents; Bacteremia; Cefepime; Cephalosporins; Citrobacter freundii; Enterobacter; Enterobacteriaceae Infections; Female; Humans; Logistic Models; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Risk Factors; Severity of Illness Index; Treatment Outcome | 2009 |
Prospective randomized trial of single dose cefuroxime against mezlocillin in elective gastric surgery.
Topics: Abscess; Cefuroxime; Cephalosporins; Clinical Trials as Topic; Humans; Mezlocillin; Penicillin Resistance; Premedication; Prospective Studies; Pseudomonas Infections; Staphylococcal Infections; Stomach; Surgical Wound Infection | 1984 |
Ceftazidime in patients with Pseudomonas infections.
Topics: Abscess; Adolescent; Adult; Aged; Ceftazidime; Cephalosporins; Diarrhea; Drug Eruptions; Drug Resistance, Microbial; Female; Humans; Leukopenia; Male; Middle Aged; Osteomyelitis; Pseudomonas Infections; Respiratory Tract Infections; Skin Diseases, Infectious; Uremia | 1983 |
Ceftizoxime in the treatment of urinary tract infections.
Topics: Adolescent; Adult; Aged; Cefamandole; Cefotaxime; Ceftizoxime; Cephalosporins; Clinical Trials as Topic; Enterobacteriaceae Infections; Female; Humans; Male; Middle Aged; Prospective Studies; Pseudomonas Infections; Random Allocation; Urinary Tract Infections | 1982 |
Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis.
Topics: Adolescent; Alcohol Deterrents; Anti-Bacterial Agents; Azlocillin; Cefoperazone; Cefotaxime; Cefsulodin; Ceftazidime; Cephalosporins; Child; Clinical Trials as Topic; Cystic Fibrosis; Double-Blind Method; Eosinophilia; Humans; Moxalactam; Penicillins; Piperacillin; Pseudomonas Infections; Random Allocation; Respiratory Tract Infections | 1983 |
Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
Topics: Acute Disease; Adolescent; Ceftazidime; Cephalosporins; Child; Clinical Trials as Topic; Cystic Fibrosis; Female; Humans; Kinetics; Lung Diseases; Male; Pseudomonas Infections | 1983 |
Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime.
Topics: Bronchiectasis; Bronchitis; Ceftazidime; Cephalosporins; Humans; Injections, Intramuscular; Kinetics; Microbial Sensitivity Tests; Pseudomonas Infections; Recurrence; Sputum; Time Factors | 1983 |
Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis.
Topics: Adolescent; Adult; Carbenicillin; Ceftazidime; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Male; Penicillin Resistance; Prospective Studies; Pseudomonas Infections; Random Allocation; Respiratory Function Tests; Respiratory Tract Infections; Tobramycin | 1983 |
Ceftazidime: aspects of efficacy and tolerance.
Topics: Bacterial Infections; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Coombs Test; Enterobacteriaceae Infections; Eosinophilia; Humans; Liver Function Tests; Neutropenia; Pseudomonas Infections; Staphylococcal Infections | 1983 |
A comparison of ceftazidime and tobramycin in the treatment of complicated urinary tract infections.
Topics: Adult; Aged; Bacterial Infections; Ceftazidime; Cephalosporins; Escherichia coli Infections; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pseudomonas Infections; Random Allocation; Tobramycin; Urinary Tract Infections | 1983 |
A random comparative trial of 0.25, 0.5 and 1.0 g ceftazidime twice daily in urinary tract infection.
Topics: Adult; Aged; Ceftazidime; Cephalosporins; Drug Administration Schedule; Enterobacteriaceae Infections; Female; Humans; Liver Function Tests; Male; Middle Aged; Pseudomonas Infections; Random Allocation; Staphylococcal Infections; Streptococcal Infections; Urinary Tract Infections | 1983 |
[Double-blind comparative clinical study of cefpiramide (SM-1652) and cefsulodin on complicated urinary tract infections due to P. aeruginosa].
Topics: Adult; Aged; Cefsulodin; Cephalosporins; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Middle Aged; Pseudomonas Infections; Urinary Tract Infections | 1983 |
[Monotherapy of systematic Pseudomonas aeruginosa infections with ceftazidime. The causes of therapeutic failures].
Topics: Ceftazidime; Cephalosporins; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 1983 |
[New cephalosporin with favorable pharmacokinetic properties].
Topics: Ceftazidime; Cephalosporins; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Pseudomonas Infections | 1983 |
Cefsulodin sodium therapy in cystic fibrosis patients.
Topics: Adolescent; Adult; Cefsulodin; Cephalosporins; Clinical Trials as Topic; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum | 1984 |
[The clinical efficacy of cefsulodin to the infection of otorhinolaryngological field].
Topics: Adult; Cefsulodin; Cephalosporins; Chronic Disease; Clinical Trials as Topic; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Otitis Media; Otorhinolaryngologic Diseases; Pseudomonas Infections | 1982 |
[Experimental and clinical evaluation of cefsulodin in the field of pediatric infection].
Topics: Adolescent; Age Factors; Cefsulodin; Cephalosporins; Child; Child, Preschool; Clinical Trials as Topic; Drug Resistance, Microbial; Female; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections | 1982 |
[Basic and clinical evaluation on cefsulodin in the field of obstetrics and gynecology].
Topics: Adult; Cefsulodin; Cephalosporins; Clinical Trials as Topic; Drug Resistance, Microbial; Female; Genital Diseases, Female; Genitalia, Female; Humans; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections | 1982 |
Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients.
Topics: Adolescent; Adult; Carbapenems; Ceftazidime; Cephalosporins; Child, Preschool; Cystic Fibrosis; Drug Tolerance; Humans; Liver; Meropenem; Microbial Sensitivity Tests; Nausea; Pseudomonas Infections; Spirometry; Sputum; Thienamycins; Transaminases; Treatment Outcome; Vomiting | 1995 |
Treatment of Pseudomonas aeruginosa-infected orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Prosthesis-Related Infections; Pseudomonas Infections | 1995 |
Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.
Topics: Adult; Anti-Infective Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross-Over Studies; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Half-Life; Humans; Male; Microbial Sensitivity Tests; Ofloxacin; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Serum Bactericidal Test | 1995 |
Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime.
Topics: Adolescent; Alanine Transaminase; Blood Sedimentation; Body Weight; Ceftazidime; Cephalosporins; Child; Creatinine; Cystic Fibrosis; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Forced Expiratory Volume; Hemoglobins; Humans; Leukocyte Count; Lung; Lung Diseases; Lung Volume Measurements; Male; Neutrophils; Patient Readmission; Platelet Count; Pseudomonas aeruginosa; Pseudomonas Infections; Pulmonary Ventilation; Recurrence; Respiratory Function Tests; Time Factors; Treatment Outcome; Veins; Vital Capacity | 1998 |
Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Pseudomonas Infections; Sputum; Statistics, Nonparametric; Tobramycin | 1998 |
[Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
Topics: Adolescent; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Ceftazidime; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Drug Administration Schedule; Drug Therapy, Combination; Humans; Pneumonia, Bacterial; Pseudomonas Infections; Tobramycin | 1998 |
Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella.
Topics: Adult; Cephalosporin Resistance; Cephalosporins; Cross Infection; Drug Resistance, Microbial; Drug Utilization Review; Guideline Adherence; Hospital Bed Capacity, 500 and over; Hospitals, Community; Humans; Imipenem; Incidence; Infection Control; Klebsiella; Klebsiella Infections; New York City; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1998 |
The combination of topical ceftazidime and aminoglycosides in the treatment of refractory pseudomonal keratitis.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cornea; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Follow-Up Studies; Humans; Keratitis; Male; Middle Aged; Ophthalmic Solutions; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Safety; Treatment Outcome; Visual Acuity | 1999 |
Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin | 1999 |
Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Child; Cystic Fibrosis; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Male; Pseudomonas Infections; Respiratory Function Tests; Respiratory Tract Infections; Time Factors; Tobramycin; Treatment Outcome | 2001 |
[Cephradine in urology].
Topics: Adolescent; Adult; Aged; Cephalosporins; Cephradine; Clinical Trials as Topic; Drug Evaluation; Enterococcus faecalis; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Streptococcal Infections; Urinary Tract Infections | 1977 |
A preliminary report on cephradine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Candidiasis; Cephalosporins; Cephradine; Escherichia coli Infections; Female; Humans; Injections, Intramuscular; Injections, Intravenous; Male; Proteus Infections; Pseudomonas Infections; Urinary Tract Infections | 1975 |
Cephalosporin therapeutics in cystic fibrosis.
Topics: Cefsulodin; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Cystic Fibrosis; Humans; Kinetics; Lung Diseases; Pseudomonas Infections; Structure-Activity Relationship | 1986 |
[Cefazolin. 3. Double blind controlled trial in urinary tract infections].
Topics: Adult; Cephaloridine; Cephalosporins; Clinical Trials as Topic; Enterococcus faecalis; Escherichia coli Infections; Female; Humans; Injections, Intravenous; Klebsiella pneumoniae; Microbial Sensitivity Tests; Micrococcus; Middle Aged; Proteus Infections; Proteus mirabilis; Proteus vulgaris; Pseudomonas Infections; Staphylococcal Infections; Streptococcal Infections; Urinary Tract Infections | 1972 |
512 other study(ies) available for cephalosporin c and Infections, Pseudomonas
Article | Year |
---|---|
Ceftolozane/tazobactam for refractory P. aeruginosa endocarditis: A case report and pharmacokinetic analysis.
Topics: Anti-Bacterial Agents; Cephalosporins; Endocarditis; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Successful prolonged cefiderocol treatment of a chronic left pleural empyema caused by Pseudomonas aeruginosa in a patient affected by COVID-19: a case report.
Topics: Cefiderocol; Cephalosporins; COVID-19; Empyema, Pleural; Humans; Pseudomonas aeruginosa; Pseudomonas Infections | 2021 |
Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States | 2021 |
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Hospitalization; Humans; Imipenem; Jupiter; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam | 2021 |
Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model.
Topics: Anti-Bacterial Agents; Cephalosporins; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Meropenem; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Thailand | 2022 |
Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Successful cefiderocol therapy of severe infections due to difficult-to-treat Pseudomonas aeruginosa in two allogeneic hematopoietic stem cell transplantation recipients.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Hematopoietic Stem Cell Transplantation; Humans; Pseudomonas aeruginosa; Pseudomonas Infections | 2022 |
Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Clone Cells; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
In-vitro activity of ceftolozane/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Hospitals; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Saudi Arabia; Tazobactam | 2022 |
Cerebrospinal fluid concentrations of cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa ventriculitis.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Cerebral Ventriculitis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2022 |
Ceftolozane/tazobactam for difficult-to-treat Gram-negative infections: A real-world tertiary hospital experience.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Tertiary Care Centers | 2022 |
Ceftolozane/tazobactam versus colistin in the treatment of ventilator-associated pneumonia due to extensively drug-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
Drug resistance rates of difficult to treat Pseudomonas aeruginosa isolates to ceftolozane-tazobactam and ceftazidime-avibactam from a tertiary hospital, Singapore.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Drug Resistance; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Singapore; Tazobactam; Tertiary Care Centers | 2022 |
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Hospitals; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States | 2022 |
Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Monitoring; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2022 |
Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Hospitals; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Borinic Acids; Carboxylic Acids; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Cyclooctanes; Humans; Imipenem; Piperidines; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
The plethora of resistance mechanisms in Pseudomonas aeruginosa: transcriptome analysis reveals a potential role of lipopolysaccharide pathway proteins to novel β-lactam/β-lactamase inhibitor combinations.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Gene Expression Profiling; Humans; Lactams; Lipopolysaccharides; Microbial Sensitivity Tests; Monobactams; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Longitudinal Evolution of the Pseudomonas-Derived Cephalosporinase (PDC) Structure and Activity in a Cystic Fibrosis Patient Treated with β-Lactams.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Cephalosporinase; Cephalosporins; Cystic Fibrosis; Humans; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas aeruginosa; Pseudomonas Infections | 2022 |
Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
Functional and Structural Characterization of OXA-935, a Novel OXA-10-Family β-Lactamase from Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aspartic Acid; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Cephalosporinase; Cephalosporins; Glycine; Humans; Microbial Sensitivity Tests; Phenylalanine; Pseudomonas aeruginosa; Pseudomonas Infections; Serine; Tazobactam | 2022 |
Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Lactams; Microbial Sensitivity Tests; Monobactams; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Ceftolozane/Tazobactam and Ceftazidime/Avibactam: An Italian Multi-center Retrospective Analysis of Safety and Efficacy in Children With Hematologic Malignancies and Multi-drug Resistant Gram-negative Bacteria Infections.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Child; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Hematologic Neoplasms; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2023 |
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020.
Topics: Anti-Bacterial Agents; Cephalosporins; Czech Republic; Humans; Hungary; Imipenem; Microbial Sensitivity Tests; Poland; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients.
Topics: Adolescent; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Child; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Enterobacteriaceae; Escherichia coli; Humans; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Biochemical Insights into Imipenem Collateral Susceptibility Driven by
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Imipenem; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016 and 2019 in China.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Hospitals; Humans; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporinase; Cephalosporins; Drug Combinations; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Ceftazidime resistance in Pseudomonas aeruginosa is multigenic and complex.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2023 |
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveil
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Doripenem; Humans; Imipenem; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Susceptibility of ceftolozane/tazobactam against multidrug-resistant and carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2023 |
Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β-lactamase inhibitor combination.
Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporinase; Cephalosporins; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Monobactams; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia.
Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Cephalosporins; Humans; Microbial Sensitivity Tests; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pseudomonas aeruginosa; Pseudomonas Infections; Salvage Therapy | 2023 |
Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
Topics: Adolescent; Anti-Bacterial Agents; Biofilms; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin | 2023 |
Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant Pseudomonas aeruginosa isolates from Melbourne, Australia.
Topics: Adult; Anti-Bacterial Agents; Australia; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Case Commentary: Successful Use of Cefepime/Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Cefepime; Cephalosporins; Humans; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pseudomonas aeruginosa; Pseudomonas Infections; Salvage Therapy | 2023 |
Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Cohort Studies; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2023 |
Class-Driven Synergy and Antagonism between a Pseudomonas Phage and Antibiotics.
Topics: Anti-Bacterial Agents; Bacteriophages; Biofilms; Cephalosporins; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Pseudomonas Phages | 2023 |
Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis p
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Compassionate Use Trials; Humans; Intraabdominal Infections; Microbial Sensitivity Tests; Monobactams; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis | 2023 |
Cefiderocol activity is compromised by acquired extended-spectrum oxacillinases in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Ceftazidime; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2023 |
Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model.
Topics: Anti-Bacterial Agents; Cephalosporins; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin | 2023 |
Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey.
Topics: Anti-Bacterial Agents; Cephalosporins; Computer Simulation; Cross Infection; Drug Resistance, Multiple, Bacterial; Genotype; Hospitals; Humans; Microbial Sensitivity Tests; O Antigens; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Public Health Surveillance; Serogroup; Serotyping; Spain; Tazobactam; Whole Genome Sequencing | 2019 |
Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Qatar; Tazobactam; Whole Genome Sequencing | 2019 |
Econometric ARIMA methodology to elucidate the evolution of trends in nosocomial antimicrobial resistance rates in the European Union.
Topics: Anti-Bacterial Agents; Cephalosporin Resistance; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Europe; European Union; Fluoroquinolones; Humans; Klebsiella Infections; Klebsiella pneumoniae; Models, Econometric; Models, Theoretical; Pseudomonas aeruginosa; Pseudomonas Infections | 2020 |
Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pharmaceutical Preparations; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2020 |
Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug-Resistant Pseudomonas aeruginosa: A Case Report.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Compassionate Use Trials; Drug Resistance, Multiple, Bacterial; Humans; Intraabdominal Infections; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2019 |
Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Cefepime; Cephalosporins; Cyclooctanes; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Lung; Mice; Microbial Sensitivity Tests; Neutropenia; Piperidines; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Specific Pathogen-Free Organisms | 2020 |
Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015-2017) Pseudomonas aeruginosa isolates from a global surveillance programme.
Topics: Asia; Cephalosporins; Europe; Female; Global Health; Humans; Latin America; Male; Microbial Sensitivity Tests; North America; Pacific Islands; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Public Health Surveillance; Sepsis; Skin Diseases, Bacterial; Tazobactam | 2020 |
Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Critical Illness; Female; Hemodiafiltration; Humans; Microbial Sensitivity Tests; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pseudomonas aeruginosa; Pseudomonas Infections | 2019 |
Heteroresistance to cefepime in Pseudomonas aeruginosa bacteraemia.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Cefepime; Cephalosporins; China; Drug Resistance, Bacterial; Female; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections | 2020 |
Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa.
Topics: Adolescent; Anti-Bacterial Agents; Biofilms; Cephalosporins; Cystic Fibrosis; Drug Synergism; Humans; Microbial Sensitivity Tests; Middle Aged; Nitric Oxide Donors; Prodrugs; Pseudomonas aeruginosa; Pseudomonas Infections; Young Adult | 2020 |
In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Intensive Care Units; Intraabdominal Infections; Portugal; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Urinary Tract Infections | 2020 |
Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Humans; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2020 |
Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?
Topics: Adolescent; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; beta-Lactamases; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Osteomyelitis; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Siderophores | 2020 |
Ceftolozane/Tazobactam Treatment of Multidrug-resistant Pseudomonas aeruginosa Infections in Children.
Topics: Adolescent; Anti-Bacterial Agents; Case-Control Studies; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Neutropenia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome; Young Adult | 2020 |
Unorthodox Parenteral β-Lactam and β-Lactamase Inhibitor Combinations: Flouting Antimicrobial Stewardship and Compromising Patient Care.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Antimicrobial Stewardship; beta-Lactamase Inhibitors; Cephalosporins; China; Drug Combinations; Drug Misuse; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Inappropriate Prescribing; India; Microbial Sensitivity Tests; Patient Care; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam; Tazobactam | 2020 |
Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Mutation; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Hungary; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Use of Ceftazidime-Avibactam and Ceftolozane-Tazobactam After Lung Transplantation.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Lung Transplantation; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United State
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States | 2021 |
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Germany; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece.
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Greece; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Immunocompromised Host; Inpatients; Intensive Care Units; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18.
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Europe; Europe, Eastern; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Healthcare-Associated Pneumonia; Humans; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Impact of the blue-carba rapid test for carbapenemase detection on turnaround time for an early therapy against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Brazil; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Secondary Prevention | 2021 |
Continuous infusion of ceftolozane-tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant Pseudomonas aeruginosa meningitis.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Meningitis; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Tazobactam | 2021 |
Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Microbial Sensitivity Tests; Portugal; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2021 |
Performance of Antipseudomonal β-Lactams on the Accelerate PhenoTest BC Kit against a Collection of Pseudomonas aeruginosa Isolates.
Topics: Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2021 |
In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Drug Resistance, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2021 |
Amending the Efficiency of Antimicrobials against Multidrug-Resistant Pseudomonas aeruginosa by Low-Frequency Magnetic Fields.
Topics: Aminoglycosides; Anti-Bacterial Agents; Burns; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Magnetic Fields; Microbial Sensitivity Tests; Penicillins; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones | 2020 |
Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Critical Illness; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Female; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Spain; Tazobactam; Treatment Outcome | 2021 |
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins latest update.
Topics: Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Humans; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections | 2021 |
Real life experience with ceftolozane/tazobactam therapy for
Topics: Adult; Aged; Anti-Bacterial Agents; APACHE; Bacteremia; Cephalosporins; Comorbidity; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Pseudomonas Infections; Tazobactam | 2021 |
Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018).
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Bacterial; Escherichia coli; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2021 |
Ceftolozane/tazobactam for Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis adult patients: a case series.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Humans; Italy; Lung; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tazobactam; Young Adult | 2021 |
Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
Topics: Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Diabetic Foot; Drug Resistance; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Trends of Antimicrobial Resistance and Combination Susceptibility Testing of Multidrug-Resistant Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients: a 10-Year Update.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2021 |
What place does ceftolozane/tazobactam have in the treatment of complicated urinary-tract infections?
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2021 |
Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Meropenem; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Real-world evaluation of ceftolozane/tazobactam therapy and clinical outcomes in France.
Topics: Adult; Cephalosporins; Humans; Male; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Enabling antibiotic allergy evaluations and reintroduction of first-line antibiotics for patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Antimicrobial Stewardship; Cephalosporins; Cystic Fibrosis; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Sulfonamides; Young Adult | 2021 |
Compassionate use of cefiderocol for VIM metallo-β-lactamase-producing Pseudomonas aeruginosa infection in a toddler with Burkitt lymphoma.
Topics: beta-Lactamases; Burkitt Lymphoma; Cefiderocol; Cephalosporins; Child, Preschool; Compassionate Use Trials; Humans; Pseudomonas Infections | 2021 |
Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporinase; Cephalosporins; COVID-19; Humans; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas aeruginosa; Pseudomonas Infections; SARS-CoV-2 | 2021 |
Trends in Antipseudomonal Agent Use Based on the 2006 to 2015 Sales Data in Japan.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Commerce; Drug Utilization; Fluoroquinolones; Humans; Japan; Penicillins; Pseudomonas Infections | 2021 |
[Utilization study in real clinical practice of ceftolozane/tazobactam vs aminoglycosides and/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa].
Topics: Aftercare; Aged; Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Patient Discharge; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2021 |
Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane/tazobactam and ceftazidime/avibactam susceptibility testing of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Phenotypic/Genotypic Profile of OXA-10-Like-Harboring, Carbapenem-Resistant Pseudomonas aeruginosa: Using Validated Pharmacokinetic/Pharmacodynamic
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Humans; Mice; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections | 2021 |
In vitro characterization of Pseudomonas aeruginosa recovered in Portugal from low respiratory tract infections in ICU patients (STEP Study).
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Microbial Sensitivity Tests; Portugal; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam | 2021 |
Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2021 |
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Female; Humans; Male; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2017 |
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Cyclooctanes; Drug Synergism; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Piperidines; Pseudomonas aeruginosa; Pseudomonas Infections | 2017 |
Ceftolozane-tazobactam for the treatment of ventilator-associated infections by colistin-resistant Pseudomonas aeruginosa.
Topics: Acute-Phase Proteins; Aged; Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Bacterial; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Successful treatment of multidrug-resistant
Topics: Cephalosporins; Cystectomy; Debridement; Drug Resistance, Multiple, Bacterial; Fistula; Humans; Male; Middle Aged; Osteomyelitis; Penicillanic Acid; Pseudomonas Infections; Pubic Symphysis; Tazobactam; Treatment Outcome | 2017 |
Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Child, Preschool; Drug Resistance, Multiple, Bacterial; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Salvage Therapy; Tazobactam; Treatment Outcome; Young Adult | 2017 |
Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam.
Topics: Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2017 |
Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Fractures, Bone; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Osteomyelitis; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2017 |
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins update.
Topics: Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Humans; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections | 2017 |
Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; beta-Lactam Resistance; Cefiderocol; Cephalosporins; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Klebsiella Infections; Klebsiella pneumoniae; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Respiratory Tract Infections | 2017 |
Antimicrobial activities of LCB10-0200, a novel siderophore cephalosporin, against the clinical isolates of Pseudomonas aeruginosa and other pathogens.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Disease Models, Animal; Female; Humans; Male; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Sepsis; Siderophores; Skin Diseases, Bacterial; Treatment Outcome; Urinary Tract Infections | 2017 |
Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Topics: Adolescent; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Fever; Fluoroquinolones; Humans; Male; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2017 |
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Catheter-Related Infections; Ceftazidime; Cephalosporins; Cross Infection; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Humans; Iatrogenic Disease; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tazobactam; Thienamycins; Tobramycin | 2017 |
Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Multilocus Sequence Typing; Penicillanic Acid; Polymorphism, Single Nucleotide; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Wound Infection | 2017 |
Role of inducers in detection of
Topics: Bacterial Proteins; beta-Lactamases; Cefoxitin; Cephalosporin Resistance; Cephalosporins; DNA Fingerprinting; Humans; Microbial Sensitivity Tests; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections | 2017 |
Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cephalosporins; Cytoskeletal Proteins; Drug Resistance, Multiple, Bacterial; Germany; Humans; Microbial Sensitivity Tests; Multilocus Sequence Typing; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Humans; Male; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2017 |
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Los Angeles; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Genome, Bacterial; Humans; Male; Middle Aged; Penicillanic Acid; Pennsylvania; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Young Adult | 2017 |
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazoba
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2018 |
Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Heart Transplantation; Heart-Assist Devices; Humans; Male; Middle Aged; Penicillanic Acid; Prosthesis-Related Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates.
Topics: Bacteremia; Cephalosporins; Drug Resistance, Bacterial; Humans; Immunocompromised Host; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gene Transfer, Horizontal; Humans; Microbial Sensitivity Tests; Multilocus Sequence Typing; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Osteomyelitis; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2018 |
Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Cephalosporins; Cross Infection; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Epidemiological Monitoring; Humans; Italy; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Whole Genome Sequencing | 2018 |
In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.
Topics: Canada; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Gene Expression; Hospitalization; Humans; Isoenzymes; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Plasmids; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Retrospective Studies; Tazobactam; United States | 2018 |
Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Microbial Viability; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Tazobactam; Urinary Tract Infections | 2018 |
Molecular Characterization of Extended-Spectrum Beta Lactamase- and Carbapenemase-Producing Pseudomonas aeruginosa Strains from a Malaysian Tertiary Hospital.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Integrons; Malaysia; Microbial Sensitivity Tests; Multilocus Sequence Typing; Pseudomonas aeruginosa; Pseudomonas Infections; Tertiary Care Centers | 2018 |
Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Oregon; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2018 |
Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Cephalosporins; Humans; Infusions, Parenteral; Lung Abscess; Male; Microbial Sensitivity Tests; Middle Aged; Outpatients; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Bacterial; Female; Follow-Up Studies; Humans; Infection Control; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Treatment Failure; Treatment Outcome; Young Adult | 2018 |
Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
Topics: Anti-Bacterial Agents; Cephalosporins; Computer Simulation; Escherichia coli; Escherichia coli Infections; Female; Humans; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Obesity, Morbid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2018 |
Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; beta-Lactamases; Ceftazidime; Cephalosporins; Clone Cells; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; Gene Expression; Humans; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Survival Analysis; Tazobactam | 2018 |
Ceftolozane-tazobactam for the treatment of multidrug-resistant
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Kidney Failure, Chronic; Male; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Renal Dialysis; Tazobactam; Treatment Outcome | 2018 |
Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tazobactam | 2018 |
Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the Program to Assess Ceftolozane-
Topics: Anti-Infective Agents; Bacteremia; Cephalosporins; Enterobacteriaceae; Enterobacteriaceae Infections; Epidemiological Monitoring; Hospitals; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States | 2018 |
Postoperative soft-tissue infection due to multidrug-resistant Pseudomonas aeruginosa: usefulness of ceftolozane-tazobactam.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Middle Aged; Postoperative Complications; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2018 |
Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands.
Topics: Aged; Cephalosporins; Drug Resistance, Multiple, Bacterial; Factor Analysis, Statistical; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2018 |
Necrotizing Otitis Externa-Analysis of 83 Cases: Clinical Findings and Course of Disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Disease Progression; Female; Hospitalization; Humans; Male; Middle Aged; Otitis Externa; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Retrospective Studies; Tertiary Care Centers; Treatment Outcome | 2019 |
Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Genotype; Humans; Microbial Sensitivity Tests; Molecular Diagnostic Techniques; Pseudomonas aeruginosa; Pseudomonas Infections; Sensitivity and Specificity; Tazobactam | 2019 |
Mechanisms of high-level ceftolozane/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin; Treatment Outcome | 2019 |
Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
[Ecthyma gangrenosum].
Topics: Anti-Bacterial Agents; Cephalosporins; Child, Preschool; Diagnosis, Differential; Ecthyma; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2018 |
Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Queensland; Tazobactam | 2018 |
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Bone Diseases, Infectious; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Skin Diseases, Bacterial; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2019 |
Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa.
Topics: Aged; Anti-Bacterial Agents; Aortic Valve; beta-Lactamases; Cefiderocol; Cephalosporins; Colistin; Compassionate Use Trials; Drug Resistance, Multiple, Bacterial; Endocarditis, Bacterial; Female; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2019 |
Impact of a multimodal strategy combining a new standard of care and restriction of carbapenems, fluoroquinolones and cephalosporins on antibiotic consumption and resistance of Pseudomonas aeruginosa in a French intensive care unit.
Topics: Aged; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Utilization; Female; Fluoroquinolones; France; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Practice Patterns, Physicians'; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Standard of Care | 2019 |
Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2019 |
Activity of Ceftolozane/Tazobactam Against Gram-Negative Rods of the Family Enterobacteriaceae and Pseudomonas Spp. Isolated from Onco-Hematological Patients Hospitalized in a Clinical Hospital in Poland.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Hospitals; Humans; Microbial Sensitivity Tests; Patients; Poland; Pseudomonas; Pseudomonas Infections; Tazobactam | 2019 |
Ceftolozane-Tazobactam Pharmacokinetics during Extracorporeal Membrane Oxygenation in a Lung Transplant Recipient.
Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Extracorporeal Membrane Oxygenation; Female; Humans; Lung Transplantation; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Transplant Recipients | 2019 |
Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Biofilms; Cephalosporins; Colistin; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Models, Theoretical; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
Successful ceftolozane-tazobactam rescue therapy in a child with endocarditis caused by multidrug-resistant Pseudomonas aeruginosa.
Topics: Cephalosporins; Child, Preschool; Endocarditis, Bacterial; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2019 |
Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Adolescent; Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Infant; Infant, Newborn; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Young Adult | 2019 |
Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Drug Resistance, Bacterial; Female; Hospitals; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Piperacillin, Tazobactam Drug Combination; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Scotland; Tazobactam; Whole Genome Sequencing | 2019 |
A Combination Antibiogram Evaluation for
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cross Infection; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Hospitals; Humans; Intensive Care Units; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; United States | 2019 |
A Novel VIM-Type Metallo-β-Lactamase Variant, VIM-60, with Increased Hydrolyzing Activity against Fourth-Generation Cephalosporins in Pseudomonas aeruginosa Clinical Isolates in Japan.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cefpirome; Cephalosporins; Humans; Hydrolysis; Japan; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2019 |
Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Fosfomycin; Humans; Meropenem; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin; United States | 2019 |
Impact of antibiotic resistance on outcomes of neutropenic cancer patients with
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; International Cooperation; Logistic Models; Multicenter Studies as Topic; Neoplasms; Neutropenia; Observational Studies as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Research Design; Retrospective Studies; Tazobactam; Time Factors | 2019 |
ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Infusions, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2019 |
Local outbreak of extended-spectrum β-lactamase SHV2a-producing Pseudomonas aeruginosa reveals the emergence of a new specific sub-lineage of the international ST235 high-risk clone.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Ciprofloxacin; Colistin; Cross Infection; Disease Outbreaks; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; France; Humans; Microbial Sensitivity Tests; Multilocus Sequence Typing; Polymorphism, Single Nucleotide; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Kinetics; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Whole Genome Sequencing | 2019 |
Optic nerve involvement from Pseudomonas aeruginosa -associated skull base osteomyelitis.
Topics: Aged; Anti-Bacterial Agents; Blindness; Cefepime; Cephalosporins; Eye Infections, Bacterial; Humans; Magnetic Resonance Imaging; Male; Meropenem; Middle Aged; Optic Nerve Diseases; Osteomyelitis; Pseudomonas aeruginosa; Pseudomonas Infections; Skull Base; Thienamycins; Visual Acuity | 2013 |
Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections.
Topics: Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Administration Schedule; Female; Humans; Intensive Care Units; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2013 |
Comparison of the prevalence of convulsions associated with the use of cefepime and meropenem.
Topics: Adult; Aged; Anti-Bacterial Agents; Brain Diseases; Cefepime; Cephalosporins; Female; Hospitals, University; Humans; Infusions, Intravenous; Japan; Male; Meropenem; Neurotoxicity Syndromes; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Renal Insufficiency; Retrospective Studies; Risk; Seizures; Staphylococcal Infections; Staphylococcus aureus; Thienamycins | 2013 |
When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Doripenem; Drug Costs; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2013 |
In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.
Topics: Anti-Bacterial Agents; Canada; Ceftazidime; Cephalosporins; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Hospitals; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2013 |
Clinical characteristics and risk factors for mortality in cefepime-resistant Pseudomonas aeruginosa bacteremia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Cefepime; Cephalosporins; Female; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors; Severity of Illness Index; Survival Analysis | 2015 |
Comparison of efficiency of intravitreal ceftazidime and intravitreal cefepime in the treatment of experimental Pseudomonas aeruginosa endophthalmitis.
Topics: Animals; Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Treatment Outcome; Vitreous Body | 2013 |
Extended Infusion Cefepime.
Topics: Anti-Bacterial Agents; Cephalosporins; Female; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections | 2013 |
Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Enterobacteriaceae Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas Infections; Retrospective Studies | 2014 |
Late manifestation of a driveline infection after heart transplantation.
Topics: Abdomen; Anti-Bacterial Agents; Cefepime; Cephalosporins; Debridement; Device Removal; Female; Heart Failure; Heart Transplantation; Heart-Assist Devices; Humans; Middle Aged; Polyethylene Terephthalates; Proteus Infections; Pseudomonas Infections; Radiography, Abdominal; Surgical Wound Infection; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Treatment failure due to induction of ciprofloxacin resistance during combination therapy with colistin and ciprofloxacin in multidrug-resistant Pseudomonas aeruginosa bacteraemia.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin; Treatment Failure | 2014 |
Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2014 |
Dissemination in Japan of multidrug-resistant Pseudomonas aeruginosa isolates producing IMP-type metallo-β-lactamases and AAC(6')-Iae/AAC(6')-Ib.
Topics: Acetyltransferases; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Inosine Monophosphate; Japan; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2014 |
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Cephalosporins; Cross Infection; Enterobacteriaceae; Enterobacteriaceae Infections; Europe; Genotype; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2014 |
Osteomyelitis of the clavicle following to a pacemaker implantation.
Topics: Anti-Bacterial Agents; Cardiac Pacing, Artificial; Cefepime; Cephalosporins; Ciprofloxacin; Clavicle; Drug Therapy, Combination; Equipment Design; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Osteomyelitis; Pacemaker, Artificial; Pseudomonas aeruginosa; Pseudomonas Infections | 2014 |
In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: comparison with ceftazidime, piperacillin/tazobactam and imipenem.
Topics: Animal Structures; Animals; Anti-Bacterial Agents; Bacterial Load; Ceftazidime; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Female; Humans; Imipenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Treatment Outcome | 2014 |
Increasing resistance rate to carbapenem among blood culture isolates of Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa in a university-affiliated hospital in China, 2004-2011.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cephalosporins; China; Drug Resistance, Bacterial; Gram-Negative Bacteria; Hospitals, University; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2015 |
Integron-borne transmission of VEB-1 extended-spectrum β-lactamase in Pseudomonas aeruginosa in a tertiary care hospital in India.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Escherichia coli Proteins; Gene Transfer, Horizontal; Humans; India; Microbial Sensitivity Tests; Plasmids; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Tertiary Care Centers; Tertiary Healthcare | 2014 |
Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Cross Infection; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Porins; Pseudomonas aeruginosa; Pseudomonas Infections | 2014 |
Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftaroline; Cephalosporins; Disease Models, Animal; Enterobacter cloacae; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Reproducibility of Results; Thigh | 2014 |
Efficacy of anti-pseudomonal antibiotics: need to reconsider the empirical use of cefepime.
Topics: Aged; Aged, 80 and over; Cefepime; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Female; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections | 2014 |
Treatment of multidrug-resistant pseudomonas aeruginosa using extended-infusion antimicrobial regimens.
Topics: Adult; Anti-Bacterial Agents; Cefepime; Cephalosporins; Colistin; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Heart-Assist Devices; Humans; Infusions, Intravenous; Metabolic Clearance Rate; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Renal Dialysis; Time Factors; Treatment Outcome | 2015 |
Use of aztreonam in association with cefepime for the treatment of nosocomial infections due to multidrug-resistant strains of Pseudomonas aeruginosa to β-lactams in ICU patients: A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefepime; Cephalosporins; Critical Care; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pilot Projects; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2015 |
Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2015 |
Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Blood Culture; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Case-Control Studies; Cephalosporins; Ciprofloxacin; Cross Infection; Female; Hospitals; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Mortality; Multivariate Analysis; Odds Ratio; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors; Severity of Illness Index; Taiwan; Thienamycins | 2017 |
In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Cephalosporins; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2015 |
Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
Topics: Anti-Bacterial Agents; Cephalosporins; Critical Illness; Drug Resistance, Multiple, Bacterial; Hemofiltration; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Prospective Studies; Prosthesis-Related Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2015 |
Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Computer Simulation; Creatinine; Drug Dosage Calculations; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Models, Statistical; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections | 2016 |
Tissue penetration and exposure of cefepime in patients with diabetic foot infections.
Topics: Cefepime; Cephalosporins; Diabetes Mellitus; Foot Diseases; Humans; Pseudomonas aeruginosa; Pseudomonas Infections | 2016 |
In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states.
Topics: Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; Biofilms; Cephalosporins; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient.
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Child; Drug Resistance, Multiple, Bacterial; Hospitalization; Humans; Leukemia; Male; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
Impact of computerized pre-authorization of broad spectrum antibiotics in Pseudomonas aeruginosa at a children's hospital in Japan.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Hospitals; Humans; Japan; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tokyo | 2016 |
Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.
Topics: Aged; Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; Cephalosporins; Chromatography, High Pressure Liquid; Critical Illness; Drug Resistance, Multiple, Bacterial; Hemofiltration; Humans; Male; Penicillanic Acid; Plasma; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome; United States | 2016 |
Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2016 |
Involvement of the Multidrug Efflux Pumps in Betalactams Resistant Pseudomonas aerugionsa Clinical Isolates Collected from Burn Patients in Iran.
Topics: Bacterial Outer Membrane Proteins; beta-Lactam Resistance; beta-Lactamases; Burns; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Genes, MDR; Humans; Imipenem; Iran; Membrane Transport Proteins; Microbial Sensitivity Tests; Phenotype; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2016 |
Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.
Topics: Aminoglycosides; Anti-Bacterial Agents; Belgium; beta-Lactamases; Carbapenems; Cephalosporins; Clone Cells; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Gene Expression; Germany; Humans; Microbial Sensitivity Tests; Multilocus Sequence Typing; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; United Kingdom | 2016 |
What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Humans; Intraabdominal Infections; Penicillanic Acid; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2016 |
Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Off-Label Use; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Clone Cells; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; France; Gene Expression; Genome, Bacterial; High-Throughput Nucleotide Sequencing; Hospitals; Humans; Microbial Sensitivity Tests; Monobactams; Mutation; Penicillins; Phylogeny; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Spain | 2016 |
Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Salvage Therapy; Shock, Septic; Survival Analysis; Tazobactam | 2017 |
Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam.
Topics: Anti-Infective Agents, Urinary; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam | 2017 |
A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteremia treated with cefepime or ceftazidime.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Cefepime; Ceftazidime; Cephalosporins; Female; Humans; Male; Microbial Sensitivity Tests; Multivariate Analysis; Propensity Score; Pseudomonas aeruginosa; Pseudomonas Infections | 2017 |
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Epidemiological Monitoring; Europe; Humans; Intraabdominal Infections; Israel; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Turkey; Urinary Tract Infections | 2017 |
Infection in burn patients in a referral center in Colombia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Burns; Catheter-Related Infections; Central Venous Catheters; Cephalosporins; Child; Child, Preschool; Colombia; Drug Resistance, Microbial; Escherichia coli; Escherichia coli Infections; Female; Folliculitis; Humans; Infant; Infant, Newborn; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Oxacillin; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Urinary Tract Infections; Wound Infection; Young Adult | 2017 |
Presentation, treatment, and clinical course of otogenic lateral sinus thrombosis.
Topics: Adult; Anti-Bacterial Agents; Anticoagulants; Cephalosporins; Cholesteatoma, Middle Ear; Chronic Disease; Combined Modality Therapy; Comorbidity; Disease Progression; Enterococcus; Female; Follow-Up Studies; Gram-Positive Bacterial Infections; Heparin; Hospitals, Teaching; Humans; Lateral Sinus Thrombosis; Magnetic Resonance Angiography; Male; Mastoid; Mastoiditis; Neurologic Examination; Otitis Media; Proteus Infections; Proteus mirabilis; Pseudomonas Infections; Retrospective Studies; Young Adult | 2009 |
Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients.
Topics: Adult; Cephalosporins; Critical Illness; Cross Infection; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Genes, Viral; Genotype; Humans; Intensive Care Units; Male; Pharynx; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Rectum; Respiratory Mucosa | 2009 |
Comparison of different methods of determining beta-lactam susceptibility in clinical strains of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Automation; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Genetic Predisposition to Disease; Humans; Imipenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascitic Fluid; Bacterial Infections; Cefepime; Cefotaxime; Cephalosporins; Drug Resistance, Bacterial; Enterococcus; Escherichia coli Infections; Female; Humans; Infusions, Intravenous; Klebsiella Infections; Klebsiella pneumoniae; Leukocyte Count; Levofloxacin; Liver Cirrhosis; Male; Microbial Sensitivity Tests; Middle Aged; Neutrophils; Ofloxacin; Peritonitis; Pneumococcal Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections | 2010 |
Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Critical Pathways; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospital Mortality; Humans; Intensive Care Units; Length of Stay; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Observation; Pneumonia, Ventilator-Associated; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin; Treatment Outcome; Vancomycin; Young Adult | 2010 |
Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Burkholderia cepacia; Burkholderia Infections; Cephalosporins; Drug Resistance, Bacterial; Female; Humans; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Young Adult | 2009 |
Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-{beta}-lactamase-producing Pseudomonas aeruginosa.
Topics: Bacterial Proteins; beta-Lactamases; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; Cefepime; Ceftazidime; Cephalosporins; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Drug Utilization; Female; Gene Expression; Genes, Bacterial; Hospitals; Humans; Integrons; Intensive Care Units; Male; Membrane Transport Proteins; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Spain | 2009 |
Cefepime and all-cause mortality.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Humans; Pseudomonas Infections; Randomized Controlled Trials as Topic | 2009 |
Class 1 integron containing metallo beta-lactamase gene blaIMP-1 in carbapenem-resistant Pseudomonas aeruginosa in Thailand.
Topics: Amino Acid Sequence; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Bacterial; Humans; Integrons; Molecular Epidemiology; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Thailand | 2009 |
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Clavulanic Acid; Gentamicins; Humans; Imipenem; Integrons; Meropenem; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam; Thienamycins | 2009 |
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Proteins; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Dose-Response Relationship, Drug; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Half-Life; Immunocompromised Host; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Hairless; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Infectious; Staphylococcal Infections; Staphylococcus aureus | 2010 |
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
Topics: Belgium; beta-Lactamases; Cephalosporinase; Cephalosporins; Cross Infection; Escherichia coli; Genes, Bacterial; Humans; Kinetics; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Isoelectric Focusing; Microbial Sensitivity Tests; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Hospitals; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Spain | 2010 |
Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2010 |
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; beta-Lactams; Cephalosporins; Genetic Variation; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2010 |
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Cross Infection; Humans; Intensive Care Units; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis.
Topics: Acinetobacter Infections; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Cohort Studies; Drug Therapy, Combination; Escherichia coli Infections; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Sepsis; Shock, Septic | 2010 |
Cefepime: an underrecognized cause of nonconvulsive status epilepticus.
Topics: Aged; Anti-Bacterial Agents; Benzodiazepines; Cefepime; Cephalosporins; Female; Humans; Kidney Failure, Chronic; Pseudomonas aeruginosa; Pseudomonas Infections; Status Epilepticus | 2010 |
Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1.
Topics: Anti-Bacterial Agents; Biofilms; Cephalosporins; Colony Count, Microbial; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Microbial Viability; Mutation; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections | 2010 |
Cefepime-resistant Gram-negative bacteremia in febrile neutropenic patients with hematological malignancies.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cefepime; Cephalosporin Resistance; Cephalosporins; Escherichia coli; Escherichia coli Infections; Fever; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hematologic Neoplasms; Humans; Klebsiella Infections; Klebsiella pneumoniae; Neutropenia; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
The importance of pharmacokinetic consultation of cefepime treatment for Pseudomonas aeruginosa bacteremia: a case report of severe thermal burn injury.
Topics: Anti-Bacterial Agents; Bacteremia; Burns; Cefepime; Cephalosporins; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections | 2011 |
Antibiotic resistance in Pseudomonas aeruginosa related to quinolone formulary changes: an interrupted time series analysis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Formularies, Hospital as Topic; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2011 |
Perioperative, postoperative, and prophylactic use of antibiotics in alloplastic total temporomandibular joint replacement surgery: a survey and preliminary guidelines.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Arthroplasty, Replacement; Bacitracin; Biofilms; Cefazolin; Cephalosporins; Clindamycin; Device Removal; Disinfection; Gentamicins; Gram-Positive Bacterial Infections; Humans; Joint Prosthesis; Penicillins; Peptostreptococcus; Peroxides; Povidone-Iodine; Practice Guidelines as Topic; Practice Patterns, Dentists'; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Staphylococcal Infections; Staphylococcus epidermidis; Surgical Wound Infection; Temporomandibular Joint; Therapeutic Irrigation; Vancomycin | 2011 |
Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Female; Gene Expression Profiling; Humans; Male; Membrane Proteins; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation, Missense; Pseudomonas aeruginosa; Pseudomonas Infections; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Carbapenems; Cephalosporins; Cross Infection; Databases, Factual; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; United States | 2011 |
Cefepime-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Case-Control Studies; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections | 2011 |
Effect of a cholesterol rich diet, recurrent infection and possible treatment modalities on the pulmonary vascular system: an experimental study.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Cefepime; Cephalosporins; Cholesterol, Dietary; Diclofenac; Hypercholesterolemia; Pseudomonas Infections; Pulmonary Artery; Rats; Wine | 2011 |
Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Blotting, Western; Cefepime; Cephalosporins; Computer Simulation; Drug Administration Schedule; Drug Interactions; Drug Resistance, Bacterial; Gene Expression Regulation, Bacterial; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Protein Synthesis Inhibitors; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tobramycin | 2012 |
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thigh | 2012 |
Cefepime: a rare cause of encephalopathy.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Female; Glomerular Filtration Rate; Humans; Neurotoxicity Syndromes; Osteomyelitis; Pseudomonas Infections; Respiration, Artificial | 2012 |
Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Binding Sites; Carbapenems; Ceftazidime; Cephalosporins; Cross Infection; Gene Expression; Humans; Imipenem; Kinetics; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Protein Binding; Protein Isoforms; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
The ecology of antibiotic use in the ICU: homogeneous prescribing of cefepime but not tazocin selects for antibiotic resistant infection.
Topics: Adult; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Prescriptions; Drug Resistance, Bacterial; Female; Humans; Intensive Care Units; Length of Stay; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Nasopharynx; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Survival Rate | 2012 |
Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response.
Topics: Acute Disease; Animals; Anti-Infective Agents; Ceftazidime; Cephalosporins; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Inflammation; Mice; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2013 |
In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Enterobacteriaceae; Female; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thigh | 2013 |
Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Chromatography, High Pressure Liquid; Critical Care; Cystic Fibrosis; Drug Stability; Drug Storage; Humans; Hydrogen-Ion Concentration; Infusion Pumps; Pseudomonas Infections; Pyridines; Syringes; Temperature | 2002 |
Prospective survey of beta-lactamases produced by ceftazidime- resistant Pseudomonas aeruginosa isolated in a French hospital in 2000.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Cephalosporinase; Cephalosporins; Data Collection; Drug Resistance, Microbial; France; Genes, Bacterial; Genotype; Humans; Microbial Sensitivity Tests; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections | 2002 |
Squamous cell carcinoma associated with a periorbital mass in a veiled chameleon (Chamaeleo calyptratus).
Topics: Abscess; Animals; Carcinoma, Squamous Cell; Ceftazidime; Cephalosporins; Diagnosis, Differential; Eye Infections, Bacterial; Lizards; Neoplasm Recurrence, Local; Orbital Neoplasms; Pseudomonas aeruginosa; Pseudomonas Infections | 2002 |
Antimicrobial-induced release of endotoxin from Pseudomonas aeruginosa: comparison of in vitro and animal models.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Carbapenems; Ceftazidime; Cephalosporins; Colony Count, Microbial; Computer Simulation; Endotoxins; Female; Lipopolysaccharides; Microscopy, Phase-Contrast; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Sprague-Dawley | 2003 |
Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa.
Topics: Cefepime; Cephalosporins; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Population Surveillance; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2003 |
[Evaluation of a E-test method to detect bactericidy of beta lactam-aminoglycoside associations against Pseudomonas aeruginosa isolates from cystic fibrosis].
Topics: Amikacin; Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2003 |
In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models.
Topics: Abscess; Animals; Area Under Curve; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Male; Methicillin Resistance; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Staphylococcal Infections; Staphylococcus aureus; Urinary Tract Infections | 2003 |
In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Interactions; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Lactams; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2003 |
Outbreak of Pseudomonas aeruginosa infections caused by commercial piercing of upper ear cartilage.
Topics: Abscess; Adolescent; Adult; Cartilage Diseases; Cephalosporins; Child; Cohort Studies; Cosmetic Techniques; Data Collection; Disease Outbreaks; Disease Transmission, Infectious; DNA Fingerprinting; Ear Cartilage; Ear Deformities, Acquired; Ear, External; Equipment Contamination; Fluoroquinolones; Humans; Oregon; Otolaryngology; Pseudomonas aeruginosa; Pseudomonas Infections; Punctures; Wound Infection | 2004 |
Virulence of metallo-beta-lactamase-producing Pseudomonas aeruginosa in vitro and in vivo.
Topics: Animals; Bacteremia; beta-Lactamases; Ceftazidime; Cephalosporins; Cilastatin; Ciprofloxacin; Drug Therapy, Combination; Imipenem; Leukopenia; Male; Mice; Mice, Inbred BALB C; Protease Inhibitors; Pseudomonas aeruginosa; Pseudomonas Infections; Stem Cells; Thienamycins | 2004 |
Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.
Topics: Alkylating Agents; Animals; Ceftazidime; Cephalosporins; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Combinations; Female; Granulocyte Colony-Stimulating Factor; Mice; Neutropenia; Pneumonia, Bacterial; Pseudomonas Infections; Survival Analysis | 2004 |
Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics.
Topics: Animals; Anti-Bacterial Agents; Cefepime; Cephalosporins; Disease Models, Animal; Drug Therapy, Combination; Endocarditis, Bacterial; Female; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 2004 |
Case report: Pseudomonas aeruginosa-related intervertebral discitis in a young boy with medulloblastoma.
Topics: Adolescent; Anti-Bacterial Agents; Antineoplastic Agents; Back Pain; Biopsy, Fine-Needle; Bone Neoplasms; Cefepime; Cephalosporins; Cerebellar Neoplasms; Cerebral Ventricle Neoplasms; Diagnosis, Differential; Discitis; Drug Therapy, Combination; Humans; Imipenem; Lumbar Vertebrae; Magnetic Resonance Imaging; Male; Medulloblastoma; Pseudomonas Infections; Thoracic Vertebrae; Treatment Outcome | 2004 |
Bacteria of preoperative urinary tract infections contaminate the surgical fields and develop surgical site infections in urological operations.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cephalosporins; Cross Infection; Escherichia coli; Escherichia coli Infections; Female; Humans; Japan; Male; Methicillin Resistance; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Specimen Handling; Staphylococcal Infections; Staphylococcus aureus; Surgical Wound Infection; Urinary Tract Infections; Urine; Urologic Surgical Procedures | 2004 |
n-6 polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant Pseudomonas aeruginosa.
Topics: alpha-Linolenic Acid; Amikacin; Animals; Anti-Bacterial Agents; Arachidonic Acid; Ceftazidime; Cephalosporins; Colony Count, Microbial; Drug Resistance, Multiple, Bacterial; Drug Synergism; Fatty Acids, Unsaturated; Lipopolysaccharides; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Sepsis; Tumor Necrosis Factor-alpha | 2004 |
Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteriological Techniques; Bronchoalveolar Lavage Fluid; Cephalosporins; Cross Infection; Early Diagnosis; Female; France; Humans; Imipenem; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillins; Pneumonia, Bacterial; Population Surveillance; Practice Guidelines as Topic; Prospective Studies; Pseudomonas Infections; Treatment Outcome; Ventilators, Mechanical | 2005 |
Pan-drug-resistant Pseudomonas aeruginosa causing nosocomial infection at a university hospital in Taiwan.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Cefepime; Cephalosporins; Child; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Hospitals, University; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Taiwan | 2005 |
Characteristics of Pseudomonas corneal infection related to orthokeratology.
Topics: Administration, Topical; Adolescent; Anti-Bacterial Agents; Cefmenoxime; Cefozopran; Cephalosporins; Contact Lenses; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections | 2005 |
Pseudomonas aeruginosa infective endocarditis presenting as bacterial meningitis.
Topics: Acyclovir; Ampicillin; Calcification, Physiologic; Cefepime; Cephalosporins; Community-Acquired Infections; Diagnosis, Differential; Echocardiography, Transesophageal; Endocarditis, Bacterial; Female; Gentamicins; Humans; Meningitis, Bacterial; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Vancomycin | 2005 |
[Efficacy and safety of cefepime in the treatment of bronchopulmonary disease exacerbation in pediatric patients with mucoviscidosis].
Topics: Adolescent; Anti-Bacterial Agents; Bronchial Diseases; Cefepime; Cephalosporins; Child; Cystic Fibrosis; Female; Humans; Lung Diseases; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Staphylococcal Infections; Staphylococcus aureus | 2005 |
Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
Topics: Animals; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Imipenem; Membrane Transport Proteins; Meropenem; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Specific Pathogen-Free Organisms; Thienamycins; Thigh; Treatment Outcome | 2007 |
Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Administration Schedule; Escherichia coli; Escherichia coli Infections; Female; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Pseudomonas aeruginosa; Pseudomonas Infections | 2006 |
Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Computer Simulation; Drug Administration Schedule; Drug Resistance, Bacterial; Humans; Hungary; Imipenem; Infusions, Intravenous; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2006 |
In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
Topics: Animals; beta-Lactamases; Burns; Cephalosporins; Drug Resistance, Multiple, Bacterial; Lung Diseases; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Urinary Tract Infections; Wound Infection | 2007 |
Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; Cefepime; Cephalosporins; Culture Media; Drug Resistance, Multiple; Fluoroquinolones; France; Hospitals, University; Humans; Incidence; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study.
Topics: Anti-Bacterial Agents; Canada; Cephalosporins; Cross Infection; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
[Clinical studies on combination therapy of cephem antibiotics in chronic complicated urinary tract polymicrobial infections due to Pseudomonas aeruginosa and other bacteria].
Topics: Aged; Bacterial Infections; Cefmenoxime; Cefotaxime; Cefotiam; Cefsulodin; Cephalosporins; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Pseudomonas Infections; Urinary Tract Infections | 1984 |
Intravenous cefotaxime in children with bacterial meningitis.
Topics: Biological Availability; Cephalosporins; Child; Child, Preschool; Drug Resistance, Microbial; Escherichia coli Infections; Female; Humans; In Vitro Techniques; Infant; Infant, Newborn; Injections, Intravenous; Male; Meningitis; Meningitis, Haemophilus; Meningitis, Pneumococcal; Pseudomonas Infections; Staphylococcal Infections; Streptococcal Infections; Streptococcus agalactiae | 1980 |
Diarrhoea and annihilation of faecal flora associated with cefpiramide.
Topics: Cephalosporins; Child; Diarrhea; Feces; Humans; Pseudomonas Infections | 1983 |
Clinical experience with Moxalactam in the treatment of pseudomonal and nonpseudomonal infections.
Topics: Adult; Aged; Bacterial Infections; Cephalosporins; Cephamycins; Female; Humans; Male; Middle Aged; Moxalactam; Pseudomonas Infections | 1982 |
Gram-negative bacillary meningitis. New therapy and changing concepts.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Cephamycins; Chloramphenicol; Enterobacteriaceae Infections; Humans; Meningitis; Moxalactam; Pseudomonas Infections | 1982 |
[Cefoperazone in infections caused by resistant agents, with special reference to Pseudomonas aeruginosa].
Topics: Anti-Bacterial Agents; Bacterial Infections; Cefoperazone; Cephalosporins; Drug Resistance, Microbial; Humans; Pseudomonas aeruginosa; Pseudomonas Infections | 1982 |
Moxalactam therapy. Its use in chronic suppurative otitis media and malignant external otitis.
Topics: Aged; Cephalosporins; Cephamycins; Chronic Disease; Diabetes Complications; Female; Humans; Male; Mastoiditis; Middle Aged; Moxalactam; Otitis Externa; Otitis Media; Otitis Media, Suppurative; Pseudomonas Infections | 1982 |
Third-generation cephalosporins in the treatment of pneumonia due to Pseudomonas aeruginosa in guinea pigs.
Topics: Animals; Cefoperazone; Cefsulodin; Ceftazidime; Cephalosporins; Cephamycins; Drug Evaluation, Preclinical; Guinea Pigs; Moxalactam; Pneumonia; Pseudomonas Infections; Ticarcillin; Tobramycin | 1982 |
Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Cephamycins; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Moxalactam; Pseudomonas aeruginosa; Pseudomonas Infections | 1982 |
Gram-negative bacterial toe web infection: successful treatment with a new third generation cephalosporin.
Topics: Adult; Aged; Bacterial Infections; Cefoperazone; Cephalosporins; Enterobacteriaceae Infections; Foot Dermatoses; Humans; Male; Middle Aged; Proteus Infections; Pseudomonas Infections; Skin Diseases, Infectious; Streptococcal Infections; Toes | 1983 |
[Studies on the combination action of sisomicin, gentamicin and piperacillin, cefmetazole against Pseudomonas aeruginosa and Serratia marcescens].
Topics: Animals; Cefmetazole; Cephalosporins; Cephamycins; Drug Evaluation, Preclinical; Drug Synergism; Gentamicins; Male; Mice; Penicillin Resistance; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Serratia marcescens; Sisomicin | 1983 |
Moxalactam-tobramycin-resistant Pseudomonas aeruginosa isolates in patients with cystic fibrosis.
Topics: Adolescent; Anti-Bacterial Agents; Cephalosporins; Cephamycins; Child; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Male; Moxalactam; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin | 1983 |
Perforated and gangrenous appendicitis: an analysis of antibiotic failures.
Topics: Anti-Bacterial Agents; Appendicitis; Bacteroides fragilis; Bacteroides Infections; Cefamandole; Cefoperazone; Cephalosporins; Clindamycin; Drug Therapy, Combination; Female; Gangrene; Gentamicins; Humans; Male; Pseudomonas; Pseudomonas Infections; Rupture, Spontaneous | 1983 |
Ceftazidime treatment in intensive care patients.
Topics: Abscess; Adolescent; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Ceftazidime; Cephalosporins; Drug Eruptions; Drug Resistance, Microbial; Female; Humans; Intensive Care Units; Male; Middle Aged; Pseudomonas Infections; Respiratory Tract Infections; Sepsis; Urinary Tract Infections | 1983 |
[Enzymatic stability in vivo of a new cephalosporin active against Pseudomonas aeruginosa: ceftazidime].
Topics: Adolescent; Ceftazidime; Cephalosporins; Humans; Male; Penicillinase; Pseudomonas aeruginosa; Pseudomonas Infections | 1984 |
Antibiotics--their administration, choice and prophylactic use.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Humans; Penicillins; Polymyxins; Pseudomonas Infections; Streptococcal Infections | 1980 |
[Cefotaxime in septicaemia and severe infections due to multiresistant Gram-negative bacilli (author's transl)].
Topics: Adult; Aged; Cefotaxime; Cephalosporins; Drug Resistance, Microbial; Enterobacteriaceae Infections; Female; Humans; Male; Meningitis; Middle Aged; Pseudomonas Infections; Respiratory Tract Infections; Sepsis; Urinary Tract Infections | 1981 |
[Cefotaxime in the treatment of purulent meningitis in children (author's transl)].
Topics: Cefotaxime; Cephalosporins; Enterobacteriaceae Infections; Female; Humans; Infant; Infant, Newborn; Male; Meningitis; Meningitis, Haemophilus; Pseudomonas Infections; Salmonella Infections | 1981 |
[Cefotaxime in digestive tract infections (author's transl)].
Topics: Adult; Aged; Cefotaxime; Cephalosporins; Digestive System Diseases; Enterobacteriaceae Infections; Female; Humans; Male; Middle Aged; Pseudomonas Infections; Staphylococcal Infections | 1981 |
Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbenicillin; Cefoperazone; Cefotaxime; Ceftazidime; Cephalosporins; Cystic Fibrosis; Imipenem; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 1981 |
[Chemotherapy of severe bacterial infections in pediatrics].
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Cefotaxime; Cephalosporins; Clindamycin; Drug Therapy, Combination; Enterobacteriaceae Infections; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Infant, Premature, Diseases; Meningitis; Metronidazole; Penicillin G; Pseudomonas Infections; Streptococcal Infections | 1983 |
[Clinical use of new cephalosporins for severe infections in internal medicine].
Topics: Bacteroides Infections; Cefotaxime; Cefoxitin; Cephalosporins; Cross Infection; Drug Therapy, Combination; Enterobacteriaceae Infections; Gentamicins; Humans; Pseudomonas Infections; Staphylococcal Infections; Structure-Activity Relationship | 1983 |
[Cefoperazone, cefsulodin and ceftazidime--3 cephalosporins active against Pseudomonas in comparison with their monobactam analogs].
Topics: beta-Lactamase Inhibitors; Cefoperazone; Cefsulodin; Ceftazidime; Cephalosporins; Chemical Phenomena; Chemistry; Clavulanic Acid; Clavulanic Acids; Drug Resistance, Microbial; Humans; Monobactams; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam | 1983 |
Treatment of Pseudomonas aeruginosa meningitis with ceftazidime.
Topics: Adolescent; Ceftazidime; Cephalosporins; Humans; Male; Meningitis; Pseudomonas Infections | 1983 |
Ceftazidime therapy for serious infections.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Ceftazidime; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Male; Middle Aged; Peritonitis; Pseudomonas Infections; Respiratory Tract Infections; Staphylococcal Infections; Urinary Tract Infections | 1983 |
Ceftazidime: a new approach in the treatment of moderate and severe infections.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Ceftazidime; Cephalosporins; Child; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Male; Meningitis; Middle Aged; Peritonitis; Pseudomonas Infections; Respiratory Tract Infections; Sepsis; Skin Diseases, Infectious; Urinary Tract Infections | 1983 |
Ceftazidime as a single agent in the treatment of severe Pseudomonas aeruginosa infections.
Topics: Adolescent; Adult; Aged; Ceftazidime; Cephalosporins; Child; Drug Resistance, Microbial; Eosinophilia; Female; Humans; Liver Function Tests; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas Infections; Respiratory Tract Infections; Sepsis; Urinary Tract Infections | 1983 |
Ceftazidime in the therapy of serious Gram-negative bacillary infections.
Topics: Acute Kidney Injury; Adult; Aged; Anaphylaxis; Bacterial Infections; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Female; Humans; Male; Middle Aged; Osteomyelitis; Pseudomonas Infections; Respiratory Tract Infections; Sepsis; Wound Infection | 1983 |
The treatment of bone infections with ceftazidime.
Topics: Acute Disease; Adult; Aged; Ceftazidime; Cephalosporins; Chronic Disease; Coombs Test; Female; Humans; Liver Function Tests; Male; Middle Aged; Osteomyelitis; Pseudomonas Infections | 1983 |
Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis.
Topics: Adolescent; Adult; Ceftazidime; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Half-Life; Humans; Kinetics; Pseudomonas Infections; Respiratory Tract Infections; Sputum; Tobramycin | 1983 |
Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.
Topics: Adolescent; Adult; Ceftazidime; Cephalosporins; Child; Cystic Fibrosis; Female; Humans; Kinetics; Male; Premedication; Probenecid; Pseudomonas Infections; Respiratory Tract Infections | 1983 |
Experience with ceftazidime in cystic fibrosis.
Topics: Adolescent; Ceftazidime; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Male; Pseudomonas Infections; Respiratory Tract Infections | 1983 |
Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia.
Topics: Adolescent; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Piperacillin; Pseudomonas Infections; Respiratory Tract Infections; Sulfamethoxazole; Tobramycin; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1983 |
Ceftazidime - a significant advance in the treatment of cystic fibrosis.
Topics: Adolescent; Adult; Ceftazidime; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Female; Floxacillin; Humans; Male; Pseudomonas Infections; Respiratory Tract Infections; Staphylococcal Infections; Tobramycin | 1983 |
Clinical pharmacology of ceftazidime in paediatrics.
Topics: Adolescent; Ceftazidime; Cephalosporins; Child, Preschool; Cystic Fibrosis; Female; Half-Life; Humans; Infant, Newborn; Infant, Newborn, Diseases; Kinetics; Male; Microbial Sensitivity Tests; Pseudomonas Infections; Respiratory Tract Infections; Tissue Distribution; Urinary Tract Infections | 1983 |
Ceftazidime in the treatment of chronic suppurative otitis media in children.
Topics: Ceftazidime; Cephalosporins; Child, Preschool; Chronic Disease; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Otitis Media; Otitis Media, Suppurative; Pseudomonas Infections; Recurrence | 1983 |
Ceftazidime in cystic fibrosis: clinical, microbiological and immunological studies.
Topics: Adolescent; Adult; Ceftazidime; Cephalosporins; Child; Cystic Fibrosis; Female; Humans; Male; Neutrophils; Pseudomonas Infections; Recurrence; Respiratory Tract Infections | 1983 |
Clinical studies on ceftazidime in surgery in Japan.
Topics: Ceftazidime; Cephalosporins; Escherichia coli Infections; Female; Humans; Japan; Male; Middle Aged; Postoperative Complications; Pseudomonas Infections; Staphylococcal Infections; Surgical Wound Infection | 1983 |
An open study of the use of ceftazidime in Gram-negative infections.
Topics: Adult; Aged; Ceftazidime; Cephalosporins; Cystic Fibrosis; Enterobacteriaceae Infections; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Middle Aged; Osteomyelitis; Pseudomonas Infections; Respiratory Tract Infections; Urinary Tract Infections; Wound Infection | 1983 |
Clinical experience with ceftazidime in urology in Japan.
Topics: Aged; Bacterial Infections; Ceftazidime; Cephalosporins; Female; Humans; Japan; Male; Middle Aged; Pseudomonas Infections; Serratia marcescens; Urinary Tract Infections | 1983 |
An open study of ceftazidime in the treatment of serious bacterial infection.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Ceftazidime; Cephalosporins; Female; Humans; Male; Middle Aged; Pseudomonas Infections; Salmonella Infections | 1983 |
Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Enterobacteriaceae Infections; Female; Humans; Male; Middle Aged; Pseudomonas Infections | 1983 |
Successful treatment of Pseudomonas aeruginosa meningitis with ceftazidime.
Topics: Aged; Ceftazidime; Cephalosporins; Humans; Male; Meningitis; Pseudomonas Infections | 1983 |
Ceftazidime in the treatment of pediatric patients with severe urinary tract infections due to Pseudomonas spp.
Topics: Adolescent; C-Reactive Protein; Ceftazidime; Cephalosporins; Child; Child, Preschool; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas Infections; Time Factors; Urinary Tract Infections | 1984 |
Ceftazidime therapy of infections caused by Enterobacteriaceae and Pseudomonas aeruginosa.
Topics: Adult; Aged; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Enterobacteriaceae Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis | 1983 |
Reduced sensitivity to beta-lactam antibiotics arising during ceftazidime treatment of Pseudomonas aeruginosa infections.
Topics: Adult; Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections | 1983 |
Treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin.
Topics: Adolescent; Adult; Ceftazidime; Cephalosporins; Child; Child, Preschool; Chronic Disease; Cystic Fibrosis; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1983 |
Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria.
Topics: Acute Disease; Adolescent; Adult; Aged; Bacterial Infections; Ceftazidime; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Drug Evaluation; Drug Resistance, Microbial; Female; Gram-Negative Bacteria; Humans; Infant; Lung Diseases; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Urinary Tract Infections | 1984 |
Single versus combination antibiotic therapy for pneumonia due to Pseudomonas aeruginosa in neutropenic guinea pigs.
Topics: Agranulocytosis; Aminoglycosides; Animals; Anti-Bacterial Agents; Azlocillin; Ceftazidime; Cephalosporins; Drug Synergism; Drug Therapy, Combination; Guinea Pigs; Netilmicin; Neutropenia; Penicillin Resistance; Penicillins; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin | 1984 |
[In vivo-acquired resistance to cefsulodin by a strain of Pseudomonas aeruginosa].
Topics: Cefsulodin; Cephalosporins; Drug Resistance, Microbial; Female; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 1984 |
In vitro properties of ceftazidime, a highly active broad-spectrum cephalosporin with antipseudomonal activity.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactamases; Ceftazidime; Cephalosporins; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas aeruginosa; Pseudomonas Infections | 1984 |
Ceftazidime disposition in acute and stable cystic fibrosis.
Topics: Adolescent; Adult; Ceftazidime; Cephalosporins; Cystic Fibrosis; Female; Half-Life; Humans; Injections, Intravenous; Kinetics; Lung Diseases; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum | 1984 |
[In vitro activity of a new cephalosporin--cefoperazone--against Enterobacteriaceae and Pseudomonas aeruginosa].
Topics: Cefoperazone; Cephalosporins; Dose-Response Relationship, Drug; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Pseudomonas Infections | 1981 |
Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic.
Topics: Bacterial Infections; Cephalosporins; Cephamycins; Drug Resistance, Microbial; Humans; Moxalactam; Pseudomonas Infections | 1981 |
The role of the laboratory in the planned use of cefoperazone for the treatment of difficult Pseudomonas infections.
Topics: Adult; Aged; Aortitis; Cefoperazone; Cephalosporins; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Osteomyelitis; Pseudomonas; Pseudomonas Infections; Sepsis | 1981 |
Moxalactam therapy for bacterial infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Cephamycins; Child; Child, Preschool; Female; Humans; Infant; Klebsiella Infections; Male; Microbial Sensitivity Tests; Middle Aged; Moxalactam; Pseudomonas Infections; Sepsis; Structure-Activity Relationship | 1981 |
Interaction of moxalactam and gentamicin: in-vitro study with strains of Staphylococcus aureus and Pseudomonas aeruginosa.
Topics: Cephalosporins; Cephamycins; Drug Interactions; Gentamicins; Humans; Microbial Sensitivity Tests; Moxalactam; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus | 1982 |
[Laboratory and clinical studies on cefsulodin (author's transl)].
Topics: Adult; Aged; Cefsulodin; Cephalosporins; Cystitis; Drug Evaluation; Female; Gentamicins; Humans; Male; Middle Aged; Penicillin Resistance; Penicillins; Piperacillin; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections | 1981 |
Cephalosporin antibiotic agents.
Topics: Bacterial Infections; Cephalosporins; Costs and Cost Analysis; Drug Resistance, Microbial; Enterobacteriaceae Infections; Humans; Meningitis, Haemophilus; Pseudomonas Infections | 1984 |
Basic design of beta-lactam antibiotics--cephalosporins.
Topics: Administration, Oral; Bacterial Infections; Bacteroides Infections; Cephalosporins; Humans; Injections; Pseudomonas Infections; Structure-Activity Relationship; Technology, Pharmaceutical | 1984 |
Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.
Topics: Adult; Anti-Bacterial Agents; Carbenicillin; Cefsulodin; Cephalosporins; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Male; Peak Expiratory Flow Rate; Pseudomonas Infections; Tobramycin | 1983 |
[Topical administration of cefsulodin in postoperative Pseudomonas aeruginosa infection of the middle ears].
Topics: Administration, Topical; Adolescent; Adult; Aged; Cefsulodin; Cephalosporins; Drug Evaluation; Female; Humans; Male; Otitis Media; Postoperative Complications; Pseudomonas Infections | 1983 |
Penetration of cefsulodin into bronchial secretions.
Topics: Bronchi; Bronchoscopy; Cefsulodin; Cephalosporins; Humans; Kinetics; Pseudomonas Infections | 1984 |
Gram-negative foot infections: antimicrobial therapy.
Topics: Aged; Aminoglycosides; Bacteroides Infections; Cephalosporins; Drug Therapy, Combination; Foot Diseases; Humans; Male; Middle Aged; Penicillins; Proteus Infections; Proteus mirabilis; Pseudomonas Infections | 1982 |
[Gram negative bacilli endocarditis ].
Topics: Adolescent; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Child; Drug Therapy, Combination; Endocarditis, Bacterial; Enterobacteriaceae Infections; Female; Heart Valve Prosthesis; Humans; Male; Middle Aged; Penicillins; Prognosis; Pseudomonas Infections | 1982 |
Gentamicin and cefsulodin efficacy in a rat abscess model.
Topics: Abscess; Anaerobiosis; Animals; Cefsulodin; Cephalosporins; Disease Models, Animal; Female; Gentamicins; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rats | 1982 |
[Pseudomonas aeruginosa bacteriaemia: new clinical and therapeutic aspects ].
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Female; Humans; Male; Middle Aged; Penicillins; Prognosis; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis | 1982 |
Treatment of pulmonary Pseudomonas aeruginosa infection in cystic fibrosis with cefsulodin.
Topics: Adolescent; Adult; Cefsulodin; Cephalosporins; Child; Cystic Fibrosis; Drug Evaluation; Female; Humans; Lung Diseases; Male; Pseudomonas aeruginosa; Pseudomonas Infections | 1982 |
[Gram negative infective endocarditis. Apropos of 27 cases].
Topics: Adult; Aged; Brucellosis; Cephalosporins; Child; Endocarditis, Bacterial; Enterobacteriaceae Infections; Female; Fusobacterium Infections; Haemophilus Infections; Heart Failure; Humans; Male; Middle Aged; Prognosis; Pseudomonas Infections; Shock, Septic | 1982 |
Ceftazidime in the treatment of urinary tract infection.
Topics: Aged; Ceftazidime; Cephalosporins; Enterococcus faecalis; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Pseudomonas Infections; Streptococcal Infections; Urinary Catheterization; Urinary Tract Infections | 1982 |
[Clinical studies on cefsulodin in the field of pediatrics].
Topics: Age Factors; Cefsulodin; Cephalosporins; Child, Preschool; Drug Evaluation; Drug Resistance, Microbial; Humans; Infant; Male; Pseudomonas aeruginosa; Pseudomonas Infections | 1982 |
[Clinical evaluation of cefsulodin in the field of pediatrics].
Topics: Adolescent; Age Factors; Cefsulodin; Cephalosporins; Child, Preschool; Drug Evaluation; Drug Resistance, Microbial; Female; Humans; Infant; Male; Pseudomonas aeruginosa; Pseudomonas Infections | 1982 |
[Experimental and clinical evaluation of cefsulodin in the pediatric field].
Topics: Adolescent; Age Factors; Cefsulodin; Cephalosporins; Child; Child, Preschool; Drug Evaluation; Drug Resistance, Microbial; Escherichia coli; Female; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcus aureus | 1982 |
Nosocomial pneumonia.
Topics: Aminoglycosides; Cephalosporins; Cross Infection; Enterobacter; Enterobacteriaceae Infections; Escherichia coli Infections; Humans; Klebsiella Infections; Klebsiella pneumoniae; Penicillin G; Pneumococcal Infections; Pneumonia; Pseudomonas Infections; Staphylococcal Infections | 1981 |
Oral antibiotics in pedal infections.
Topics: Administration, Oral; Anti-Bacterial Agents; Cephalosporins; Erythromycin; Escherichia coli Infections; Foot Diseases; Humans; Penicillins; Proteus Infections; Pseudomonas Infections; Staphylococcal Infections; Surgical Wound Infection | 1980 |
New antimicrobials.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Bacterial Infections; Cephalosporins; Humans; Penicillins; Pseudomonas Infections | 1982 |
The new cephalosporins.
Topics: Bacterial Infections; Cephalosporins; Chemical Phenomena; Chemistry; Humans; Pseudomonas Infections | 1982 |
[The effectiveness of recent cephalosporins against urinary tract and wound infection bacteria including Pseudomonas aeruginosa].
Topics: Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas Infections; Urinary Tract Infections; Wound Infection | 1982 |
[Clinical studies on cefsulodin in the pediatric field].
Topics: Administration, Intranasal; Adolescent; Age Factors; Cefsulodin; Cephalosporins; Child; Drug Evaluation; Female; Humans; Infant, Newborn; Injections, Intravenous; Male; Pseudomonas Infections; Sputum | 1982 |
[Clinical evaluation of cefsulodin in Pseudomonas infections in children].
Topics: Adolescent; Age Factors; Cefsulodin; Cephalosporins; Child; Child, Preschool; Drug Evaluation; Female; Humans; Infant; Infant, Newborn; Male; Pseudomonas Infections | 1982 |
[Evaluation of cefsulodin in the field of pediatrics].
Topics: Age Factors; Cefsulodin; Cephalosporins; Child, Preschool; Drug Evaluation; Humans; Infant; Infusions, Parenteral; Male; Pseudomonas Infections | 1982 |
[The experimental and clinical studies on cefsulodin in the pediatric field].
Topics: Age Factors; Cefsulodin; Cephalosporins; Child; Child, Preschool; Drug Evaluation; Female; Humans; Male; Pseudomonas Infections | 1982 |
[Clinical studies of cefsulodin in the pediatric field].
Topics: Age Factors; Cefsulodin; Cephalosporins; Child; Child, Preschool; Drug Evaluation; Female; Humans; Infusions, Parenteral; Injections, Intravenous; Kinetics; Pseudomonas Infections | 1982 |
[Clinical application of cefsulodin in gravely ill children with Pseudomonas infection].
Topics: Adolescent; Age Factors; Cefsulodin; Cephalosporins; Child; Drug Evaluation; Humans; Infant; Infusions, Parenteral; Injections, Intravenous; Male; Pseudomonas Infections | 1982 |
Selection of antimicrobial therapy.
Topics: Anti-Bacterial Agents; Cephalosporins; Child; Enterobacteriaceae Infections; Humans; Osteomyelitis; Penicillins; Pseudomonas Infections; Staphylococcal Infections; Streptococcal Infections; Surgical Wound Infection; Vascular Diseases | 1982 |
[Transfer of cefsulodin into human otorrhea after intravenous administration].
Topics: Adolescent; Adult; Aged; Cefsulodin; Cephalosporins; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Otitis Media; Pseudomonas Infections; Suppuration | 1982 |
[Clinical evaluation of cefsulodin for the infection caused by P. aeruginosa in otorhinolaryngological field].
Topics: Adolescent; Adult; Cefsulodin; Cephalosporins; Child; Drug Evaluation; Humans; Infusions, Parenteral; Male; Middle Aged; Otitis Media; Pseudomonas Infections; Suppuration | 1982 |
[Clinical study of cefsulodin on infectious diseases in otorhinolaryngological field].
Topics: Adult; Cefsulodin; Cephalosporins; Child; Drug Evaluation; Female; Humans; Male; Middle Aged; Otitis Media; Pseudomonas Infections | 1982 |
[Clinical study of cefsulodin on Pseudomonas aeruginosa infections in otorhinolaryngology].
Topics: Adult; Aged; Cefsulodin; Cephalosporins; Chronic Disease; Drug Evaluation; Female; Humans; Male; Middle Aged; Otitis Media; Pseudomonas Infections; Surgical Wound Infection | 1982 |
[Clinical experience with cefsulodin in the field of otorhinolaryngology].
Topics: Cefsulodin; Cephalosporins; Chronic Disease; Drug Evaluation; Female; Humans; Male; Otitis Media; Pseudomonas Infections; Surgical Wound Infection | 1982 |
[Basic and clinical studies on cefsulodin for the otorhinolaryngological infections].
Topics: Adolescent; Adult; Cefsulodin; Cephalosporins; Child; Drug Evaluation; Female; Humans; Male; Middle Aged; Otorhinolaryngologic Diseases; Pseudomonas Infections; Tissue Distribution | 1982 |
Antipseudomonal activity of beta-lactam antibiotics.
Topics: Cephalosporins; Pseudomonas Infections | 1981 |
[Clinical application of cefsulodin to Pseudomonas aeruginosa infections in the surgical field (author's transl)].
Topics: Adult; Aged; Burns; Cefsulodin; Cephalosporins; Child; Drug Evaluation; Female; Humans; Male; Middle Aged; Pseudomonas Infections; Surgical Wound Infection | 1981 |
[Cefsulodine concentrations in cerebral ventricles during parenteral treatment of ventriculitis due to Pseudomonas aeruginosa (author's transl)].
Topics: Cefsulodin; Cephalosporins; Cerebral Ventricles; Encephalitis; Humans; Male; Middle Aged; Pseudomonas Infections | 1981 |
[Treatment of Pseudomonas infections in children with cefsulodin (author's transl)].
Topics: Anti-Bacterial Agents; Cefsulodin; Cephalosporins; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Humans; Infant; Infant, Newborn; Pseudomonas Infections | 1981 |
New cephalosporins and related compounds.
Topics: Cephalosporins; Humans; Pseudomonas Infections | 1980 |
Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporin Resistance; Cephalosporins; Drug Therapy, Combination; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Microbial Sensitivity Tests; Models, Biological; Pseudomonas aeruginosa; Pseudomonas Infections | 1995 |
Postantibiotic effect of carbapenems against Pseudomonas aeruginosa.
Topics: Animals; Ceftazidime; Cephalosporins; Female; Imipenem; Meropenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1995 |
[A rare case of malignant otitis external in a non-diabetic patient].
Topics: Aged; Ceftazidime; Cephalosporins; Diagnostic Imaging; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Osteomyelitis; Otitis Externa; Pseudomonas aeruginosa; Pseudomonas Infections | 1995 |
Efficacy of a novel injectable cephalosporin, Cefclidin, on the experimental complicated urinary tract infections with urinary stones caused by Pseudomonas aeruginosa and Proteus mirabilis.
Topics: Animals; Cephalosporins; Disease Models, Animal; Drug Resistance, Microbial; Female; Imipenem; Kidney Calculi; Proteus Infections; Proteus mirabilis; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Urinary Bladder Calculi; Urinary Calculi; Urinary Tract Infections | 1994 |
Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa.
Topics: Animals; Cefpirome; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Endocarditis, Bacterial; Female; Microbial Sensitivity Tests; Pseudomonas Infections; Rabbits | 1994 |
Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations.
Topics: Cephalosporins; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections | 1993 |
Fever and neutropenia during intensive chemotherapy.
Topics: Agranulocytosis; Aminoglycosides; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cephalosporins; Drug Therapy, Combination; Fever; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Pseudomonas Infections; Vancomycin | 1993 |
Therapeutic effect of cefozopran (SCE-2787), a new parenteral cephalosporin, against experimental infections in mice.
Topics: Animals; Bacterial Infections; Cefozopran; Cephalosporins; Female; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred CBA; Mice, Inbred ICR; Muscular Diseases; Pseudomonas Infections; Respiratory Tract Infections; Staphylococcal Infections; Staphylococcus aureus; Urinary Tract Infections | 1993 |
Cephalosporins having a heterocyclic catechol in the C3 side chain. I. Enhancement of efficacy against gram-negative bacteria.
Topics: Animals; Ceftazidime; Cephalosporins; Half-Life; Imipenem; Mice; Microbial Sensitivity Tests; Pseudomonas Infections; Stereoisomerism; Structure-Activity Relationship | 1993 |
Combination therapy of Pseudomonas aeruginosa pyelonephritis in neutropenic mice with human antilipopolysaccharide monoclonal antibody and cefsulodin.
Topics: Animals; Antibodies, Monoclonal; Bacteremia; Cefsulodin; Cephalosporins; Combined Modality Therapy; Female; Flow Cytometry; Humans; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Neutropenia; Neutrophils; Phagocytosis; Pseudomonas Infections; Pyelonephritis | 1996 |
Experimental endogenous septicaemia caused by Klebsiella pneumoniae and Escherichia coli in mice.
Topics: Ampicillin; Animals; Bacteremia; Ceftazidime; Cephalosporins; Cyclophosphamide; Disease Models, Animal; Escherichia coli Infections; Fluorouracil; Immunosuppressive Agents; Klebsiella Infections; Klebsiella pneumoniae; Male; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Penicillins; Pseudomonas Infections; Survival Analysis | 1996 |
Pseudomonas bacteremia precipitated by ticlopidine-induced neutropenia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Ceftazidime; Cephalosporins; Filgrastim; Gentamicins; Granulocyte Colony-Stimulating Factor; Humans; Male; Neutropenia; Platelet Aggregation Inhibitors; Pseudomonas aeruginosa; Pseudomonas Infections; Recombinant Proteins; Ticlopidine | 1996 |
Corneal ulcers in two institutions in Singapore: analysis of causative factors, organisms and antibiotic resistance.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Chloramphenicol Resistance; Contact Lenses; Corneal Ulcer; Drug Resistance, Microbial; Equipment Contamination; Eye Diseases; Eye Injuries; Female; Gentamicins; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Keratitis; Male; Middle Aged; Occupational Diseases; Proteus Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors; Singapore | 1995 |
Botryomycosis caused by Pseudomonas vesicularis.
Topics: Cefuroxime; Cephalosporins; Hand Dermatoses; Humans; Male; Middle Aged; Pseudomonas Infections | 1996 |
[Antibiotic-induced prolonged cholestasis: suspected induction by ceftibuten].
Topics: Adult; Ceftibuten; Cephalosporin Resistance; Cephalosporins; Cholestasis, Intrahepatic; Fatal Outcome; Female; Humans; Liver; Otitis Externa; Pseudomonas Infections; Sepsis | 1996 |
[Spontaneous bacterial peritonitis caused by Pseudomonas aeruginosa].
Topics: Ampicillin; Ascitic Fluid; Ceftazidime; Cephalosporins; Enterococcus faecalis; Humans; Male; Middle Aged; Penicillins; Peritonitis; Pseudomonas aeruginosa; Pseudomonas Infections | 1996 |
Differential distributions in tissues and efficacies of aztreonam and ceftazidime and in vivo bacterial morphological changes following treatment.
Topics: Animals; Aztreonam; Ceftazidime; Cephalosporins; Enterobacter cloacae; Enterobacteriaceae Infections; Female; Fibrin; Microbial Sensitivity Tests; Monobactams; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Serratia Infections; Serratia marcescens | 1997 |
Therapeutic effects of cefozopran against experimental mixed urinary tract infection with Enterococcus faecalis and Pseudomonas aeruginosa in mice.
Topics: Ampicillin; Animals; Cefozopran; Ceftazidime; Cephalosporins; Cilastatin; Enterococcus faecalis; Female; Gram-Positive Bacterial Infections; Imipenem; Mice; Mice, Inbred CBA; Ofloxacin; Pseudomonas Infections; Urinary Tract Infections | 1997 |
In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
Topics: Animals; Carbapenems; Ceftazidime; Cephalosporins; Culture Media; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Imipenem; In Vitro Techniques; Male; Meropenem; Mice; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1997 |
Experimental pseudomonal posttraumatic endophthalmitis in a swine model. Treatment with ceftazidime, amikacin, and imipenem.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Eye Injuries, Penetrating; Follow-Up Studies; Imipenem; Injections; Pseudomonas aeruginosa; Pseudomonas Infections; Sclera; Swine; Thienamycins; Vitreous Body | 1997 |
Potentiating effect of EDTA-Tris on the activity of antibiotics against resistant bacteria associated with otitis, dermatitis and cystitis.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Buffers; Cephaloridine; Cephalosporins; Cystitis; Dermatitis; Dog Diseases; Dogs; Drug Synergism; Edetic Acid; Enrofloxacin; Escherichia coli Infections; Female; Fluoroquinolones; Kanamycin; Male; Otitis; Proteus Infections; Proteus mirabilis; Pseudomonas Infections; Quinolones; Staphylococcal Infections; Time Factors; Tromethamine | 1997 |
Serum bactericidal activity of ceftazidime administered as continuous infusion of 3 g over 24 h versus intermittent bolus infusion of 2 g against Pseudomonas aeruginosa in healthy volunteers.
Topics: Ceftazidime; Cephalosporins; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Serum Bactericidal Test | 1997 |
Therapeutic efficacy of intravitreal ceftazidime, imipenem, and amikacin in a swine model of posttraumatic Pseudomonas aeruginosa endophthalmitis.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Eye Injuries, Penetrating; Imipenem; Pseudomonas Infections; Swine; Vitreous Body | 1997 |
Predictive value of several signs of infection as surrogate markers for mortality in a neutropenic guinea pig model of Pseudomonas aeruginosa sepsis.
Topics: Animals; Anti-Bacterial Agents; Biomarkers; Ceftazidime; Cephalosporins; Diarrhea; Disease Models, Animal; Female; Guinea Pigs; Imipenem; Meropenem; Movement Disorders; Neutropenia; Predictive Value of Tests; Pseudomonas Infections; Regression Analysis; Respiration; Thienamycins; Time Factors; Tobramycin; Weight Loss | 1997 |
Ceftazidime, gentamicin, and rifampicin, in combination, kill biofilms of mucoid Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Biofilms; Bronchi; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Synergism; Drug Therapy, Combination; Gentamicins; Humans; Polysaccharides, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Rifampin; Time Factors | 1997 |
Corneal ulcer associated with contamination of aerosol saline spray tip.
Topics: Aerosols; Anti-Bacterial Agents; Cefazolin; Cephalosporins; Contact Lens Solutions; Contact Lenses, Hydrophilic; Cornea; Corneal Transplantation; Corneal Ulcer; Drug Therapy, Combination; Equipment Contamination; Eye Infections, Bacterial; Female; Humans; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Sodium Chloride; Tobramycin | 1997 |
Practical approach for detection and identification of OXA-10-derived ceftazidime-hydrolyzing extended-spectrum beta-lactamases.
Topics: beta-Lactamases; Ceftazidime; Cephalosporin Resistance; Cephalosporins; Humans; Mutation; Nucleic Acid Hybridization; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 1998 |
Risks and routes for ventilator-associated pneumonia with Pseudomonas aeruginosa.
Topics: Bacterial Proteins; Bronchi; Cephalosporins; Cohort Studies; Critical Care; DNA, Bacterial; Environmental Microbiology; Female; Follow-Up Studies; Forecasting; Humans; Incidence; Length of Stay; Lung; Lung Diseases, Obstructive; Male; Middle Aged; Multivariate Analysis; Patient Admission; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Assessment; Risk Factors; Sputum; Ventilators, Mechanical | 1998 |
Chemotactic factors in bronchial secretions of cystic fibrosis patients.
Topics: Adolescent; Adult; Aminoglycosides; Anti-Bacterial Agents; Bronchi; Bronchoalveolar Lavage Fluid; Cephalosporins; Chemotactic Factors; Chemotaxis, Leukocyte; Child; Chromatography, Gel; Cystic Fibrosis; Drug Therapy, Combination; Humans; Middle Aged; Pseudomonas Infections; Sputum | 1998 |
An in-vitro study of carbapenem-induced morphological changes and endotoxin release in clinical isolates of gram-negative bacilli.
Topics: Ceftazidime; Cephalosporins; Endotoxins; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1998 |
[Therapeutic effect of cefluprenam on polymicrobial urinary tract infection associated with Enterococcus faecalis, using the infectious urolithiasis model in rats].
Topics: Animals; Ceftazidime; Cephalosporins; Disease Models, Animal; Enterococcus faecalis; Female; Gram-Positive Bacterial Infections; Proteus Infections; Proteus mirabilis; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Urinary Calculi; Urinary Tract Infections | 1998 |
[Meningitis caused by Pseudomonas aeruginosa. Treatment with meropenem].
Topics: Aged; Blood-Brain Barrier; Cefepime; Cefotaxime; Cephalosporins; Cerebrospinal Fluid; Cerebrospinal Fluid Shunts; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Hydrocephalus; Male; Meningitis, Bacterial; Meropenem; Postoperative Complications; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1998 |
Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp.
Topics: Acinetobacter; Acinetobacter Infections; beta-Lactamases; Cefepime; Cephalosporins; Cross Infection; Humans; Microbial Sensitivity Tests; Nucleic Acid Hybridization; Pseudomonas aeruginosa; Pseudomonas Infections; Turkey | 1998 |
Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime.
Topics: Bacteremia; Cefepime; Cephalosporins; Evaluation Studies as Topic; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Reference Standards; Reproducibility of Results; Sensitivity and Specificity | 1998 |
Neonatal Pseudomonas putida infection presenting as staphylococcal scalded skin syndrome.
Topics: Ceftazidime; Cephalosporins; Diagnosis, Differential; Fatal Outcome; Humans; Infant, Newborn; Male; Pseudomonas Infections; Pseudomonas putida; Skin Diseases, Bacterial; Staphylococcal Scalded Skin Syndrome | 1998 |
Canadian Pseudomonas aeruginosa susceptibility study from 48 medical centers: focus on ciprofloxacin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Canada; Carbenicillin; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Resistance, Microbial; Geography; Hospitals; Humans; Imipenem; Microbial Sensitivity Tests; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Urinary Tract Infections | 1998 |
Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects.
Topics: Anti-Infective Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Endotoxins; Humans; Imipenem; Lipopolysaccharides; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1998 |
Infectious dermatitis in a ball python (Python regius) colony.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Boidae; Cefotaxime; Cephalosporins; Dermatitis; Disease Outbreaks; Fatal Outcome; Female; Male; Proteus Infections; Proteus vulgaris; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Infectious | 1998 |
Nosocomial infections with ceftazidime-resistant Pseudomonas aeruginosa: risk factors and outcome.
Topics: Ceftazidime; Cephalosporins; Cross Infection; Drug Resistance, Microbial; Female; Hospitals, Teaching; Humans; Logistic Models; Male; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Taiwan | 1999 |
Subcutaneous nodules with pseudomonas septicaemia in an immunocompetent patient.
Topics: Adult; Ceftazidime; Cephalosporins; Community-Acquired Infections; Female; Gentamicins; Humans; Immunocompetence; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Skin Diseases, Bacterial | 1999 |
A resuscitated case from asphyxia by large bronchial cast.
Topics: Airway Obstruction; Asphyxia; Bronchial Diseases; Bronchiectasis; Bronchopneumonia; Bronchoscopy; Ceftazidime; Cephalosporins; Female; Humans; Middle Aged; Pseudomonas Infections; Radiography, Thoracic; Resuscitation; Suction; Tomography, X-Ray Computed; Treatment Outcome | 1999 |
Bilateral Pseudomonas corneal ulcer in a disposable contact lens wearer.
Topics: Adolescent; Cephalosporins; Cephalothin; Contact Lenses, Hydrophilic; Cornea; Corneal Ulcer; Disposable Equipment; Drug Therapy, Combination; Eye Infections, Bacterial; Follow-Up Studies; Gentamicins; Humans; Male; Ophthalmic Solutions; Patient Education as Topic; Pseudomonas aeruginosa; Pseudomonas Infections | 1999 |
Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azlocillin; Ceftazidime; Cephalosporins; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1999 |
Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Imipenem; Lung; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar | 1999 |
Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Ceftazidime; Cephalosporins; Colony Count, Microbial; Drug Therapy, Combination; Humans; Mice; Pneumonia, Bacterial; Pseudomonas Infections; Survival Analysis; Time Factors; Urinary Tract Infections | 1999 |
In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Clarithromycin; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Mice; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 2000 |
Inactivation of the ampD gene in Pseudomonas aeruginosa leads to moderate-basal-level and hyperinducible AmpC beta-lactamase expression.
Topics: Ampicillin; Bacterial Proteins; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Cephalosporins; Enzyme Induction; Genetic Complementation Test; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; N-Acetylmuramoyl-L-alanine Amidase; Penicillins; Phenotype; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2000 |
Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: a time series analysis.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Drug Utilization; Forecasting; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Models, Biological; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Time Factors | 2000 |
Ceftazidime for outpatient parenteral antibiotic therapy (OPAT) of chronic suppurative otitis media due to Pseudomonas aeruginosa.
Topics: Ambulatory Care; Ceftazidime; Cephalosporins; Child; Chronic Disease; Female; Humans; Injections, Intramuscular; Male; Otitis Media, Suppurative; Patient Compliance; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2000 |
Aminoglycosides and renal magnesium homeostasis in humans.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Child; Cystic Fibrosis; Drug Therapy, Combination; Electrolytes; Female; Homeostasis; Humans; Kidney; Lung Diseases; Magnesium; Male; Pseudomonas aeruginosa; Pseudomonas Infections | 2000 |
Status epilepticus associated with cefepime.
Topics: Adult; Cefepime; Cephalosporins; Electroencephalography; Female; Humans; Male; Pseudomonas Infections; Status Epilepticus | 2000 |
Treatment of peritoneal dialysis related peritonitis--an Australian and New Zealand perspective.
Topics: Algorithms; Anti-Bacterial Agents; Australia; Catheterization; Cephalosporins; Humans; New Zealand; Peritoneal Dialysis; Peritonitis; Pseudomonas Infections; Vancomycin | 1999 |
Filamented Pseudomonas aeruginosa and a markedly high level of endotoxin in cerebrospinal fluid.
Topics: Adult; Cefozopran; Cephalosporins; Cerebrospinal Fluid; Endotoxins; Fatal Outcome; Humans; Japan; Male; Meningitis, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections | 2000 |
Antibacterial properties of Pseudomonas aeruginosa immunotype 1 lipopolysaccharide-specific monoclonal antibody (MAb) in a murine thigh infection model: combined effects of MAb and ceftazidime.
Topics: Animals; Antibodies, Monoclonal; Ceftazidime; Cephalosporins; Combined Modality Therapy; Disease Models, Animal; Female; Humans; Immunoglobulin G; Immunoglobulins; Lipopolysaccharides; Mice; Neutrophils; Phagocytosis; Pseudomonas aeruginosa; Pseudomonas Infections; Thigh | 2000 |
Pharmacokinetics of ceftazidime in dogs following subcutaneous administration and continuous infusion and the association with in vitro susceptibility of Pseudomonas aeruginosa.
Topics: Animals; Ceftazidime; Cephalosporins; Chromatography, High Pressure Liquid; Disease Susceptibility; Dog Diseases; Dogs; Infusions, Intravenous; Injections, Subcutaneous; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2000 |
[Malignant or necrotizing otitis externa: experience in 22 cases].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Cephalosporins; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Female; Fluoroquinolones; Gallium Radioisotopes; Humans; Hyperbaric Oxygenation; Immunocompromised Host; Male; Middle Aged; Otitis Externa; Pseudomonas Infections; Recurrence; Retrospective Studies; Technetium; Tomography, X-Ray Computed; Treatment Outcome | 2000 |
Locally delivered antibodies combined with systemic antibiotics confer synergistic protection against antibiotic-resistant burn wound infection.
Topics: Animals; Burns; Ceftazidime; Cephalosporins; Combined Modality Therapy; Cross Infection; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Drug Synergism; Female; Immunoglobulins, Intravenous; Infusions, Intravenous; Injections, Subcutaneous; Mice; Mice, Inbred Strains; Pseudomonas Infections; Survival Analysis; Wound Infection | 2000 |
Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing Pseudomonas aeruginosa due to chromosomal beta-lactamase.
Topics: Animals; Bacterial Proteins; beta-Lactamases; Biofilms; Ceftazidime; Cephalosporins; Chromosomes, Bacterial; Chronic Disease; Drug Resistance, Microbial; Electrophoresis, Gel, Pulsed-Field; Female; Isoelectric Focusing; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pregnancy; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Inbred Lew; Time Factors | 2000 |
Cavernous sinus thrombosis complicating odontogenic parapharyngeal space neck abscess: a case report and discussion.
Topics: Aged; Anti-Infective Agents; Cavernous Sinus Thrombosis; Ceftriaxone; Cephalosporins; Combined Modality Therapy; Diplopia; Drainage; Drug Therapy, Combination; Exophthalmos; Humans; Male; Metronidazole; Nafcillin; Ophthalmoplegia; Penicillins; Periodontal Abscess; Pseudomonas Infections; Retropharyngeal Abscess; Tomography, X-Ray Computed | 2000 |
Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children.
Topics: Adolescent; Ceftazidime; Cephalosporins; Child; Child, Preschool; Chronic Disease; Cystic Fibrosis; Female; Humans; Infusion Pumps; Male; Microbial Sensitivity Tests; Nutritional Status; Pseudomonas Infections | 2000 |
Studies on anti-MRSA parenteral cephalosporins. I. Synthesis and antibacterial activity of 7beta-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)- hydroxyiminoacetamido]-3-(substituted imidaz.
Topics: Animals; Cefozopran; Cephalosporins; Male; Methicillin Resistance; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Oximes; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Structure-Activity Relationship | 2000 |
Studies on anti-MRSA parenteral cephalosporins. II. Synthesis and antibacterial activity of 7beta-[2-(5-amino-1,2,4- thiadiazol-3-yl)-2(Z)-alkoxyiminoacetamido]-3-(substituted imidaz.
Topics: Animals; Cefozopran; Cephalosporins; Gram-Negative Bacteria; Magnetic Resonance Spectroscopy; Male; Methicillin Resistance; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Structure-Activity Relationship | 2000 |
Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis.
Topics: Adolescent; Anti-Bacterial Agents; Body Mass Index; Cephalosporins; Chemoprevention; Child; Child, Preschool; Cystic Fibrosis; Databases as Topic; Forced Expiratory Volume; Humans; Infant; Lung; Macrolides; Pseudomonas aeruginosa; Pseudomonas Infections; Registries; Staphylococcal Infections; Staphylococcus aureus; Statistics, Nonparametric; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Vital Capacity | 2001 |
Urinary tract infection in neurogenic bladder.
Topics: Acute Disease; Anti-Infective Agents, Urinary; Carbapenems; Cephalosporins; Chronic Disease; Epididymitis; Escherichia coli Infections; Female; Fever; Gram-Negative Bacterial Infections; Humans; Klebsiella Infections; Male; Prostatitis; Pseudomonas Infections; Pyelonephritis; Urinary Bladder; Urinary Bladder, Neurogenic; Urinary Catheterization; Urinary Tract Infections | 2001 |
Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase.
Topics: beta-Lactamases; Cephalosporins; Cross Infection; Disease Outbreaks; Drug Resistance, Microbial; Drug Resistance, Multiple; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Humans; Intensive Care Units; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2001 |
Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance.
Topics: Adult; Amikacin; Bacterial Outer Membrane Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Disease Outbreaks; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Ribotyping | 2001 |
Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: a review of 104 cases.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Equipment Contamination; Female; Gentamicins; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Netilmicin; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Pseudomonas Infections; Retrospective Studies; Secondary Prevention; Vancomycin | 2001 |
Post-antibiotic and synergic effects of fluoroquinolones and ceftazidime in combination against Pseudomonas strains.
Topics: Anti-Infective Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Comamonas testosteroni; Drug Synergism; Humans; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas Infections | 2001 |
Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli.
Topics: Ampicillin; Anti-Bacterial Agents; Cephalosporins; Cohort Studies; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Middle Aged; Pseudomonas; Pseudomonas Infections; Statistics as Topic; Sulbactam | 2001 |
CF and antistaphylococcal prophylaxis.
Topics: Cephalexin; Cephalosporins; Child; Cystic Fibrosis; Humans; Infant; Pseudomonas Infections; Staphylococcal Infections | 2001 |
[Survey of the antibiotic sensitivity of Pseudomonas aeruginosa in France and the distribution of beta-lactam resistance mechanisms: the GERPB 1999 study].
Topics: Academic Medical Centers; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cephalosporinase; Cephalosporins; Chromosomes, Bacterial; Drug Resistance; France; Humans; Microbial Sensitivity Tests; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; R Factors; Serotyping | 2001 |
Sepsis in a newborn due to Pseudomonas aeruginosa from a contaminated tub bath.
Topics: Ampicillin; Anti-Bacterial Agents; Baths; Cefotaxime; Cephalosporins; Drug Therapy, Combination; Gentamicins; Humans; Infant, Newborn; Pseudomonas aeruginosa; Pseudomonas Infections | 2001 |
In vivo selection of oxacillinase-mediated ceftazidime resistance in Pseudomonas aeruginosa.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Carrier Proteins; Ceftazidime; Cephalosporin Resistance; Cephalosporins; Conjugation, Genetic; DNA, Bacterial; Escherichia coli; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Sequence Data; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections | 2001 |
Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumonia.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Cefozopran; Cephalosporins; Cilastatin; Ciprofloxacin; Disease Models, Animal; Imipenem; Infusions, Parenteral; Male; Mice; Pneumonia, Bacterial; Protease Inhibitors; Pseudomonas aeruginosa; Pseudomonas Infections; Respiration, Artificial; Thienamycins | 2001 |
Nosocomial spread of the integron-located veb-1-like cassette encoding an extended-pectrum beta-lactamase in Pseudomonas aeruginosa in Thailand.
Topics: beta-Lactamases; Ceftazidime; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Gene Frequency; Humans; Integrases; Microbial Sensitivity Tests; Nucleic Acid Hybridization; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Thailand; Transduction, Genetic | 2002 |
Emergence of new pathogens in CF: the devil we know or the devil we don't know?
Topics: Antibiotic Prophylaxis; Cephalexin; Cephalosporins; Cystic Fibrosis; Humans; Opportunistic Infections; Pneumonia, Bacterial; Pneumonia, Staphylococcal; Pseudomonas Infections | 2002 |
Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Fluoroquinolones; Global Health; Humans; Population Surveillance; Pseudomonas aeruginosa; Pseudomonas Infections | 2002 |
In-vitro activity of new cephalosporin (HR 756) and cefazolin.
Topics: Cefazolin; Cephalosporins; Drug Evaluation; Drug Resistance, Microbial; Humans; In Vitro Techniques; Pseudomonas aeruginosa; Pseudomonas Infections | 1978 |
[Therapy of chronic respiratory tract infections in children, including mucoviscidosis (author's transl)].
Topics: Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Drug Combinations; Humans; Infant; Infant, Newborn; Long-Term Care; Pseudomonas Infections; Recurrence; Respiratory Tract Infections; Staphylococcal Infections; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1979 |
Antibiotic treatment of respiratory sepsis.
Topics: Ampicillin; Anti-Bacterial Agents; Carbenicillin; Cephalosporins; Chloramphenicol; Cloxacillin; Fosfomycin; Gentamicins; Haemophilus Infections; Humans; Methicillin; Penicillin G; Polymyxins; Pseudomonas Infections; Respiratory Tract Infections; Sepsis; Staphylococcal Infections; Streptococcal Infections | 1976 |
Comparative in vivo activities of cefsulodin, sulbenicillin, and gentamicin against Pseudomonas aeruginosa.
Topics: Animals; Cephalosporins; Gentamicins; Mice; Penicillin G; Penicillin Resistance; Pseudomonas Infections; Sulbenicillin | 1978 |
[Azlocilline and HR 756 in urosepsis and urinary tract infection with multiresistant pseudomonas and proteus morganii].
Topics: Adolescent; Cephalosporins; Female; Humans; Penicillin Resistance; Penicillins; Proteus Infections; Pseudomonas Infections; Sepsis; Tobramycin; Urinary Tract Infections | 1979 |
Common bacterial infections in infancy and childhood. 5. Infections of the skeletal system.
Topics: Arthritis, Infectious; Bacterial Infections; Cephalosporins; Child; Chloramphenicol; Female; Gentamicins; Haemophilus Infections; Haemophilus influenzae; Humans; Infant; Male; Osteomyelitis; Penicillins; Pseudomonas Infections; Staphylococcal Infections | 1978 |
[Progress in antibacterial chemotherapy].
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbenicillin; Cephalosporins; Cephalothin; Enterobacter; Enterobacteriaceae Infections; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Penicillins; Proteus Infections; Pseudomonas Infections | 1978 |
[New antibiotics].
Topics: Aminoglycosides; Ampicillin; Anti-Bacterial Agents; Cephalosporins; Escherichia coli Infections; Gram-Negative Aerobic Bacteria; Humans; Klebsiella Infections; Penicillin Resistance; Penicillins; Pseudomonas Infections; Sepsis | 1979 |
SCE-129, antipseudomonal cephalosporin: in vitro and in vivo antibacterial activities.
Topics: Animals; Bacterial Proteins; Cephalosporins; Depression, Chemical; DNA, Bacterial; Drug Resistance, Microbial; Male; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; RNA, Bacterial; Staphylococcus aureus | 1978 |
Antibiotics in pyelonephritis.
Topics: Aminoglycosides; Ampicillin; Anti-Bacterial Agents; Cephalosporins; Enterobacteriaceae Infections; Humans; Klebsiella Infections; Microbial Sensitivity Tests; Proteus Infections; Pseudomonas Infections; Pyelonephritis | 1979 |
Clinical experience with cefamandole for treatment of serious bone and joint infections.
Topics: Adolescent; Adult; Aged; Arthritis, Infectious; Bacterial Infections; Bacteroides Infections; Bursitis; Cefamandole; Cephalosporins; Child; Child, Preschool; Enterobacteriaceae Infections; Female; Humans; Male; Middle Aged; Osteomyelitis; Pseudomonas Infections; Staphylococcal Infections; Streptococcal Infections; Surgical Wound Infection | 1978 |
Evaluation of antibiotic efficacy using electron microscopy: morphological effects of guanylureido cephalosporin, chlorobenzoylureido cephalosporin, BL-P1654, and carbenicillin on Pseudomonas aeruginosa.
Topics: Animals; Carbenicillin; Cephalosporins; Chlorobenzoates; Guanidines; Leucine; Mice; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Penicillanic Acid; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections | 1976 |
Urinary infections in total hip arthroplasty. Influences of prophylactic cephalosporins and catheterization.
Topics: Arthroplasty; Cephalosporins; Enterobacteriaceae Infections; Female; Hip; Humans; Male; Pseudomonas Infections; Surgical Wound Infection; Urinary Catheterization; Urinary Tract Infections | 1976 |
[The bacterial infections in patients with acute leukemia and their treatment by antibiotics, with special reference to Klebsiella and Pseudomonas infections (author's transl)].
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Cephalosporins; Humans; Klebsiella Infections; Leukemia; Male; Penicillins; Pseudomonas Infections | 1975 |
Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model.
Topics: Amikacin; Aztreonam; Cefepime; Ceftazidime; Cephalosporins; Drug Therapy, Combination; Half-Life; Humans; In Vitro Techniques; Pseudomonas Infections | 1992 |
Evaluation of the usefulness of a novel injectable cephalosporin, E1040, and ceftazidime for management of complicated urinary tract infections caused by Pseudomonas aeruginosa and Proteus mirabilis by using the rat urolithiasis model.
Topics: Animals; Ceftazidime; Cephalosporins; Drug Evaluation, Preclinical; Female; Injections, Intramuscular; Proteus Infections; Proteus mirabilis; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Inbred Strains; Urinary Calculi; Urinary Tract Infections | 1992 |
Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model.
Topics: Animals; Cefepime; Ceftazidime; Cephalosporins; Citrobacter freundii; Disease Models, Animal; Drug Resistance, Microbial; Enterobacter cloacae; Enterobacteriaceae Infections; Female; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Peritonitis; Pseudomonas aeruginosa; Pseudomonas Infections; Serratia Infections; Serratia marcescens; Virulence | 1992 |
[Multiply resistant Pseudomonas aeruginosa in the pediatric field].
Topics: Age Factors; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Microbial; Humans; Infant; Monobactams; Penicillin Resistance; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones | 1991 |
[Diagnosis and therapy of pneumonia caused by gram-negative bacillus including legionella].
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Haemophilus Infections; Humans; Klebsiella Infections; Legionnaires' Disease; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections | 1991 |
Comparative therapy with cefpirome alone and in combination with rifampin and/or gentamicin against a disseminated Pseudomonas aeruginosa infection in leukopenic mice.
Topics: Animals; Cefpirome; Cephalosporins; Drug Therapy, Combination; Gentamicins; Kidney; Leukopenia; Liver; Lung; Male; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Spleen | 1990 |
A new antipseudomonal cephalosporin CP6162 and its congeners.
Topics: Animals; Bacteria; Cephalosporins; Chromatography, Thin Layer; Magnetic Resonance Spectroscopy; Male; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Stereoisomerism | 1990 |
[Pathogenic and clinical changes of pneumonia in the recent 10 years].
Topics: Adult; Cephalosporins; Drug Resistance, Microbial; Female; Gentamicins; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections | 1990 |
New aminothiazolylglycylcephalosporins with a 1,5-dihydroxy-4-pyridone-2-carbonyl group. I. Synthesis and biological activity of cephalosporin derivatives leading to MT0703.
Topics: Animals; Cephalosporins; Chemical Phenomena; Chemistry; Escherichia coli Infections; Klebsiella Infections; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Microbial Sensitivity Tests; Pseudomonas Infections; Spectrophotometry; Structure-Activity Relationship | 1990 |
New aminothiazolylglycylcephalosporins with a 1,5-dihydroxy-4-pyridone-2-carbonyl group. II. Synthesis and antibacterial activity of MT0703 and its diastereomers.
Topics: Animals; Cephalosporins; Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Escherichia coli Infections; Magnetic Resonance Spectroscopy; Mice; Microbial Sensitivity Tests; Pseudomonas Infections; Stereoisomerism; Structure-Activity Relationship | 1990 |
Therapeutic effects of cefpirome, a new cephalosporin, on various models of infections in mice and rats.
Topics: Animals; Cefpirome; Cephalosporins; Escherichia coli; Female; Klebsiella Infections; Klebsiella pneumoniae; Lung Diseases; Male; Methicillin; Mice; Penicillin Resistance; Pseudomonas Infections; Pyelonephritis; Rats; Staphylococcal Infections; Staphylococcus aureus; Uterine Diseases | 1990 |
[Pulmonary Pseudomonas infections].
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Female; Humans; Lung Diseases, Obstructive; Male; Middle Aged; Pneumonia; Pseudomonas; Pseudomonas Infections; Respiratory Insufficiency | 1990 |
[Cephalosporins in the treatment of urinary tract infections].
Topics: Cephalosporins; Drug Evaluation; Enterobacteriaceae Infections; Humans; Pseudomonas Infections; Urinary Tract Infections | 1990 |
A new aminothiazolylcephalosporin having 1-carboxyethoxyimino group, ME1228.
Topics: Animals; Bacteria; Bacterial Infections; Cephalosporins; Chemical Phenomena; Chemistry; Escherichia coli Infections; Isomerism; Male; Mice; Mice, Inbred ICR; Pseudomonas Infections | 1990 |
L-658,310, a new injectable cephalosporin. II. In vitro and in vivo interactions between L-658,310 and various aminoglycosides or ciprofloxacin versus clinical isolates of Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Drug Synergism; Female; Gentamicins; Isoindoles; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1989 |
Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.
Topics: Bacterial Infections; Bacterial Proteins; beta-Lactamases; Cefepime; Cefotaxime; Ceftazidime; Cell Membrane Permeability; Cephalosporins; Drug Resistance, Microbial; Enzyme Induction; Gram-Negative Bacteria; Isoelectric Focusing; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 1989 |
In vitro and in vivo antibacterial activities of BO-1341, a new antipseudomonal cephalosporin.
Topics: Animals; Bacteria; Bacterial Infections; beta-Lactamases; Cephalosporins; Drug Resistance, Microbial; Male; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 1989 |
Management of osteomyelitis of the skull base.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Gallium Radioisotopes; Humans; Osteomyelitis; Otitis Externa; Penicillins; Pseudomonas Infections; Radionuclide Imaging; Skull; Technetium | 1989 |
L-658,310, a new injectable cephalosporin. III. Experimental chemotherapeutics and pharmacokinetics in laboratory animals.
Topics: Animals; Bacterial Infections; Ceftazidime; Cephalosporins; Diabetes Mellitus, Experimental; Drug Resistance, Microbial; Enterobacter; Enterobacteriaceae Infections; Female; Gentamicins; Half-Life; Isoindoles; Macaca mulatta; Male; Mice; Neutropenia; Pseudomonas Infections | 1989 |
The importance of pharmacodynamics in determining the dosing interval in therapy for experimental pseudomonas endocarditis in the rat.
Topics: Animals; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Therapy, Combination; Endocarditis, Bacterial; Gentamicins; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rats; Rats, Inbred Strains; Time Factors | 1986 |
[Current aspects of pseudomonas meningitis].
Topics: Aminoglycosides; Anti-Bacterial Agents; Azlocillin; Bacteriological Techniques; Brain Injuries; Cefsulodin; Cephalosporins; Diagnosis, Differential; Fosfomycin; Humans; Meningitis; Penicillins; Polymyxins; Pseudomonas Infections | 1985 |
Clinical consequences of development of resistance to third generation cephalosporins.
Topics: Adolescent; Adult; Aged; Cephalosporins; Child; Citrobacter; Drug Resistance, Microbial; Enterobacter; Enterobacteriaceae Infections; Gram-Negative Bacteria; Humans; Immune Tolerance; Klebsiella; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Serratia marcescens | 1987 |
Therapeutic efficacy of cefpiramide-ciprofloxacin combination in experimental Pseudomonas infections in neutropenic mice.
Topics: Agranulocytosis; Animals; Cephalosporins; Ciprofloxacin; Cyclophosphamide; Drug Therapy, Combination; Female; Mice; Microbial Sensitivity Tests; Neutropenia; Pseudomonas Infections | 1987 |
Therapeutic efficacy of cefpiramide and cefoperazone alone and in combination with gentamicin against pseudomonal infections in neutropenic mice.
Topics: Animals; Cefoperazone; Cephalosporins; Cyclophosphamide; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Female; Gentamicins; Half-Life; Injections, Intraperitoneal; Injections, Subcutaneous; Kinetics; Lethal Dose 50; Mice; Neutropenia; Pseudomonas Infections | 1986 |
Effect of inflammation on antibiotic penetration into the anterior segment of the rat eye.
Topics: Administration, Topical; Animals; Anterior Eye Segment; Anti-Bacterial Agents; Cephalosporins; Cephradine; Gentamicins; Injections, Intravenous; Keratitis; Male; Permeability; Pseudomonas Infections; Rats; Rats, Inbred Strains; Staphylococcal Infections | 1986 |
Experimental efficacy of apalcillin and cefpiramide compared with that of six other antipseudomonal agents in Pseudomonas aeruginosa burn infections.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Burns; Cephalosporins; Female; Mice; Naphthyridines; Pseudomonas Infections; Wound Infection | 1986 |
A rat model of bacterial keratitis. Effect of antibiotics and corticosteroid.
Topics: Animals; Bacterial Infections; Cephalosporins; Cephradine; Disease Models, Animal; Drug Therapy, Combination; Gentamicins; Keratitis; Leukocyte Count; Penicillin G; Prednisolone; Pseudomonas Infections; Rats; Staphylococcal Infections; Streptococcal Infections | 1985 |
Multistrain comparison of three antimicrobial prophylaxis regimens in experimental postoperative Pseudomonas endophthalmitis.
Topics: Animals; Anti-Bacterial Agents; Cefazolin; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Drug Evaluation, Preclinical; Eye Diseases; Gentamicins; Inflammation; Postoperative Period; Pseudomonas Infections; Rabbits | 1985 |
Comparative activity of seven extended-spectrum cephalosporins against gram-negative bacilli from blood cultures.
Topics: Cefmenoxime; Cefoperazone; Cefotaxime; Ceftazidime; Ceftizoxime; Ceftriaxone; Cephalosporins; Cross Infection; Enterobacteriaceae; Enterobacteriaceae Infections; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis | 1985 |
[HR 810 (cefpirome). Experimental evaluation of the in vitro and in vivo antibiotic activity of a new amino-2-thiazole methoxy- imino cephalosporin].
Topics: Animals; Bacterial Infections; Cefpirome; Cephalosporins; Citrobacter; Enterobacter; Enterobacteriaceae; Enterococcus faecalis; Klebsiella Infections; Male; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Salmonella Infections, Animal; Salmonella typhimurium; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes | 1985 |
Experimental efficacy and pharmacokinetic properties of cefpiramide, a new cephalosporin.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Female; Kinetics; Male; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Inbred Strains; Staphylococcal Infections | 1985 |
Use of aminoglycosides in immunocompromised patients.
Topics: Agranulocytosis; Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Immune Tolerance; Infusions, Parenteral; Kidney Diseases; Microbial Sensitivity Tests; Neutropenia; Pseudomonas Infections; Sepsis | 1985 |
Diagnosis and management of infections associated with immunosuppression. New antibiotics of potential importance for immunosuppressed patients.
Topics: Amino Sugars; Bacteria; Carbenicillin; Cephalexin; Cephaloridine; Cephalosporins; Cephalothin; Escherichia coli Infections; Glycosides; Immunization, Passive; Immunosuppression Therapy; Kanamycin; Penicillin Resistance; Penicillins; Proteus Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Structure-Activity Relationship | 1973 |
Antibiotics, 1972.
Topics: Amino Sugars; Anti-Bacterial Agents; Bacteria; Candidiasis; Carbenicillin; Cephalosporins; Cryptococcosis; Drug Synergism; Flucytosine; Glycosides; Gonorrhea; Humans; Meningococcal Infections; Minocycline; Pseudomonas Infections; Spectinomycin; Sulfonamides; Tetracycline; Trimethoprim | 1972 |
[The incidence of infection in orthopedic and traumatologic operations (author's transl)].
Topics: Arthritis, Infectious; Cephalosporins; Cloxacillin; Dicloxacillin; Germany, West; Humans; Kanamycin; Lincomycin; Orthopedics; Osteomyelitis; Oxacillin; Penicillin G; Penicillin Resistance; Penicillin V; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Surgical Wound Infection; Tetracycline | 1973 |
[Chemotherapy and chemoprophylaxis of surgical infections].
Topics: Bacteria; Cephalosporins; Chloramphenicol; Drug Antagonism; Drug Incompatibility; Humans; Infections; Nitrofurantoin; Penicillin G; Penicillin Resistance; Penicillins; Polymyxins; Proteus Infections; Pseudomonas Infections; Staphylococcal Infections; Streptococcal Infections; Sulfonamides; Surgical Wound Infection; Tetracycline | 1967 |
Antimicrobial drugs for treatment of infections caused by aerobic gram-negative bacilli.
Topics: Aminoglycosides; Ampicillin; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbenicillin; Cephalosporins; Chloramphenicol; Dysentery, Bacillary; Escherichia coli Infections; Gentamicins; Haemophilus Infections; Humans; Kanamycin; Klebsiella Infections; Polymyxins; Proteus Infections; Pseudomonas Infections; Salmonella Infections; Sulfonamides; Tetracycline | 1974 |
Correlations between in vitro sensitivity testing and therapeutic response in urinary tract infections.
Topics: Bacteriuria; Cephalosporins; Drug Resistance, Microbial; Escherichia coli Infections; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pseudomonas Infections; Statistics as Topic; Urinary Tract Infections | 1973 |
[Antibacterial chemotherapy of the chronic bronchitis syndrome].
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Carbenicillin; Cephalosporins; Chloramphenicol; Chronic Disease; Drug Synergism; Escherichia coli Infections; Gentamicins; Humans; Penicillin G; Pseudomonas Infections; Staphylococcal Infections; Sulfonamides; Syndrome; Tetracycline; Trimethoprim | 1974 |
[Urosepsis in urinary calculi].
Topics: Adult; Ampicillin; Carbenicillin; Cephalosporins; Drug Therapy, Combination; Escherichia coli Infections; Female; Gentamicins; Humans; Klebsiella Infections; Male; Nephrectomy; Proteus Infections; Pseudomonas Infections; Sepsis; Urinary Calculi | 1974 |
Venous perfusion of the limb with antibiotics for osteomyelitis and other chronic infections.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bone and Bones; Catheterization; Cephalosporins; Chronic Disease; Drainage; Erythromycin; Femur; Follow-Up Studies; Humans; Humerus; Injections, Intravenous; Leg; Methicillin; Middle Aged; Osteomyelitis; Penicillins; Perfusion; Pressure; Pseudomonas Infections; Radiography; Recurrence; Staphylococcal Infections; Streptococcal Infections; Tourniquets | 1972 |
Cephacetrile--a new cephalosporin antibiotic.
Topics: Adult; Bacterial Infections; Cephalosporins; Drug Interactions; Female; Furosemide; Humans; Injections, Intramuscular; Injections, Intravenous; Kidney; Male; Microbial Sensitivity Tests; Pneumonia; Proteus; Proteus Infections; Pseudomonas; Pseudomonas Infections; Respiratory Tract Infections; Sepsis; Urinary Tract Infections | 1973 |
Recent developments in the treatment of infectious diseases. II. Alternatives to penicillin in the treatment of infections caused by gram-positive organisms.
Topics: Anti-Bacterial Agents; Cephalosporins; Escherichia coli Infections; Humans; Infections; Lincomycin; Penicillins; Protozoan Infections; Pseudomonas Infections; Salmonella Infections; Staphylococcal Infections | 1971 |
The newer antibiotics: some therapeutic considerations.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbenicillin; Cephalexin; Cephaloglycin; Cephalosporins; Enterobacteriaceae Infections; Gentamicins; Humans; Pseudomonas Infections; Rifampin; Staphylococcal Infections | 1972 |
[Clinical results of the use of cephaloridine in lung diseases, especially pulmonary tuberculosis].
Topics: Adult; Bronchiectasis; Cephaloridine; Cephalosporins; Empyema, Tuberculous; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Pseudomonas Infections; Respiratory Therapy; Sputum; Tuberculosis, Pulmonary | 1967 |
Recent advances in chemotherapy.
Topics: Bacteroides Infections; Cephalosporins; Drug Therapy; Enterobacteriaceae Infections; Haemophilus Infections; Humans; Lincomycin; Penicillins; Pneumococcal Infections; Pseudomonas Infections; Staphylococcal Infections | 1968 |